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Abstract 
Chronic graft-versus-host disease (cGVHD) remains a major complication of allogeneic 
haematopoietic stem cell transplantation. Traditionally, GVHD has been approached as a T-cell-
mediated process and current therapies reflect this understanding. The successful treatment of 
a proportion of refractory cGVHD patients with a CD20-depleting-agent supports a pathological 
role for B cells.  To study the role of B cells in cGVHD, I designed a comprehensive multi-
parameter panel of surface antibodies to distinguish different B cell subsets. The panel was 
validated on a number of healthy volunteers and applied to peripheral blood samples from 
cGVHD patients. I showed that patients with active chronic GVHD have an expanded population 
of CD21- with an ‘exhausted’ phenotype, based on upregulation of inhibitory receptors, altered 
expression of chemokine receptors and poor proliferative capacity.  A similar subset of CD21- 
exhausted B cells was described in patients with chronic HIV viraemia. Interestingly, there was 
a significant correlation between frequencies of CD21- B cells and the severity of cGVHD. Further 
work to identify the potential antigens that drive the expansion of these cells is currently 
underway. I also explored the role of IL10 producing regulatory B cells (Breg); powerful 
regulators of immune responses. A number of B cell subsets have been described in murine 
models of autoimmunity and some human autoimmune diseases.  I investigated the presence 
of IL10 producing B cells in the peripheral blood of healthy donors. Using intracellular cytokine 
staining for IL10 and surface phenotyping, I showed that IL10 producing B cells are enriched 
within the CD27+ IgMhi (IgM memory) B-cell subset. The purified populations of IgM memory B 
cells had regulatory properties and are capable of suppressing CD4+ T cell proliferation and IFNγ 
in vitro. Finally, I showed that B cells from cGVHD patients produce significantly less IL10 
compared with both HC and “no-GVHD” patients. I thereby propose that B cells play a significant 
role in the pathogenesis of cGVHD. Ex vivo expanded and adoptively transferred IgM memory 
B-cells may offer a potentially effective immunomodulatory therapy for the treatment of 
refractory cGVHD. 
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Chapter I. Introduction  
I.1 Allogeneic Haematopoietic Stem cell Transplantation (AHSCT) 
Allogeneic hematopoietic stem cell transplantation (AHSCT) is currently the only 
curative option for numerous haematological diseases. Since the first successful 
allogeneic bone marrow transplantation in humans in 1968(Bach et al., 1968, Gatti et 
al., 1968), the indications for AHSCT have been continuously growing to include immune 
deficiency syndromes, bone marrow failure syndromes, metabolic disorders, enzymatic 
deficiencies, autoimmune conditions, solid tumours and malignant and non-malignant 
haematological diseases (Tan et al., 2007). The introduction of reduced intensity 
conditioning protocols, growing cumulative experience of transplantation centres, and 
well-established supportive care practices have extended its use to older patients and a 
new spectrum of medical conditions (Resnick et al., 2005). In Europe alone, over 24,000 
stem cell transplants are currently performed annually (ESH-EBMT, 2008, Tan et al., 
2007). 
Despite the high curative potential of AHSCT, its wide application in clinical practice is 
offset by the associated high rate of complications (Pallera and Schwartzberg, 2004) and 
mortality (Gratwohl et al., 2005). Careful consideration of the multiple interacting 
factors is therefore crucial before a decision is made to proceed to transplant (Ringden 
et al., 2003).  
The therapeutic effect of AHSCT is attained through the myeloablative and 
immunosuppressive qualities of the conditioning regimen on the recipient 
haematopoietic system (Georges and Storb, 2003). Furthermore, the immunological 
24 
 
disparity between the donor and recipient gives rise to the graft-versus-leukaemia effect 
(Slavin, 2003, Alousi and de Lima, 2007), albeit at the risk of developing graft versus host 
disease (Resnick et al., 2005). Achieving GVL without the detrimental risk of GVHD is the 
ultimate goal in allogeneic stem cell transplantation. 
I.2 Graft-versus Host Disease (GVHD) and Graft-versus 
Leukaemia (GVL) 
 
The beneficial effect of the alloimmune GVL effect was first observed in transplant 
murine models in the 1950s when it was shown that irradiated mice receiving bone 
marrow from a different strain of mice died of a wasting diarrhoeal syndrome, now 
known as GVHD, but without any signs of residual leukaemia(Barnes and Loutit, 1957).  
Later studies in human leukocyte antigen (HLA)-matched AHSCT provided evidence that 
both GVL and GVHD effects result from the cellular allo- immune responses induced by 
disparities of minor histocompatibility antigens (mHA) between recipient and donor 
(Mutis et al., 2010). This observation was first harnessed clinically in the 1990s by 
demonstrating the curative potential of donor lymphocyte infusion (DLI) in relapsed 
leukaemia following AHSCT (Kolb et al., 1995, Deol and Lum, 2010, Helg et al., 1998).  
A number of leukaemia-specific antigens and mHA have been described and are 
believed to be the targets for the cytotoxic T lymphocytes (CTL) responses in GVL (Mutis 
and Goulmy, 2002). However, in the majority of cases the beneficial GVL effect is 
associated with the harmful effects of GVHD.  
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Graft versus host disease continues to be a major cause of morbidity and mortality 
following AHSCT (Gratwohl et al., 2005). Similar to the pathophysiology of GVL, GVHD 
involves activation of donor T-cells directed against mismatched mHA presented on 
primed recipient antigen presenting cells (APC) early after AHSCT (Shlomchik, 2007). 
Much work has been centred around the role of T cells in the pathogenesis of GVHD and 
clinical practice reflects this paradigm; for instance, T cell depletion of the graft and T 
cell-directed immunosuppression form the cornerstone of the prevention and 
treatment of GVHD (Ferrara et al., 2009); although, in some cases without significant 
success (Khaled et al., 2009). 
Recent data support the involvement of B cells in the pathogenesis of GVHD 
(Shimabukuro-Vornhagen et al., 2009). However, more insight into their role is required 
to help tailor more specific treatments with the aim of improving the overall outcome 
of AHSCT. 
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I.3 B cell development: 
Differentiation of irreversibly committed PAX5 expressing B cell precursors, that derive 
from the common lymphoid progenitors, is guided by several micro-environmental 
components and cellular interaction in the bone marrow niches (Nagasawa, 2006). After 
the rearrangement of the DH (diversity) and JH (junction) segments of Ig heavy chain 
gene, CD34+CD19+ pro B cells undergo further rearrangement of the VH segment, 
yielding a pre B cell. Upon coupling of cytoplasmic µH (rearranged DJV segments) with 
surrogate light chain Vpre B and λ 5 components, Pre B cells express Pre B cell receptor 
(pre-BCR) at a later stage of their differentiation; figure (I-1) (Cambier et al., 2007). 
Signalling from the pre-BCR prevents further recombination and promotes positive 
selection and proliferation. In contrast, a failure of pre-BCR signalling will cause 
developmental arrest, apoptosis or receptor editing (Edry and Melamed, 2004). This 
stage of development is Ag independent and takes place in the bone marrow stromal 
environment with a central role for IL7 (Maddaly et al., 2010). Hardy and colleagues 
illustrated that the stepwise transition is marked by differential expression of surface 
markers (Hardy et al., 1991). Pre B cells then initiate preferentially κ light chain 
rearrangement resulting, when successful, in surface IgM and later IgD co-expression; 
namely the BCR (Marie-Cardine et al., 2008). The release of immature B cells to the 
peripheral blood is strictly governed by negative selection checkpoints where auto-
reactive B cells are removed from the overall B cell repertoire (Sims et al., 2005, Hartley 
et al., 1991, Duty et al., 2009). In this process, the vast majority of the newly produced 
immature B cells, i.e. transitional B cells, die rapidly while the surviving B cells make their 
way to the peripheral blood (Forster and Rajewsky, 1990, Allende et al., 2010, 
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Wardemann et al., 2003). Transitional B cells mature mainly in the splenic micro-
environment into follicular or marginal zone B cells depending on the strength of BCR 
signalling and Ag specificity (Allman and Pillai, 2008, Carsetti et al., 2004).  Ag activated 
naïve B cells can receive T cell help to form germinal centres and undergo isotype switch 
and somatic hyper-mutation. This process produces memory B cells, short and long-
lived, and plasma cells and forms the basis for the adaptive humoral immune response 
(Good-Jacobson and Shlomchik, 2010). Marginal zone B cells on the other hand, are T 
cell independent with regards to Ag response and bear lower levels of somatic mutation 
(Weill et al., 2009). A better understanding of B cell development is essential to improve 
the outcome of therapy for a number of non-malignant and malignant medical 
conditions involving B cell disorders (Vale and Schroeder, 2010). 
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Figure I-1: B cell development  
Schematic figure shows the stages of B cell development in both bone marrow and the periphery. Adopted from Cambier et al (Cambier et al., 
2007). 
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I.4 Peripheral blood B cell subsets: 
I.4.1 Immature and transitional B cells: 
Transitional B cells, the early emigrants from the bone marrow, are functionally 
immature i.e. short lived and undergo apoptosis rather than proliferation upon BCR 
engagement (Sims et al., 2005, Palanichamy et al., 2009). The transition from a less to 
more mature stage within the transitional B cell populations is associated with 
considerable cell loss (Allman et al., 2001). Transitional B cells play an important role in 
repopulating the B cell ontogeny following bone marrow transplantation (Marie-Cardine 
et al., 2008) and B cell depletion therapy (Anolik et al., 2007). In mice spleen, two distinct 
transitional B cell populations, T1 and T2 cells, were characterised based on their high 
expression of both heat-stable antigen (HSA, CD24) and IgM and the differential higher 
expression of CD21, CD23 and IgD in T2 (Loder et al., 1999). Allman et al identified 3 
subsets based on the expression of the B-lineage precursor marker CD93/AA4, CD23 and 
IgM (Allman et al., 2001). Furthermore, Meyer-Bahlburg et al, using CD21 expression, 
divided transitional B cells into two phenotypically and functionally distinguished CD21lo 
T1 and CD21int T2 populations (Meyer-Bahlburg et al., 2008). 
Similarly in humans, two subsets of transitional B cells that phenotypically resemble 
murine T1 and T2 were described in the peripheral blood (Sims et al., 2005). A third 
subset (T3) defined by lack of the ATP-binding cassette Transporter (ABCB1) was later 
characterised in the peripheral blood following rituximab therapy and considered a 
developmental intermediate between T2 and mature B cells (Palanichamy et al., 2009). 
Since the majority of transitional B cells are self-reactive, they are subject to rigorous 
30 
 
early negative and later positive selection processes which take place principally in the 
bone marrow (Hartley et al., 1991) and spleen (Meyer-Bahlburg et al., 2008).  
Transitional B cells are found in the bone marrow, mostly (T1), spleen (T2), peripheral 
blood and cord blood mainly (T3) (Palanichamy et al., 2009) and in small numbers in 
lymph nodes (Carsetti et al., 2004). Maturation of transitional B cells to follicular naive 
B cells or marginal zone B cells occurs in the spleen, depending on the strength of BCR 
signalling (Carsetti et al., 2004, Weill et al., 2009). Moreover, there is some evidence to 
suggest that transitional B cells could mature to IgM producing memory cells in vitro 
upon TLR activation (Capolunghi et al., 2008). 
Transitional B cells constitute 2.2 to 7 % of circulating human B cells (Sims et al., 2005, 
Palanichamy et al., 2009, Marie-Cardine et al., 2008). They could be identified in the 
peripheral blood by their high expression of two developmentally regulated markers, 
CD24 and CD38(Carsetti et al., 2004, Palanichamy et al., 2009), or CD38hi IgD+ (Sims et 
al., 2005)  within the CD19+ population.  Transitional B cells are negative for CD27 and 
express increasingly CD44, CD21, CD23, CD22 and decreasing levels of IgM, CD5, and 
CD10 in accord with their maturation (Palanichamy et al., 2009).  
I.4.2 Mature B cells; naïve and memory B cells: 
I.4.2.1 Naïve B cells: 
Further maturation of transitional B cells to naive B cells bearing functional BCR in 
germline configuration occurs in the spleen (Pascual et al., 1994). The functional 
maturity is reflected by acquisition of surface IgD expression, longer life and 
proliferation upon BCR engagement (Allman et al., 2001). Naive B cells account for 40 to 
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60% of total B cells and express CD24int, CD38int and CD21 and are negative for CD27, 
CD10 and CD5 (Carsetti et al., 2004, Palanichamy et al., 2009). Naive B cells can be 
discriminated from CD27− memory B cells by their expression of the ABCB1 (Wirths and 
Lanzavecchia, 2005). 
Mature B cells attain the capacity to circulate in the periphery and home to and survive 
in the follicular niches of the secondary lymphoid tissue (BAFF dependent) and around 
the vascular sinusoids in the bone marrow (BAFF- independent) (Allman and Pillai, 
2008). Having escaped the elimination checkpoints, naïve B cells have high affinity to 
specific non-self-antigens. However, only a minority of auto-reactive anergic naive B 
cells expressing IgD can normally be found in the periphery (Duty et al., 2009). Activation 
of the follicular B cells requires BCR engagement and CD40 signalling (T cell dependent 
TD) (Allman and Pillai, 2008). In the TD germinal centre, Ag-specific B cells undergo 
numerous rounds of division, somatic hyper-mutation (SHM), class-switch 
recombination, and affinity selection. Several hypotheses have been proposed to 
explain why some activated B cells differentiate into memory or plasma cells; however 
the determining factors remain unclear (Good-Jacobson and Shlomchik, 2010). 
Lower Ag affinity and weaker BCR signalling direct T2 B cells to differentiate towards 
marginal zone B cells (Carsetti et al., 2004, Weill et al., 2009). Recently, Srivastava et al 
proposed that marginal zone B cells are derived from CD21hiCD23+ intermediate 
precursors enriched within the T2 population (Srivastava et al., 2005). Marginal zone B 
cells (MZB), located to the marginal zone in the spleen, are innate-like cells and mediate 
a T cell independent response to blood borne lipid antigens, differentiating into short-
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lived plasma cells (Allman and Pillai, 2008). Marginal zone B cells share a similar 
phenotype to the so-called IgM+IgD+ memory B cells and are CD27+ (Weill et al., 2009). 
I.4.2.2 Memory B cells 
Memory B cells are large Ag experienced cells, that secrete Ig following stimulation, 
persist in the absence of the immunising agents and respond rapidly during a secondary 
response (Good-Jacobson and Shlomchik, 2010, Weill et al., 2009). They are 
characterised by the acquired somatic mutation in their rearranged Ig V region genes. A 
direct link between somatic hyper-mutation and surface CD27 expression was 
established by Klein and co-workers (Klein et al., 1998, Tangye et al., 1998). CD27 
expression has, therefore, been used as a universal marker for memory B cells. However, 
CD27 is expressed briefly at early stages of B cell development in the bone marrow; pro 
– /pre – B cells. These cells do not normally circulate in the peripheral blood and can be 
identified by flow cytometry based on the expression of CD34 and the lack of BCR 
expression (Vaskova et al., 2008, Scheeren et al., 2008). 
Therefore, the classification of memory B cells on the basis of a single marker expression 
is far too simplistic (Sanz et al., 2008). About a third of the circulating memory B cells 
carrying mutated BCRs are CD27- (Fecteau et al., 2006). The mutation rate of this 
subgroup of memory cells is somewhat lower than in CD27+ memory B cells, possibly as 
a result of incomplete GC reaction. The origin and function of this category of cells is yet 
to be understood (Sanz et al., 2008). CD27- memory B cells are larger than naive B cells, 
are isotype switched i.e. IgG+ and express higher levels of CD80 and CD86 (Tangye and 
Good, 2007, Fecteau et al., 2006). 
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Furthermore, Shlomchik and colleagues have identified, using a transgenic Ag specific 
BCR knock-in mouse model, that Ag specific memory B cells contained both mutated as 
well as un-mutated memory B cells with the latter being enrich in the CD35+CD80+ 
fraction (Anderson et al., 2007). 
In the peripheral blood of healthy people, CD27+ memory B cells can be divided into two 
major groups, IgM-IgD-, isotype switched, and IgM+IgD+ memory B cells. Isotype switched 
memory B cells are the final product of a successful T-cell dependent (TD) germinal 
centre reaction (Good-Jacobson and Shlomchik, 2010). On the other hand, IgM+IgD+ 
memory B cells develop in the marginal zone of the spleen (Weller et al., 2004). Contrary 
to the isotype switched memory B cells, IgM+IgD+ memory B cells show a higher clonal 
diversity, comparable to naive B cells, while harbouring somatic mutations. Upon 
activation with a polysaccharide antigen, this pre-diversified subset of memory cells 
produces IgM, IgG and IgA, independent of T cell help (Weill et al., 2009, Weller et al., 
2004).  
Two smaller subsets of CD27+ B cells exist in the peripheral blood; namely, IgM only and 
IgD only memory B cells. IgM only memory B cells, occasionally confused with IgM+IgD+ 
memory B cells , are thought to be GC derived and the direct precursor of the isotype 
switched cells (Weill et al., 2009). Similarly, a small population of germinal centre 
memory cells have class-switched to IgD at the genetic level referred to as Cδ-CS; these 
cells are enriched in auto-reactivity (Koelsch et al., 2007).  
When defined by CD27 expression, memory B cells represent 30-60% of total B cells with 
equal shares of each major subset (10-15%) (Sanz et al., 2008, Weill et al., 2009). IgD 
only and IgM only memory cells account for a small percentage in healthy subjects and 
34 
 
may be expanded in some autoimmune conditions e.g. SLE (Weill et al., 2009). The CD27- 
memory B cells can be recognised by negativity for CD27, IgD and IgM and account for 
5% of total B cells i.e. around a third of total IgG+ and IgA+ isotype switched memory B 
cells (Sanz et al., 2008, Weill et al., 2009, Wei et al., 2007). Memory B cells express 
CD24int, CD38int, however, the level of expression of these markers varies relative to 
CD27 expression (Sanz et al., 2008).   
Germinal centre derived memory B cells differentiate to early (T cell dependent) and 
late (BAFF dependent) Ig secreting plasmablasts upon re-exposure to a specific antigen. 
This process is associated with early up-regulation of CD27, followed by acquisition of 
division-linked CD38 in the late phase (Avery et al., 2005). Plasmablasts represent a 
minor subset in the peripheral blood accounting for around 1% of total B cells (Piatosa 
et al., 2010). 
Memory B cells survive in secondary lymphoid tissues and mediate secondary responses 
upon re-challenge with specific antigens. Plasma cells, on the other hand, are terminally 
differentiated cells that home to spleen and bone marrow and are the main providers 
for Ig. However, it is unlikely that long-lived plasma cells will maintain a persistent supply 
of specific antibody over the human lifetime. Lazavache and colleagues proposed that 
constant polyclonal activation of memory B cells via bystander T cells and CpG DNA 
provides a means to preserve serological memory for a human lifetime (Bernasconi et 
al., 2002). 
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I.5 IgM+ IgD+ CD27+ memory B cells; “IgM memory B cells”: 
I.5.1 IgM memory B cell characteristics and phenotype: 
IgM memory B cells possess somatically hypermutated variable region genes but have 
not undergone class switching (Tangye and Good, 2007, Moens et al., 2008). IgM 
memory B cells are large cells with abundant cytoplasm (Shi et al., 2003, Takizawa et al., 
2006) and constitute 40 to 50% of CD27+ B cells in the peripheral blood (Lucas, 2004, 
Weller et al., 2005). The number of IgM memory B cells in the peripheral blood is low 
after birth (Agematsu et al., 1997) and increases gradually during the first year of life 
(Kruetzmann et al., 2003, Weller et al., 2003).  Some investigators detected IgM memory 
B cells in neonatal cord blood, foetal liver, LNs and BM at 14 and 16 weeks of gestation, 
however, others could not detect IgM memory B cells in cord blood (Kruetzmann et al., 
2003). The number peaks at the age of 30 to 40 years and declines remarkably after 70 
years of age (Shi et al., 2003, Shi et al., 2005).  
IgM memory B cells are IgMhi, IgD+, CD1c+, CD23-, CD21hi, CD27+ and CD5-  (Weill et al., 
2009, Weller et al., 2004, Won and Kearney, 2002). The higher expression level of CD21 
(complement receptor 2) compared to follicular B cells and recirculating mature naive B 
cells (Pillai and Cariappa, 2009, Capolunghi et al., 2008) is necessary to recognise 
bacterial polysaccharides, coupled with complement component C3d (Zandvoort et al., 
2001). Membrane-bound IgM i.e. B cell receptor on the surface of IgM memory B cells, 
is in a monomer or dimer configuration in contrast to the pentamer structure of the 
secreted IgM (Ehrenstein and Notley, 2010, Pierce and Liu, 2010).  
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Compared with switched memory B cells, IgM memory B cells have higher surface 
expression of CD72 (but lower than in naive B cells), lower CD80 and absent CD86 and 
CD95 expression (Shi et al., 2003). IgM memory B cells express chemokine receptors: 
CXCR4, CXCR5 and CCR7 (Tangye and Tarlinton, 2009). In contrast to switched memory 
B cells which produce IgM, IgA and IgG upon in-vitro stimulation, IgM memory B cells do 
not switch isotype and predominantly produce IgM (Shi et al., 2005). This subset of B 
cells cannot be induced to differentiate into switched memory B cells under different in-
vitro experimental conditions. Upon stimulation, IgM memory B cells mature to CD20- 
IgM producing plasmablasts with higher CD27 and CD38 expression (Capolunghi et al., 
2008, Shi et al., 2003).  
Some authors define IgM memory B cells as CD27+, IgM expressing B cells with no or 
little expression of IgD (Liu et al., 1988, Klein et al., 1997) or CD27+, IgD expressing B cells 
with or without co-expression of IgM (Shi et al., 2003), whilst others consider IgM only 
B cells as a distinct subset of B cells (Klein et al., 1997). In this thesis, I will refer to the 
non-switched IgM+IgD+CD27+ memory B cells as IgM memory B cells. 
I.5.2 IgM memory B cells in pathological conditions: 
IgM memory B cells are reduced in SLE (Odendahl et al., 2000, Wehr et al., 2004), PNH 
(Richards et al., 2000), CVID (Hart et al., 2007, Carsetti et al., 2005), IBD (Di Sabatino et 
al., 2005, Di Sabatino et al., 2004) and HIV, suggesting a possible immunoregulatory role 
for this subset (Nagase et al., 2001, Hart et al., 2007). In patients with Crohn’s disease, 
anti-TNFα treatment is associated with the recovery of IgM memory B cell number and 
function (Di Sabatino et al., 2008). In HIV positive patients, there is a direct correlation 
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between IgM memory B cells and the total CD4 count i.e. lower CD4 count is associated 
with lower IgM memory B cell frequencies (D'Orsogna et al., 2007). A similar association 
is also observed with the switched memory B cell compartment, supporting a role for 
CD4+ helper T cells in B cell memory maintenance (Hart et al., 2007). There is some 
evidence that EBV may preferentially infect IgD+CD27+ B cells (Ito et al., 2011). 
Conversely, expanded clonal IgM memory B cells may have a pathogenic role in anti-
myelin-associated glycoprotein  (MAG) neuropathy (Maurer et al., 2012) and HCV 
positive patients with mixed cryoglobulinaemia (Terrier et al., 2011, Charles et al., 2008). 
These data suggest that IgM memory B cells may play a role in immune pathologies. 
I.5.3 IgM memory B cells; source and maintenance:  
IgM memory B cells are considered to be the circulating counterpart of marginal zone B 
cells (MZB), as they share the same gene-expression profile and phenotype. MZB cells 
reside mainly in the marginal zone (MZ) of the spleen (Weller et al., 2004). Therefore, 
the spleen has been implicated as the source for IgM memory B cell maintenance 
(Kruetzmann et al., 2003). A number of observations support this notion; congenitally 
asplenic individuals have undetectable levels of IgM memory B cells in the peripheral 
blood (Kruetzmann et al., 2003) and the progressive appearance of IgM memory B cells 
in the circulation during the first two years of life correlates with the development of 
the splenic MZ (Lucas, 2004, Kruetzmann et al., 2003). Conversely, the decline in spleen 
function with ageing is associated with a reduction in IgM memory B cell frequencies in 
the periphery (Shi et al., 2005, Birjandi et al., 2011, Zago, 1989, Markus and Toghill, 
1991). MZB cells also reside in the MZ of other lymphoid organs such as the tonsils 
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(Takizawa et al., 2006) and lymph nodes (Tierens et al., 1999). A large registry study 
reported that splenectomised patients lose their IgM memory B cells by 6 months post 
splenectomy. However, the loss is not complete which supports the existence of other 
sources of IgM memory B cell maintenance (Cameron et al., 2011). Likewise, older 
splectomised patients have lower IgM response to pneumococcal vaccine compared to 
younger patients splenectomised for hereditary spherocytosis, suggesting age-related 
loss of extra splenic sites involved in the maintenance of this cell population 
(Wasserstrom et al., 2008). Additionally, in children younger than 2 years, 
IgM+IgD+CD27+ B cells can still be found in small numbers in the peripheral blood despite 
the absence of a distinct anatomical MZ structure (Zandvoort et al., 2001, Weller et al., 
2003).  
These data suggest that the marginal zone of the spleen, and possibly other lymphoid 
organs, are the primary sites where IgM memory B cells are maintained.  
I.5.4 IgM memory B cell development: 
In mice, the unmutated MZB cells develop from a common transitional precursor subject 
to the cell fate pathway NOTCH2 (Saito et al., 2003). A nonproliferative subset of 
CD21hiCD23+ transitional B cells, dubbed marginal zone precursors (MZP), has been 
identified as an intermediate subset in the development of MZ B cells (Srivastava et al., 
2005, Pillai and Cariappa, 2009). The generation of human IgM+IgD+CD27+ B cells was 
also shown to be NOTCH2- dependent; using an in vivo model of lymphocyte 
development (Scheeren et al., 2008). Other factors related to cell migration, BCR 
transduction, BAFF and NFκB pathways are also involved in IgM memory B cell 
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development (Pillai and Cariappa, 2009). The strength of BCR signalling of developing B 
cells may constitute a positive selection process in the spleen, where weaker self-
antigen affinity favours the development of B cells into MZB cells (Wen et al., 2005).  
Following fate determination, these cells undergo a number of SMH rounds and acquire 
memory cell properties (Weller et al., 2004, Klein et al., 1997). In view of the complete 
absence of AID in human splenic MZ, an absolute prerequisite for SHM, Willenbrok et al 
concluded that MZB cells cannot originate in the splenic marginal zone (Willenbrock et 
al., 2005). Likewise, Shi et al demonstrated the absence of mRNA AID in this subset in 
the PB (Shi et al., 2003). However, there is some evidence that early post-rearrangement 
Ig diversification of this subset might take place in humans through induction of SHM 
during foetal life (Scheeren et al., 2008). Indeed, upon stimulation with CPG, cord blood 
derived antigen-inexperienced transitional B cells mature in vitro to IgM memory B cells. 
The maturation is associated with the up-regulation of AID and Blimp1 and their 
differentiation into plasma cells with IgM specificity against pneumococcal 
polysaccharides (Capolunghi et al., 2008). To this end, it remains unclear how and where 
these cells undergo SHM (Weller et al., 2005, Scheeren et al., 2008) and whether this 
process is part of the early development of this subset or whether it could occur later in 
the spleen or somewhere else.  
I.5.5 IgM memory B cell ontogeny: 
The ontogeny of IgM memory B cells is not fully resolved; whether this population 
derives from precursor transitional B cells or whether they arise during GC B cell 
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differentiation remains uncertain (Weller et al., 2005, Moens et al., 2008, Tangye and 
Good, 2007, Kurosaki et al., 2010).  
It has been demonstrated that IgM+IgD- B cells i.e. IgM only CD27+ memory B cells, 
undergo SHM before isotype switching and hence, may represent TD CG exit (Tangye 
and Good, 2007). In addition, IgM+CD27+ memory B cells have mutated Bcl-6 gene, a 
genetic footprint of GC experience, demonstrating that at least some of the IgM+CD27+ 
B cells derive from a GC reaction during a T-cell-dependent response (Seifert and 
Kuppers, 2009). Therefore, early exit from a GC reaction after SHM and before isotype 
switching has been proposed as an explanation for the source and mutated state of IgM 
memory B cells (Klein et al., 1997, Dunn-Walters et al., 1995). Proponents of this theory 
consider IgM memory B cells to be a direct result of maturation of naive B cells during 
GC differentiation.  
However, IgM only CD27+ memory B cells were recently shown to have a proliferation 
history and SHM state equal to that of a GC population. IgM memory B cells, on the 
other hand, have a lower proliferation history and SHM, indicating that while IgM only 
B cells may be a result of primary GC reaction, IgM memory B cells seem to have a 
different origin (Berkowska et al., 2011). Furthermore, the identification of functional 
unmutated IgG memory B cells from Bcl6 deficient mice (Toyama et al., 2002) and in 
experimental inducible co-stimulator (ICOS) blockade models (Inamine et al., 2005) 
further strengthens the idea that memory B cells can develop independent of the GC 
pathway (Kurosaki et al., 2010).  
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Others suggest that MZB cells, and therefore IgM memory B cells are pre-diversified with 
a wide range of affinities independent of T cell help, Ag experience and GC reactions 
(Weller et al., 2005). Weller et al proposed a second T cell independent (TI) pathway in 
which mutations may occur as part of an intrinsic developmental pathway that is known 
to occur in sheep (Lucas, 2004). A second round of SHM that takes place a few days 
following TI challenge may represent selection and activation of intra-clonal cell 
populations with higher affinity (Weller et al., 2004). In humans almost all MZB (Weller 
et al., 2005) and IgM memory B cells (Klein et al., 1997) are mutated, albeit to a lesser 
extent than that of switched memory B cells.  
I.5.6 IgM memory B cell function: 
Generally, B cell responses are classified as T-dependent (TD) where antigens are 
processed and peptides presented on MHC class II molecules for recognition by helper 
T cells and T independent. T-independent (TI) antigens are divided into type I: mitogenic 
stimuli such as LPS, CpG, or poly-IC that elicit polyclonal B cell activation via Toll-like 
receptors and type II: polysaccharides (PS) that engage the B cell receptor and thus 
induce antigen-specific B cell responses (Obukhanych and Nussenzweig, 2006). PS-
specific antibodies can mediate opsono-phagocytosis with or without complement 
mediated lysis, hence facilitating bacterial clearance (Vos et al., 2000). 
IgM memory B cells play a major role in protection against bacterial infections, especially 
Streptococcus pneumoniae in a TI manner (Kruetzmann et al., 2003). In view of their 
close anatomical proximity to sinuses, IgM memory B cells are the first subset to see the 
blood-borne bacterial polysaccharides through their interaction with the marginal zone 
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macrophages and the more recently described B cell-helper neutrophils (Kruetzmann et 
al., 2003, Guinamard et al., 2000, Koppel et al., 2005, Puga et al., 2012). The response is 
fast (Lopes-Carvalho and Kearney, 2004); IgM memory cells generate IgM producing 
plasmablasts within 3 days of a primary response to particulate bacterial antigens 
(Martin et al., 2001). Indeed, hyposplenic individuals mount poor responses to 
polysaccharide vaccines (Molrine et al., 1999). Shi et al have shown that IgM memory B 
cells acquire a plasma cell phenotype i.e. CD38hi CD20- at a higher rate with BCR and 
CD40 engagement (Shi et al., 2003). The affinity of produced antibodies are enhanced 
with affinity-increasing replacement (R) mutation in the antigen-binding CDRs (Shi et al., 
2003, Klein et al., 1998). Tsuiji et al showed that VH3 antibodies were over represented 
in IgM memory B cells that bind to Staphylococcus protein A (Tsuiji et al., 2006).  
The fast response and recognition of bacterial DNA and LPS through TLR in the absence 
of cytokines represents the first-line defence from birth with an array of natural 
antibodies (Shi et al., 2005, Capolunghi et al., 2008). Although this process is T cell 
independent, IgM memory B cells are better suited to help shape and bring about the 
adaptive T cell dependent immune response. First, this subset facilitates antigen 
deposition onto follicular dendritic cells promoting GC formation (Ferguson et al., 2004, 
Pillai and Cariappa, 2009).  Indeed, Guo et al have shown that IgM knockout (IgM-/-) 
mice have poor GC formation (Guo et al., 2008). Second, it appears that IgM memory B 
cells are more efficient than follicular B cells in stimulating CD4 T cells, which in turn 
facilitates the GC reaction (Attanavanich and Kearney, 2004). Third, there is some 
evidence that IgM memory B cells respond to TD antigen producing IgG as well as 
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forming GCs (Song and Cerny, 2003). In humanised mouse models, IgM memory B cells 
produce mainly IgM isotype in response to both capsular polysaccharides and proteins 
and, IgG, the product of isotype switching, to the higher immunogenicity serotype 
(Moens et al., 2008). Hendricks et al have found a small number of class-switched MZB 
cells in the rat spleen, speculating that these cells may provide a rapid source of IgG 
against a blood-borne pathogen (Hendricks et al., 2011). 
IgM memory B cells in essence bridge and co-ordinate the response between innate and 
adaptive memory. Due to their pre-diversified nature, they react equally to a new 
antigen as a naïve B cell sharing the same affinity to polysaccharide antigens 
(Obukhanych and Nussenzweig, 2006). The authors also demonstrated that hapten-
protein specific (HS) B cells disappear quickly from the marginal zone after a secondary 
encounter where specific isotype switched memory B cells exist. Moreover, they also 
showed that IgG levels regulate the IgM response from HS specific cells (Obukhanych 
and Nussenzweig, 2006). 
MZB cells and hence IgM memory B cells may play a role in the production of natural 
IgM which has protective and regulatory functions (Ehrenstein and Notley, 2010). It is 
believed that by virtue of their high avidity and poly-reactivity, natural IgM B cells 
promote self-tolerance by mopping up excess self-antigen or masking their 
immunogenic epitopes (Ehrenstein and Notley, 2010).   
The central location of the splenic marginal zone allows B cells to clear circulating self-
antigens released by apoptotic cells. In fact, it has been shown that the MZ is enriched 
for self-reactive B cells (Li et al., 2002). Apoptotic cells induce MZB cells to produce IL10, 
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ameliorating inflammatory arthritis (Gray et al., 2007). Whether this reaction is a result 
of pooled polyclonal innate-like MZB with weak BCR signalling or Ag specific MZB with 
stronger BCR signalling is not fully understood. There is some evidence to suggest that 
it may be Ag specific (Chen et al., 2009). Breaking the tolerance in pathological states 
such as in SLE leads to clonal expansion of anti-DNA specific MZB cells with dislocation 
to intra-follicular spaces (Zhou et al., 2011). It is reasonable to propose that auto-
reactive MZ or IgM B cells regulate the immune response by mopping up circulating self-
antigens, thereby preventing their abundance, and dampening the immune response by 
secreting the immunomodulatory cytokine IL10.  Finally, cytokine production by B cells 
is important in B cell homeostasis and has been implicated in the pathogenesis of 
multiple diseases (Wojciechowski et al., 2009).  
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I.6 CD21 –B cells: 
I.6.1 CD21 (CR2) molecule: 
Human complement receptor (CR) CD21 (CR2) is a membrane glycoprotein expressed 
on B cells, follicular dendritic cells and in developing thymic T cells (Fischer et al., 1999). 
So far, four ligands for CD21 have been identified: complement C3 fragments, gp350 
EBV protein, immunoregulatory protein CD23, IFNα and more recently DNA and 
chromatin in the absence of C3 ligation (Asokan et al., 2006, Asokan et al., 2013).  CD21 
is an essential molecule for B cell activation and development. CD21 forms a complex 
with CD19 and CD81 (the B cell coreceptor complex) and stabilises the B cell receptor 
(BCR), significantly lowering the threshold for B cell activation (Carroll, 1998, Barrington 
et al., 2005, Cherukuri et al., 2001). The CD19/CD21 complex also enhances responses 
to T cell dependent immune reactions (Cherukuri et al., 2001, Carroll, 1998),  as well as 
T cell independent responses via binding C3d coated bacterial polysaccharides to IgM 
memory cells (Zandvoort et al., 2001, Fearon and Carroll, 2000). Consequently, germinal 
centre (GC) formation is dependent on CD21 expression, on both B cells and follicular 
dendritic cells, and on the achievement of sufficient B cell activation (Fischer et al., 1998, 
Carroll, 1999). In addition to its importance in the regulation of mature B cell activation, 
CD21 has a critical role in immune regulation and self-tolerance induction through the 
regulation of programmed death of anergic cells with low antigenic affinities and 
clearing of soluble self-antigens and circulating fragment of DNAs (Barrington et al., 
2005, Asokan et al., 2013, Fearon and Carroll, 2000).  
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I.6.2 CD21 expression by peripheral blood B cells: 
In healthy individuals, almost all B lymphocytes in the peripheral blood express CD21 at 
variable levels with up to 4% of peripheral B cells being CD21-/lo (Moir et al., 2008). IgM 
memory B cells have the highest expression level of this marker (Zandvoort et al., 2001). 
CD21 negative subsets include i) pro and pre B cells, although  these cells do not 
normally circulate in the PB (Schwab and Illges, 2001a) ii) early transitional B cells, known 
to be enriched for auto-reactive clones, also do not express CD21 and only gain CD21 
expression once they mature beyond the elimination checkpoints (Suryani et al., 2010) 
iii) activated memory B cells and plasmablasts (Weiss et al., 2009, Moir et al., 2008, Jego 
et al., 1999) and iv) apoptotic B cells may also have lower or no expression of CD21 
(Segundo et al., 1999), probably consequent on stimulation-induced proteolytic 
shedding of the molecule (Sengstake et al., 2006, Masilamani et al., 2003). The different 
subsets of CD21- B cells can be distinguished based on their surface phenotype. CD21- 
transitional B cells are CD24hi, CD38hi, CD27-, CD10+, IgMhi, IgD+ and CD20+. Both 
activated memory cells and plasmablasts are CD27+, CD10- and double negative for IgD 
and IgM. While activated memory B cells are CD24hi, CD38-/lo and CD20+, the short lived 
plasmablasts are CD38hi and CD24 and CD20 negative.  
I.6.3 Loss of CD21 expression: 
Not only has CD21 been shown to be important for normal B-cell functions such as 
activation of naïve B cells, GC survival, and persistence of B-cell memory, but CD21 is 
also known to be involved in the negative selection of self-reactive B cells. 
Downregulation of CD21 expression by B cells is likely to result in an increased BCR 
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signalling threshold and compromise the ability of CD21−/lo B cells to be activated. In 
addition, CD21 is able to break anergy in B cells, further suggesting that its down-
regulation contributes to an anergic stage. In autoimmunity, the lower CD21 expression 
raises the activation threshold of B cells and silences self-recognising clones, thereby 
inducing B cell anergy (Isnardi et al., 2010) and potentially offsetting the impact of  CD19 
over-expression by autoreactive B cells (Tedder et al., 2005). CD21 downregulation also 
facilitates B cell apoptosis via the Fas-pathway (Barrington et al., 2005, Charles, 2011). 
For instance in SLE, up-regulation of CD95 expression correlates with CD95-mediated 
apoptosis of CD21lo B cells (Warnatz et al., 2002). In addition to the direct effect of lower 
CD21 expression on B cell activation through CD19 pathway, upregulation of a number 
of inhibitory receptors that diminish B cell receptor responses have been observed in 
CD21- B cell populations. Therefore, downregulation of CD21 may be a direct or indirect 
sign of B cell exhaustion, which in turn further reinforces tolerance in such conditions. 
Similar findings are also observed in chronic infections such as HIV, HCV and malaria 
where tolerance may actually be counter-productive (Visentini et al., 2012, Charles et 
al., 2008, Moir et al., 2008, Weiss et al., 2009). However in some cases, lower CD21 
expression may prevent B cell infection by EBV, as infection of B cells is initiated by the 
interaction of the major EBV glycoprotein gp350 with CD21 on the B cell surface 
(Shannon-Lowe and Rowe, 2011).    
While the developmental lack of CD21 expression by early pro and pre B cells is 
regulated by DNA methylation, the acquired loss of its expression is not (Schwab and 
Illges, 2001a, Schwab and Illges, 2001b). B cell stimulation reduces both CD21 mRNA 
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expression and serine kinase induced production of CD21 proteins (Illges et al., 2000, 
Shubinsky et al., 1997). A distinct gene profile was found in clonally activated CD21lo B 
cells including upregulation of IFN-induced, B cell anergy and pro-apoptotic genes 
(Charles, 2011).  
This process is associated in most cases with the expression of an array of inhibitory 
receptors. Transcriptional profiling of clonal B cells in patients with HCV-associated 
mixed cryoglobulinaemia (MC) revealed transcriptional features of anergy and apoptosis 
with abundant transcripts of Stra13, a powerful negative regulator of B-cell proliferation 
and homeostasis (Visentini et al., 2012).   
Loss of CD21 expression has been described both in congenital and acquired conditions. 
A recent report described the case of a patient with congenital CD21 deficiency who 
presented with recurrent infections and hypogammaglobulinaemia, resultant from 
compound heterozygous deletion in the CD21 gene (Thiel et al., 2012).  CD21- B cells are 
also increased in a number of autoimmune and chronic infection conditions e.g. 
rheumatoid arthritis (Isnardi et al., 2010), SLE (Wehr et al., 2004), HCV infection (Terrier 
et al., 2011Charles, 2011), chronic HIV viraemia (Moir et al., 2008), chronic malarial 
infestation(Weiss et al., 2009), CVID (Rakhmanov et al., 2009), and cGVHD (Greinix et 
al., 2008). 
I.6.4 Low CD21 expression and B cell exhaustion: 
A number of investigators have described expansion of CD21- B cell populations in viral 
infections and CVID as associated with autoimmune and lymphoproliferative 
complications (Charles et al., 2008, Terrier et al., 2011, Warnatz et al., 2002, Rakhmanov 
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et al., 2009). Similar increases in CD21lo B cells were also observed in autoimmune 
diseases such as RA and SLE (Reparon-Schuijt et al., 2001, Wehr et al., 2004, Isnardi et 
al., 2010). Interestingly, sCD21 was also significantly decreased in sera of SLE patients. 
Therefore, it is unlikely that increased shedding of CD21 accounts for the low cell surface 
expression of CD21 in these patients (Wehr et al., 2004). More recently, Moir et al 
described a population of CD21- B cells in HIV positive patients. The subset was 
designated tissue-like memory B cell in view of their phenotypic resemblance to tonsillar 
tissue memory B cells (Ehrhardt et al., 2005). Tissue-like memory B cells expressed 
significantly higher levels of inhibitory receptors such as CD22, CD85J and FCRL4 and a 
profile of trafficking receptors consistent with migration to sites of chronic 
inflammation. Their homing receptor profile including CXCR3, CD11c, CCR7, and CD62L 
is reminiscent of that of virus-specific CD8+ exhausted T in chronic LCMV and HIV 
infections (Moir et al., 2008). A similar population was also found to be significantly 
expanded in Plasmodium falciparum exposed and chronically infected Malian adults and 
children (Weiss et al., 2009).  
Despite differences in CD21- B cells with regards to their mutational status (clonal versus 
poly clonal) and allocation to different B cell subsets (naïve versus memory), these cells 
share important features. These populations all display low proliferation and reduced 
Ca2+ response, a hallmark of B cell exhaustion. Although CD21 downregulation may help 
reduce the deleterious effects of autoreactive antibodies, it also favours the persistence 
of pathogens by limiting pathogen-specific humoral responses. This may indicate that 
downregulation of CD21 expression and the associated changes in B cell phenotype is 
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the result of chronic B cell activation and exhaustion. It is not clear if exhaustion is 
limited to the Ag specific clone or whether it represents a global B cell phenomenon 
(Moir et al., 2008, Charles et al., 2008). This is important as exhaustion might potentially 
be reversible by using a combination of stimuli such as the addition of IL2 and IL10 
(Visentini et al., 2012, Moir et al., 2008). Furthermore, by using siRNA to downregulate 
inhibitory receptor genes such as FCRL4, Kardava and colleagues have demonstrated 
reversibility of B cell exhaustion in HIV (Kardava et al., 2011). Targeting the exhaustion 
may thereby improve B cell immune responses against viruses; however, it remains 
unclear if reversal of B cell exhaustion in autoimmune disorders might aggravate tissue 
damage. 
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I.7 B cell and Graft versus host disease: 
I.7.1 Stem cell transplantation (SCT): 
Stem cell transplantation (SCT) involves the adoptive transfer of stem cells from a donor 
to replace the host haematopoietic system. The main consideration for SCT is matching 
for the major histocompatibility antigens known as human leukocyte antigens (HLA). 
Other important factors in donor selection include, sex, age, ABO blood group and CMV 
serostatus (Tay et al., 2012). A number of other factors are being recognised to play a 
role in the outcome of allogeneic stem cell transplantation such as cytokine gene 
polymorphisms, KIR status and minor histocompatibility antigen mismatches (Gratwohl, 
2007, Dickinson and Charron, 2005).  
Successful SCT requires the engraftment and homing of stem cells and education of the 
emerging donor immune system. The process is complicated by the fact that some 
competent mature donor lymphocytes are infused into the recipient with the graft, 
despite efforts to deplete them (Daniele et al., 2012). In the adult population, the age 
related involution of the thymus means that T cell education and tolerisation towards 
self are compromised (Lynch et al., 2009). Exposure to the hostile transplantation 
environment created by the conditioning protocol, release of inflammatory cytokines 
and breakdown in the innate physical barriers affect the maturation and recovery of the 
immune system (Novitzky and Davison, 2001). These factors contribute to the 
pathogenesis of graft versus host disease (GVHD).  
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I.7.2 GVHD- clinical manifestations and classification: 
Graft versus host disease remains a major obstacle to the success of allogeneic SCT. The 
challenge of GVHD stems from difficulties in controlling the full blown disease and the 
limited understanding of its pathogenesis to allow development of targeted therapies.  
GVHD is a clinical syndrome that follows allogeneic SCT; nonetheless, it has rarely been 
reported in some autologous SCT settings (Zenz et al., 2006). Another similar fatal entity 
is encountered when competent lymphocytes are transfused during blood product 
transfusion into immune-compromised HLA haplotype sharing recipients (Sage et al., 
2005).  
Historically, GVHD is divided based on its time of onset post-transplant into acute 
(aGVHD), in the first 100 days following SCT, and chronic (cGVHD) beyond this period 
(Shulman et al., 1980, Martin et al., 1990). The introduction of reduced intensity 
conditioning (RIC) and donor lymphocyte infusion (DLI) with the delayed emergence of 
aGVHD and overlap syndromes have changed this concept (Hymes et al., 2012).  
In an attempt to standardise the clinical and pathological criteria and to account for the 
emerging late onset aGVHD and the overlap syndrome, the National Institute of Health 
published a new consensus criteria for the diagnosis of GVHD table (I-1) (Filipovich et 
al., 2005). 
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Table I-1: NIH consensus criteria for GVHD diagnosis 
 
                                                                                                  Adopted from Filipovich et al 2005 
 
Numerous risk factors have been identified for the development of acute and chronic 
GVHD such as HLA disparity, female to male donation, older age of donor and recipient, 
and peripheral blood mobilised grafts, TBI, CD3 content of the graft and CMV serostatus 
(Flowers et al., 2011, Atkinson et al., 1990, Hahn et al., 2008). 
Chronic graft versus host disease is a wasting syndrome, which involves specific targeted 
organs and shares considerable resemblance with autoimmune diseases. It affects 30 to 
65% of patients following allo-SCT with 5 year mortality of 30 to 50% (Blazar et al., 
2012b). The main target organs for cGVHD include the skin and its appendages, the GI 
tract, genitalia, mouth, eyes and liver. It is usually associated with cytopenias, 
autoimmune haemolysis and thrombocytopaenia. Bone marrow failure and red cell 
aplasia may also ensue in the course of the disease. In the acute disease, the skin, gut 
and the liver are mainly involved (Filipovich et al., 2005, Ferrara et al., 2009). 
Category Time of symptoms after SCT or DLI
(days)
Presence of aGVHD 
Features
Presence of cGVHD 
features
Acute GVHD
Classic aGVHD <100 Yes No
Persistent,   recurrent, late-onset aGVHD >100 Yes No
Chronic GVHD
Classic cGVHD No time limit No Yes
Overlap syndrome No time limit Yes Yes
54 
 
Prophylaxis and treatment of GVHD is aimed at addressing the breakdown in self-
tolerance and is based on suppressing the immune system. Therefore, the treatment 
thus far has included corticosteroids, calcineurin inhibitors (e.g. cyclosporin (CsA) 
(Vogelsang, 2001) and tacrolimus , mTOR inhibitors (rapamycin) (Abouelnasr et al., 
2013), mycophenolate mofetil, and monoclonal antibodies against CD25 and TNFα 
(Rodriguez et al., 2007). Recent experimental treatments for GVHD include tyrosine 
kinase inhibitors (Olivieri et al., 2011), anti-CD20 (Kim et al., 2010), bortezomib (Koreth 
et al., 2012), and extracorporeal photopheresis (ECP) (Kuzmina et al., 2009). A number  
of novel pathway targeting agents and cellular therapies such as mesenchymal stem 
cells (MSC) are under investigation (Blazar et al., 2012b). However, none of these current 
therapies are approved by the FDA. More prospective, well designed studies are 
required to investigate the role of novel therapies in the prevention and treatment of 
GVHD (Inamoto and Flowers, 2011).  
I.7.3 Pathophysiology of GVHD:  
Billingham defined the triad of factors required for the development of GVHD. These 
include i) an immunocompetent graft with viable and functional immune cells. ii) 
immunological disparity between recipient and donor and,  iii) the recipient is 
immunocompromised and therefore cannot reject the donor cells (Billingham, 1966). 
The pathophysiology of acute graft versus host disease is thought to happen in a three-
step process: i) the conditioning induces tissue damage and the resulting cytokine storm 
leads to priming of host antigen presenting cells (APC); ii) activation of allo-reactive 
donor T cells and the subsequent clonal expansion and secretion of IL2 and IFNγ; iii) 
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inflammation induced by LPS-activated neutrophils and mononuclear phagocytes, with 
the subsequent recruitment of effector cells such as cytotoxic T cells including Th17 and 
NK cells. The process culminates in tissue damage of target organs (Ferrara and Reddy, 
2006).  
While acute GVHD is mediated by the inflammatory environment of the early post-
transplant period, little inflammation is involved in triggering of chronic GVHD 
(Schroeder and DiPersio, 2011). The hallmark of cGVHD is the accumulation of Th-2 
polarised CD4+ T cells in the presence of impaired negative selection in the damaged 
thymus. Th-2 type cytokines lead to the production of pro-fibrotic cytokines such as IL2, 
IL10 and TGFβ and platelets derived growth factor (PDGF), that promote tissue fibroblast 
proliferation (Blazar et al., 2012b). More recent studies have underlined the importance 
of regulatory dysfunction, especially FoxP3+ regulatory T cells, in the development of 
cGVHD (Rezvani et al., 2006, Zorn et al., 2005). Increasing evidence supports a role for B 
cell dysregulation in the development of cGVHD (Shimabukuro-Vornhagen et al., 2009). 
Several autoantibodies have been reported in association with cGVHD and in some 
cases, have been implicated in the pathogenesis of the disease (Kapur et al., 2008, 
Svegliati et al., 2007). A potential role for a IL10-producing human regulatory B cell was 
recently described in some autoimmune diseases (Blair et al., 2010, Iwata et al., 2010). 
Further insight into the role of B cells, especially the regulatory subsets, is imperative to 
improve our understanding of cGVHD and to help with the development of novel 
therapies. 
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I.7.4  B cell in cGVHD 
I.7.4.1    B cell reconstitution following SCT 
B cell reconstitution following allogeneic SCT recapitulates B cell ontogeny (Storek et al., 
1993). Similar to recovery following B cell depletion, transitional B cells are the first 
subset to appear in the peripheral blood after SCT. They progressively diminish, while 
giving rise to naïve B cells (Marie-Cardine et al., 2008), (Anolik et al., 2007). The early 
period following allogeneic SCT is characterised by supranormal B cell numbers, likely 
driven by high homeostatic levels of B cell activating factor (BAFF) (Storek et al., 1993, 
Sarantopoulos et al., 2009). The majority of circulating B cells is antigen-naïve, and the 
memory compartment remains significantly lower than normal for the first year after 
SCT (Avanzini et al., 2005, Bemark et al., 2012, Cuss et al., 2006, Storek et al., 1997). 
Generally, memory B cell recovery following allogeneic SCT and regaining the 
immunoglobulin repertoire may need many years to reach normalcy (Storek et al., 1997, 
Avanzini et al., 2005, Velardi et al., 1988). The pre immune repertoire of B cells post SCT 
resembles that of healthy individuals (Glas et al., 1997). However, there is some 
evidence that B cells from SCT patients accumulate less antigen-driven T cell-dependent 
somatic mutations (Glas et al., 2000). Intrinsic B cell deficit or impaired T-B cell cross talk 
rather than T cell help defect may explain this observation (Glas et al., 2000). Damaged 
lymph node structure and functional hyposplenism associated with SCT interrupts 
immune cell interaction (Cuthbert et al., 1995, Sale et al., 1992).  
Several variables may influence B cell recovery following stem cell transplantation. 
Following GCSF mobilized PBSCT, the higher B cell content and the increased activation 
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state of B cells compared to bone marrow grafts results in faster B cell reconstitution 
(Abrahamsen et al., 2005, Tayebi et al., 2001). The development of acute and chronic 
GVHD, the type and duration of immunosuppression as well as the conditioning regimen 
can affect the kinetics of B cell recovery (D'Costa et al., 2001, Maris et al., 2003).  
A crucial aspect of B development is determined by the early checkpoint, at the 
transitional B cell stage during which time self-reacting B cells are deleted from the 
peripheral repertoire and self-tolerance is maintained. The survival of auto-reactive B 
cells is influenced by the strength of receptor cross linking with the Ag (Hartley et al., 
1991), the availability of high BAFF levels, and possibly the quality of B cell recovery 
following transplantation (Lesley et al., 2004).  An understanding of normal B cell 
reconstitution is important to define patterns of B cell reconstitution that may be 
associated with cGVHD or may be predictive of increased susceptibility to infectious 
complications (Avanzini et al., 2005).  
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I.7.4.2 B cells disturbances in human GVHD: 
I.7.4.2.1 The role of B cells in GVHD- mouse models: 
There is a considerable body of pre-clinical evidence highlighting the role of donor B cells 
in pathogenesis of chronic GVHD. In an MHC matched murine transplant model, both 
donor B and CD4+ T cells are required for the development of cGVHD (Zhang et al., 2006, 
Schultz et al., 1995). The mechanism through which the two immune cells interact and 
trigger the process is not fully understood. 
Recipient and donor APC activate allo-reactive donor CD4+T cells. Activated donor T cells 
can stimulate donor B cells and facilitate germinal centre formation. Activated B cells 
expand robustly, undergo SHM, class switch and produce potentially pathogenic allo-
antibodies (Srinivasan et al., 2012). In addition, activated B cells express co-stimulatory 
molecules and in turn can serve as potent APC to allo-reactive donor CD4+ T cells and 
have the potential to produce cytokines that polarise T cells towards Th2 (Shustov et al., 
2000). B cells therefore depend on T cell help to be primed and in turn augment T cell 
function further. Expanded allo-specific T cells can cause damage thereafter, 
independent of B cells (Young et al., 2012). B cell activation, however, also occurs 
independent of T cells in which case B cells themselves can initiate the pathogenic 
process.  
Antigen presentation by recipient APCs is fundamental for the development of cGVHD 
but is not exclusive to B cells, as depletion of recipient B cells (Matte-Martone et al., 
2010) or in fact all APC, does not prevent GVHD (Li et al., 2012a). The currently available 
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cGVHD mouse models do not mirror human cGVHD, and this deficiency limits the 
translational value of murine studies of cGVHD (Schroeder and DiPersio, 2011). 
I.7.4.2.2 The role of B cells in human aGVHD: 
The role of donor B cells in the development of aGVHD is not understood. A recent study 
from the International Blood and Marrow Transplant Registry (IBMTR) reported that 
prior treatment with rituximab was associated with less acute GVHD following 
allogeneic stem cell transplantation (Christopeit et al., 2009), (Ratanatharathorn et al., 
2009). These findings are further supported by the recent demonstration that a high 
concentration of B cells in the graft is associated with more acute GVHD (Iori et al., 
2008). Furthermore, Kamble et al reported successful treatment of refractory aGVHD 
with rituximab in 3 patients (Kamble et al., 2006). On the other hand, post-transplant 
administration of rituximab failed to have a significant effect on the incidence of acute 
GVHD in a small cohort of patients with aggressive NHL (Glass, 2008). Moreover, another 
study reported that higher frequencies of B cell progenitors in the apheresis product are 
associated with less aGVHD (Michonneau et al., 2009). 
I.7.4.2.3 The role of B cells in human cGVHD: 
Traditionally, T cells have been the main focus of research in the pathogenesis of GVHD 
(Inamoto and Flowers, 2011). Recent studies suggest that donor B cells as well as T cells 
contribute to the immune pathology in cGVHD (Zhang et al., 2006). However, it has been 
suggested that longer survival of host B cells might be involved in the pathogenesis of 
cGVHD (Barrett, 2006).  
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Indeed, at least 35 auto-antibodies have been strongly associated with cGVHD (Kapur et 
al., 2008). Antibodies to H-Y minor histocompatibility antigens produced in males 
receiving female grafts correlated with cGVHD development and remission (Miklos et 
al., 2004, Miklos et al., 2005). The frequent production of auto-antibodies in patients 
with cGVHD may reflect critical breakdown in peripheral B-cell tolerance after allogeneic 
HSCT. Whether this phenomenon merely results from B cell recovery in the permissive 
post-transplant environment or in response to antigenic disparity, ensuing direct tissue 
damage is not fully known. Direct causal relationship of auto-antibodies in cGVHD has 
only rarely been demonstrated (Svegliati et al., 2007).  
Many factors following SCT may contribute to the survival of autoreactive B cells, such 
as high levels of BAFF and activated and primed B cells (Granholm and Cavallo, 1992). 
BAFF is a member of the TNF family, also known as TALL-1, THANK, BlyS and zTNF4, and 
is a critical B cell survival factor with homeostatic properties. It is secreted by monocytes, 
dendritic cells and some T cells and is increased following reduction of the B cell count 
(Saito et al., 2008). It is also increased following B cell depleting therapy (BCDT) e.g. with 
rituximab (Ansell et al., 2009) and interestingly in the majority of autoimmune 
conditions (Zhou et al., 2009). It has been shown that under conditions where BAFF 
levels are elevated, auto-reactive B cells can escape the negative selection process, 
predisposing to the development of autoimmunity (Lesley et al., 2004). Indeed, 
Sarantopoulos et al have found that high BAFF to B cell ratio following allogeneic stem 
cell transplant correlates with the development of chronic GVHD (Sarantopoulos et al., 
2009). In addition, B cells derived from cGVHD patients are primed for CpG stimulation 
and express higher toll-like receptor 9, required for autoantibody production (She et al., 
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2007).  Other authors have demonstrated that B cells in the cGVHD environment are 
actually in an activated state (Allen et al., 2012). It has been shown that GCSF mobilised 
graft may be associated with higher frequencies of activated CD25+ B cells, and a higher 
risk of cGVHD post-transplant (Tayebi et al., 2001).  
The total number of CD27+ B cells was found to be significantly lower in cGVHD patients 
compared with their no cGVHD counterparts (D'Orsogna et al., 2009, Hilgendorf et al., 
2012, Greinix et al., 2008, Corre et al., 2010). Several studies have reported similar 
observations, but with variable impact on the class-switched and non-switched CD27+ 
memory B cells. In one study, IgM+ CD27+ memory B cells were selectively reduced in 
patients with a history of cGVHD (D'Orsogna et al., 2009). In other studies however, both 
subpopulations of IgM memory and class-switched memory B cells were numerically and 
proportionally reduced in cGVHD compared to patients without GVHD (Hilgendorf et al., 
2012, Greinix et al., 2008). In contrast, Sarantopoulos et al reported that cGVHD patients 
maintain their memory B cell compartment in the setting of relative naïve B 
lymphopenia and high BAFF: naïve B cell ratio (Levine et al., 2012).   
Interestingly, abnormal persistence of a high fraction of CD21- immature/ transitional B 
cells was observed in patients with cGVHD (Greinix et al., 2008). The CD21- B cell 
population correlated with more severe infections post SCT and poorer response to ECP 
(Kuzmina et al., 2009, Greinix et al., 2008). In addition, the increase in CD21- B cells 
correlated with lower serum immunoglobulin levels among cGVHD patients (Kuzmina et 
al., 2011). The authors concluded that CD21- transitional B cells are increased and 
correlate with the severity of cGVHD. However, other groups have reported that 
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transitional B cells are low in cGVHD patients (Hilgendorf et al., 2012, Storek et al., 1993). 
Expansion of the CD21- B cell compartment in the peripheral blood has been reported 
previously in a number of autoimmune and immune deficiency conditions SLE (Wehr et 
al., 2004), CVID (Wehr et al., 2008) suggesting that CD21- B cells may be involved in the 
pathogenesis of cGVHD as an auto-allo-immune condition. 
There is substantial evidence that B cells can both amplify and suppress immune 
responses by mechanisms that do not involve antibody production. For example, B cells 
respond to Toll-like receptor (TLR) ligands and present antigens. B cells also organise the 
structure of lymphoid tissues and regulate lymphangiogenesis. In addition, B cells 
produce cytokines and can be subdivided into discrete cytokine-producing “regulatory” 
and “effector” B subsets (Sanz et al., 2007). In the SCT setting, host B cells have been 
shown to play a protective role in GVHD.  After total body irradiation, B cells can secrete 
IL10, thus inhibiting alloreactive T-cell expansion and subsequent induction of acute 
GVHD (Rowe et al., 2006). It is therefore possible that B cells with immunoregulatory 
function may play a role in the pathogenesis of GVHD.  
I.7.4.2.4 Chronic GVHD effects on B cells 
The relationship between B cells and cGVHD is rather complex. While B cells certainly 
can play a causative role in cGVHD pathogenesis, cGVHD on the other hand appears to 
have profound effects on B cell recovery following allogeneic SCT.  It has been shown 
that cGVHD affects B lymphopoiesis and sites of B cell maturation.  Chronic GVHD is 
associated with alloimmune damage to lymph nodes, a major location for antigen 
encounter and T cell interaction. Altered follicular dendritic reticular cell structure, in 
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addition to intranodal reversal of CD4/CD8 ratio contribute to the B cell dysfunction 
observed in cGVHD patients (Sale et al., 1992). Moreover, cGVHD worsens the splenic 
hypofunction seen in SCT patients further (Cuthbert et al., 1995). There is experimental 
evidence to support that cGVHD-associated damage to the bone marrow niche impairs 
B cell lymphopoiesis (Shono et al., 2010). Collectively, the development of cGVHD 
translates into impaired B cell reconstitution (Storek et al., 1993). In line with this notion, 
early studies have demonstrated that extensive cGVHD or its treatments are associated 
with lower bone marrow B cell precursors (Abrahamsen et al., 2005, Storek et al., 2001, 
Fedoriw et al., 2012). This may explain why cGVHD patients have lower circulating total 
B cells and immunoglobulin levels compared to patients without cGVHD (Corre et al., 
2010, Abrahamsen et al., 2005). A case of almost complete absence of B cell 
lymphopoiesis attributed to severe chronic GVHD was reported (Takahashi et al., 2002). 
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I.8 Regulatory B cells 
I.8.1 Evidence for regulatory B cells: 
Early experimental animal models have identified a potential role of B cells in immune 
regulation. Transfer of splenocytes lacking B cells in an in vivo mouse model failed to 
prevent T cell induced delayed-type skin hypersensitivity (Katz et al., 1974, Neta and 
Salvin, 1974). A series of published reports by Shimamura et al suggested that splenic B 
cells from mice immunised with sheep erythrocytes suppressed the response of 
syngeneic recipients to the same antigen via induction of suppressor T cells (Shimamura 
et al., 1982a, Shimamura et al., 1984, Shimamura et al., 1982b). The later development 
of B cell deficient mouse models helped to further elucidate the immune-modulatory 
role of B cells. B cell deficient µMT mice failed to recover from induced experimental 
autoimmune encephalomyelitis (EAE) (Wolf et al., 1996). Subsequent animal studies 
demonstrated that B cell regulatory function was mediated through a number of 
mechanisms including linking antigen presenting cells (APC) to tolerogenic regulatory T 
cells (D'Orazio and Niederkorn, 1998), regulating the function of pathogenic CD4 T 
cells(Mizoguchi et al., 2000), inhibiting induced lymphocyte proliferation(Sasaki et al., 
1993) or modulating IFNᵞ production by antigen specific T cells (Wijesuriya et al., 1998).  
However, the mechanism by which B cells or their products contributed to tolerance 
induction remained unclear. The notion that IL10 production may be essential for 
regulatory B cell function was demonstrated simultaneously in two different 
inflammatory models (Mizoguchi et al., 2002, Fillatreau et al., 2002). In the first study, 
µMT as well as IL10 B cell deficient mice failed to recover from experimental autoimmune 
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encephalomyelitis (EAE). In the second study, IL10 producing B cells inhibited the 
progression of spontaneous colitis in a murine model. Similarly, in a collagen induced 
arthritis mouse model, the adoptive transfer of IL10 producing B cells controlled synovial 
inflammation in arthritic mice (Mauri et al., 2003). Later work by Yanaba and colleagues 
indicated that IL10 producing B cells are specialised cells with inducible IL10 production 
capacity. Measuring 31 cytokines transcript levels, the defined mouse B cell subset 
uniquely produced IL10 (Yanaba et al., 2009). Subsequently a number of experimental 
models of chronic inflammatory conditions which helped further studies of different 
regulatory pathways involved were developed (Mizoguchi and Bhan, 2006).  
I.8.2 B cells and immune regulation; the regulatory B cell: 
B cells, long known to be mediators of humoral immunity, are increasingly appreciated 
for other roles including antigen presentation, cytokine secretion and immune response 
modulation (Allman and Pillai, 2008). The regulatory function of B cells is mediated by a 
number of mechanisms such as cytokine and Ig production, interactions with other 
cellular subsets and Ag presentation. Although a number of studies have demonstrated 
the regulatory function of a bulk of B cells without denoting a specific regulatory subset, 
it is most likely that one or more B cell subsets possess these regulatory abilities. They 
are collectively referred to as regulatory B cells. So far, the most extensively studied 
regulatory B cell population is the IL10 producing B cell.  
IL10 producing B cells are directly involved in the suppression of inflammatory  immune 
responses of both the innate and adaptive immune systems (Mizoguchi and Bhan, 2006).  
IL10 reduces antigen presentation and expression of co-stimulatory molecules, blocks 
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cytokine production and modifies chemokine receptor expression, culminating in 
restraint of T cell activation to specific immune responses. Some of the IL10 
immunoregulatory function can be attributed to the induction of Tr1 differentiation 
(Pestka et al., 2004). Although IL10 is produced by a variety of immune cells, IL10-
producing B cells appear to play a nonredundant role in immune regulation (Madan et 
al., 2009). Other cytokines produced by B cells, such as TGF-β, IL12 and IL4, have also 
been shown to induce immune tolerance (Gonnella et al., 2001, Parekh et al., 2003, 
Sugimoto et al., 2007, Tian et al., 2001). In addition, regulatory B cells either recruit or 
act in unison with the wider immune regulatory network in cytokine dependent and 
independent ways to exert their immunomodulatory effects (Ray et al., 2012). Breg 
maintain the FoxP3+ regulatory pool, promote the conversion of effector T cells to FoxP3- 
IL10+ producing Tr1 cells and recruit CD4+ CD8α+ T cells (Carter et al., 2011, Wei et al., 
2005, Ray et al., 2012).  
A major role for Breg is the suppression of pathogenic effector immune cells such as Th1 
and Th17 (Carter et al., 2012), and modulation of Th2-mediated responses (Fillatreau et 
al., 2002). This property is mediated via secretion of anti-inflammatory cytokines, in 
particular IL10, and through direct cell to cell contact. In addition, Breg negatively 
regulate APC function, thereby breaking the effector inflammatory circuit (Lo-Man, 
2011).  
Another mechanism by which B cells may regulate immune responses is by inducing 
apoptosis of pathogenic T cells (Lundy, 2009). A suppressive B cell subset expressing Fas 
ligand, designated killer B cells, was shown to induce apoptosis of arthritogenic T cells, 
thereby reducing the inflammation (Lundy, 2009). 
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B cells may also indirectly contribute to immune regulation through immunoglobulin 
production, for instance, Ig mediated DC suppression, clearance of pathogenic apoptotic 
cells and immune complexes and potentially via the production of anti-inflammatory 
IgG4 (Hussaarts et al., 2011); figure (I-2). 
I.8.3 Regulatory B cell functions:  
Regulatory B cells play a critical role in reducing self-destruction and autoimmunity by 
controlling autoreactive T cells. It has been observed that IL10 producing B cells control 
autoreactive CD4 as well as MCMV-specific CD8+ T cells in two different mouse models 
of adoptive therapy (Knoechel et al., 2005, Madan et al., 2009). Endogenous B cells 
prevented the differentiation of effector autoreactive T cells that follows the initial 
expansion of T cells (Knoechel et al., 2005)  and played a significant role in recruiting 
other regulatory cells (Wei et al., 2005). There is evidence that LPS activated B cells with 
regulatory function suppress APC function, thereby breaking the autoreactive cycle (Tian 
et al., 2001).  Regulatory B cells also help induce or maintain immune tolerance to self-
antigens released from apoptotic cells (Gray et al., 2007). Recently, Breg were shown to 
react to DNA bearing apoptotic cells by IL10 production in a TLR9 dependent way (Miles 
et al., 2012). Another potential role of Breg is in the regulation of neonatal immune 
responses, by fostering Th2 biased environment to limit the harmful systemic effects of 
exacerbated Th1 responses (Sun et al., 2005). In addition to the protective immune 
suppression of regulatory B cells in variable inflammatory processes, the same property 
can be exploited by pathogens and tumour cells to escape immune responses (van der 
Vlugt et al., 2012, Schioppa et al., 2011, Jeong et al., 2012). 
68 
 
Notably, Breg are not detected in the normal state and develop at the sites of 
inflammation, either in vivo or in vitro, in an Ag specific and non-specific way (Mizoguchi 
et al., 2002). 
  
I.8.4 Regulatory B cells: polyclonal versus antigen specific 
Studies in animal models suggest that regulatory B cells are capable of responding both 
in an antigen specific as well as in an innate-like polyclonal manner. One could propose 
that in the antigen specific model (Fillatreau et al., 2002), Breg are recruited to the 
centre of induced inflammation, in close vicinity to the antigen, and are likely to require 
T cell help to undergo expansion in the local draining lymph node. This process will 
require a longer time and the suppressive effect may be limited to the specific antigen 
only. In the non-specific model, bystander regulatory B cells are induced via their 
interaction with activated CD154-expressing T cells or pathogen particles such as un-
methylated DNA regardless of antigen specificity, and are therefore likely to be more 
abundant in the periphery to prevent progression of the inflammatory process. In the 
second scenario, the response is fast and will comply more with the innate immune 
system. In fact, experimental data support the existence of both proposed mechanisms 
(Wei et al., 2005, Yanaba et al., 2009).  
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Figure I-2 : Regulatory mechanisms of IL10-producing B cells 
A. Different regulatory mechanisms of induced IL10-producing Breg on effector and other 
regulatory immune cells, B. Breg may interfere with tumour clearance through suppressing 
tumour specific cytotoxic cells and C. other potential IL10-independent regulatory mechanisms 
displayed by B cells. Figure adopted from Mauri et al (Mauri and Bosma, 2012). 
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I.8.5 Regulatory B cells in mouse models: 
Studies in murine models of chronic inflammation including experimental autoimmune 
encephalomyelitis (EAE), inflammatory bowel disease (IBD) and collagen-induced 
arthritis (CIA) have elegantly shown that the absence of B cells intensifies the 
pathological condition, whereas the adoptive transfer of regulatory B cells attenuates 
the pathology (Yanaba et al., 2009).  
I.8.5.1 Induction of regulatory phenotype in B cells:  
The activation of regulatory B cells either by challenging with target antigens or using 
external stimuli is required to induce the regulatory function.  A number of studies have 
shown that engagement of various toll-like receptors (TLR), for instance, TLR2, TLR4 or 
TLR9 induces IL10 and to a lesser degree IL-6 production by marginal zone B cells, while 
follicular B cells respond mainly by producing IFNγ and IL6 (Mauri and Bosma, 2012, Barr 
et al., 2007, Lenert et al., 2005). In addition, multiple studies have identified CD40-CD154 
crosslinking as an essential step for Breg activation. Mizoguchi et al, have shown that in 
a TCRα-/- and αμ-/- mouse model characterised by severe and spontaneous ulcerative 
colitis mediated by pathogenic TCRα- TCRβlo CD4+ T cells, adoptive transfer of CD40-/- B 
cells fails to suppress the pathogenic T cells (Mizoguchi et al., 2000). Although some 
studies have suggested a role for BCR-mediated pathways, the data remain 
contradictory (Yanaba et al., 2009, Mauri and Bosma, 2012). Other co-stimulatory 
molecules such as CD80 and CD86 have also been shown to play a potential role in 
induction of cellular tolerance in murine models of transplantation. These data suggest 
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that direct cellular crosstalk may be even more important than cytokine mediated 
immune suppression (Deng et al., 2007). 
I.8.5.2 Regulatory IL10+ B cell phenotype(s): 
More than one phenotype of B cells have been proposed to define Breg; however, it 
remains unclear if these subsets of regulatory B cells  are distinct or share the same 
development pathways (Mauri and Blair, 2010). In murine models, IL10 producing B cells 
were found to be enriched in the spleen and gut-associated lymphoid tissue; with a 
phenotype similar to MZ B and their precursors T2 MZP B cells i.e. CD19+, CD1dhi 
(Mizoguchi et al., 2002). Subsequently, a subset of B cells dubbed (B10), expressing CD5 
and CD1dhi CD19hi CD21int/hi CD23loCD24hiCD43+/-CD93- was shown to produce IL 10 upon 
stimulation and reduce inflammation in contact hypersensitivity response and EAE 
models (Yanaba et al., 2009), (Yanaba et al., 2008, Watanabe et al., 2010, Matsushita et 
al., 2008).  Other groups have defined IL10 producing B cells as marginal zone B (MZB) 
cells; CD21hiCD23−CD24hiIgMhiIgDloCD1dhi (Gray et al., 2007), or marginal zone 
precursors (T2-MZP), which share the same phenotype with the exception of CD23 
positivity, reported to be expressed by regulatory B cells in collagen induced arthritis 
(Mauri et al., 2003, Evans et al., 2007, Blair et al., 2009). In another study Madan et al 
reported IL10 production in both splenic and lymphoid organ B cells, as well as 
CD19+CD138+ plasma cells (Madan et al., 2009). Similarly, in a recent study 
implementing IL10 reporter mice, B10 cells,  
IgMhiCD1dhiCD5+CD19hiCD23lowCD38hiB220hi, could differentiate into CD138+ B cells, 
capable of secreting both IgM and IgG (Maseda et al., 2012).  
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Despite differences observed in the phenotype of IL10 producing B cells, these cells 
share overlapped expression of some markers such as CD1dhi, IgMhi, CD38hi and CD24hi. 
Whether these different Breg are one or more specialised subsets and whether or not 
they share one origin remains unclear; figure (I-3). Breg studies will remain suboptimal 
until the identification of a specific marker or constellation of markers, or a unique 
transcriptional factor that can be assigned to Breg, analogous to Foxp3 in Treg.  
I.8.5.3 IL10 independent Breg cells: 
A distinct subset of suppressive B cells expressing CD5 and Fas ligand, designated killer 
B cells ( CD5+ , CD178+), was shown to induce apoptosis of arthritogenic T cells, thereby 
reducing inflammation (Lundy, 2009).  
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Figure I-3: Phenotypic profiles of IL10-producing Breg in mice 
Summarises the phenotypic profile of the two main subsets of IL10 producing Breg in mice; 
namely, T2-MZP and B10 cells. The colour code depicts shared and unshared surface markers by 
both cell subsets. Adopted from Mauri et al(Mauri and Blair, 2010a).  
 
I.8.6 Human regulatory B cells: 
Similar to murine B cells, human B cells are capable of producing cytokines under 
different conditions. Human B cells stimulated with CpG and CD40L produce IL10 among 
other cytokines (Gantner et al., 2003, Wagner et al., 2004).  
I.8.6.1 Human IL10+ regulatory B cells: subset(s) and phenotype(s) 
To date, studies of regulatory B cells in humans have defined these cells as IL10 
producing with more than one phenotype.  
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Evidence for IL10-dependent, B cell mediated immune regulation in humans, was first 
described by Duddy et al (Duddy et al., 2004). The authors reported that B cells produce 
distinct profiles of cytokines, depending on the stimulation condition; whereas CD40 
ligation alone  favoured IL10 production, dual stimulation with CD40L  in combination 
with BCR cross-linking favoured secretion of pro-inflammatory cytokines (Duddy et al., 
2004). Subsequently, they showed that IL10 producing B cells are contained within the 
naive CD27- B cell population, while memory B cells preferentially produce pro 
inflammatory cytokines such as IL6, TNFα and lymphotoxin. In another study, naïve B 
cells (defined as CD11b−CD5−CD27− and IgD+) from MS patients infected with intestinal 
helminths were shown to produce more IL10 compared to the subnormal levels of IL10 
reported in non-infected MS patients. In vitro, IL10 producing B cells from helminth-
infected MS patients were shown to suppress CD4+ T cell proliferation and IFNγ 
production in response to an MS associated Ag (Correale et al., 2008).  
In agreement with this, Blair et al, using sort purified B cell subsets from healthy controls, 
showed that Breg are enriched within the CD24hi CD38hi transitional (Tr) B cell 
compartment, and mediate their suppressive function on CD25- CD4+ effector T cells 
through the production of IL10 but not TGFβ. Co-culture of transitional B cells with T 
cells resulted in significant suppression of IFNγ and TNFα production by effector T cells 
(Blair et al., 2010). Interestingly, Bouaziz et al showed that IL 10 producing human B cells 
exist across both CD27+ and CD27-CD38hi transitional B cells(Bouaziz et al., 2010). In their 
experimental setting, suppression of CD25- CD4+ effector T cell function was partially 
IL10 dependent. Similar observations were reported in relapsing remitting MS (RRMS) 
patients. Whereas in remission, 60% of IL10 producing B cells had a naïve CD27- 
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phenotype, the majority of Breg during relapsing periods were CD27+ (Knippenberg et 
al., 2011). Recently, a subset of Breg analogous to mouse B10 was characterised in the 
peripheral blood of healthy controls by Tedder et al. The group found that IL10 
producing regulatory B cells and their  progenitors are enriched within CD24hi CD27+ B 
cells (Iwata et al., 2010). Although no specific inhibitory impact on effector CD4+ T cells 
was shown, CD24hi CD27+ B cells inhibited proliferation and cytokine production by 
CD14+ monocytes. The identified B10 subset expressed markers of memory B cells such 
as CD27 and CD148. Similarly, Miles et al recently reported that in response to DNA 
bearing apoptotic cells, human IgM- and IgM+ CD27+ memory B cells produce significantly 
more IL10 than CD27- naïve B cells (Miles et al., 2012). 
I.8.6.2 Human regulatory B cells in disease conditions: 
Human regulatory B cells have been studied in a number of autoimmune conditions 
where immune dysregulation is implicated. Mouse models of chronic inflammation have 
substantiated an indispensable role for B cells in preventing, as well as alleviating, 
destructive immune responses.   
In agreement with the likely involvement of Breg in autoimmune disease, B cells derived 
from active multiple sclerosis (MS) produced less IL10 compared with normal controls 
(Duddy et al., 2007, Correale et al., 2008). Interestingly, remission induction using 
mitoxantrone or following autologous HSCT was associated with restoration of IL10 
production by B cells (Duddy et al., 2007). This observation provides a potential role for 
impaired Breg function in the pathogenesis of MS. Similarly, although Tr B cells, believed 
to be enriched in Breg, are increased in SLE patients, their IL10 production and 
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suppressive properties are compromised. Furthermore, Breg from SLE patients are more 
refractory to CD40 activation (Blair et al., 2010). Idiopathic thrombocytopenic purpura 
(ITP) is another example of broken self-tolerance with circulating anti-platelets 
antibodies. In a recent study, Li and colleagues reported reduced IL10 production by B 
cells, measured by intracellular cytokine staining techniques, in a cohort of ITP patients 
off treatment.  B cells from ITP patients exerted reduced suppressive effect on CD14+ 
monocytes. Interestingly, IL10+ B cell frequency and their suppressive effect on 
monocyte function improved in ITP patients who responded to therapy. The authors did 
not phenotype IL10+ B cells, nor did they sort enriched populations to carry out 
functional studies. They reported reduced transitional B cell frequencies in ITP patients, 
and based on previous published studies, they assume that IL0 B cells are enriched 
within this population (Li et al., 2012b). 
In contrast, human B10 cells were found to be increased and exhibited  higher IL10 
production than healthy controls in 90 patients with a variety of autoimmune disorders 
including SLE (Iwata et al., 2010). Similarly, higher frequencies of IL10+ B cells were 
recently reported in patients with untreated active sarcoidosis compared to patients 
with inactive disease and healthy controls. This was associated with increased BAFF 
level, hypergammaglobulinaemia and contracted memory and expanded transitional 
compartments. The authors proposed that these cells act as a “rheostat” to control 
inflammation (Saussine et al., 2012). In a recent study, spondylarthritis patients were 
shown to have increased CD5 expressing B cells, mainly naïve and IgM+ memory B cells, 
compared with RA patients and HC. Upon in vitro stimulation with anti BCR but not CpG, 
these cells produced IL10 (Cantaert et al., 2012). The findings of the latter two studies 
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suggest that the increase in B10 cells may be a compensatory response to restrain the 
autoimmune process.  
Another disease where regulatory B cells might be involved is helminthic infections.  
There is some evidence that induced Breg might be exploited by some pathogens to 
evade or dampen the effective immune responses.  B cells from MS patients infected 
with intestinal helminths produced more IL10 than both non-infected MS patients and 
healthy controls (Correale et al., 2008). In addition, Schistosoma haematobium-infected 
children had increased PB IL10 producing CD1dhi B cell number compared with 
uninfected healthy controls (van der Vlugt et al., 2012). Another example comes from 
the recently published work by Das et al showing that patients with chronic hepatitis B 
virus infection have higher IL 10 levels as well as increased frequencies of IL10+ B cells. 
IL10 producing B cells were found to be enriched within the CD19+CD24hiCD38hi 
immature population and suppressed HBV-specific CD8+ T cell responses in an IL10–
dependent manner (Das et al., 2012). Although increased IL10 availability may protect 
from extensive liver damage, it will inadvertently suppress viral specific CD8 T cell 
responses.    
Overall, there is ample evidence for the existence of human Breg and their derangement 
in autoimmunity, although these cells are not yet fully characterised. Whereas impaired 
Breg function may fail to dampen a self-targeted immune insult, resulting in excessive 
uncontrolled immune responses, an increase in induced Breg might in turn be exploited 
by some pathogens to evade effective immune responses. In analogy one may argue 
that cancer cells may use similar strategies to evade immune surveillance. Furthermore, 
little data exist on the potential role of B cells in GVHD as an auto-allo-immune condition. 
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Hypothesis and Aims 
The limited understanding of immune mechanisms that underlie the development of 
graft-versus-host disease (GVHD) hinders our ability to develop effective targeted 
therapies that could improve the survival of patients undergoing allogeneic 
haematopoietic stem cell transplantation (HSCT). There is increasing evidence that 
donor and/or recipient B cells are deranged in GVHD; whether this is a cause or effect is 
not yet known. 
I hypothesise that B cells play a crucial role in induction of chronic GVHD and that the 
development of chronic GVHD is associated with an abnormal pattern of B cell recovery.  
I further propose that an imbalance in effector: regulatory B cell ratio during immune 
reconstitution in the recipient, determines the occurrence of GVHD and autoimmune 
phenomena frequently seen following SCT.  
The specific aims of this thesis are: 
1. To design a comprehensive phenotypic and functional B cell panel to study 
human B cell subsets 
2. To evaluate the pattern of B cell recovery in patients with cGVHD by comparing 
them with SCT patients with no cGVHD and healthy controls. 
3. To characterise human IL10 producing B cells in healthy controls and assess 
their regulatory properties 
4. To examine IL10+ B cells in patients with cGVHD compared to patients without 
cGVHD.             
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Chapter II. Material and methods 
II.1 Patients: 
Informed consent for the use of patient material was obtained from all patients at 
Imperial NHS Trust, Hammersmith Hospital. The study was approved by both the 
National Research Ethics Committee (NREC) and  local R&D reviewboard. Peripheral 
blood mononuclear cells (PBMC) were collected from patients undergoing allo-HSCT 
prospectively before and at regular time points following allo-HSCT: days 30, 60, 90, 180 
days post-transplant.                
Informed consent for the use of archived patient material was obtained from all patients 
at initial presentation to Imperial NHS Trust, Hammersmith Hospital. 
II.2 Sample processing: 
II.2.1 Isolation of peripheral blood mononuclear cells:  
A maximum of 20-30ml of whole blood was collected from patients and healthy controls. 
PBMC were isolated using density gradient separation technique (Lymphoprep). Briefly, 
15 ml of EDTA anticoagulated whole blood was diluted 1:1 with RPMI 1640 media 
(GIBCO / Invitrogen) in a 50ml falcon tube and 10ml of Lymphoprep (Axis Shield, UK) 
was gently layered under the diluted blood. After centrifugation at 1800 rpm for 30 min, 
the interface layer between plasma and Lymphoprep, which contains mononuclear cells, 
was collected and re-suspended in fresh RPMI 1640. Cells were washed twice with RPMI 
1640 media and centrifuged at 1200 rpm for 10 min. PBMC were re-suspended in 10% 
foetal calf serum (FCS)/ RPMI, cells were counted and cell viability was assessed using 
Trypan Blue (TB). 
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II.2.2 Plasma collection: 
One heparinised blood sample (7ml) per patient was obtained at each collection time-
point. The sample was centrifuged at 2500 rpm for 30 minutes. The clear supernatant 
was gently aspirated to avoid contamination with blood components. Multiple plasma 
aliquots per patient were then frozen at -20° C for future batch ELISA assays.    
II.2.3 Cell freezing: 
PBMC were suspended in freezing media (RPMI-CM with 20% foetal calf serum (FCS) 
and 20% Dimethyl Sulphoxide (DMSO) (Sigma-Aldrich, UK) on ice and aliquoted into 
cryovials and stored in -80° C (max 1 week) before transfer to liquid nitrogen. 
II.2.4 Cell thawing: 
Cryovials of PBMC were transferred from liquid nitrogen on dry ice. Each vial was thawed 
in a water bath at 37 ºC. Once thawed  PBMC were  transferred immediately to a 15 ml 
falcon tube containing 10 ml thawing media (RPMI 20% FCS containing 50,000 unit 
DNase). PBMC were centrifuged at 1200 rpm for 10 min, pelleted and re-suspended in 
1 ml of media for cell count and viability assessment. 
 
II.3 Cell lines- L cells and control cells: 
Frozen CD154 (CD40L) expressing transfected fibroblasts (L cells) with their 
corresponding CD154 negative control (cntl) cells were kindly donated by Dr. Simon 
Wagner. To ascertain that CD40L is indeed expressed on CD40L transfected L cells, 
CD154 expression was assessed by Fluorescence-activated cell sorting (FACS) analysis 
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after staining with CD154-PE mAb, figure (II-1). Cell aliquots were kept in the -80° C 
freezer and thawed as required following the protocol outlined in II-2.4. 
L cells were grown in complete RPMI 1640 (Sigma-Aldrich), supplemented with 12.5 
μg/ml Gentamicin, 5 μM HEPES both from (GIBCO/ Invitrogen, Paisley, UK), and 10% 
FCS. Once cells were confluent in the vented T25 culture flasks, the culture media was 
removed and the adherent L cells were incubated with 1 to 2 ml of 0.05% Trypsin-EDTA 
(GIBCO/ Invitrogen Cat. 25300-054) at 37°C for 3 min. L cells were then detached by 
gentle tapping of the flask and washed by centrifugation. Cells were then frozen as 
outlined in section II-2.3 and stored at – 80 ° C before transfer to liquid nitrogen.  After 
trypsinisation, the viability of L cells was checked and CD154 was confirmed to exclude 
any impact of trypsin on CD154 expression (Stelzer et al., 1997). Periodic checks of the 
CD154 expression were performed to assure that the level of expression was not 
reduced by frequent passaging.  In addition, contamination of L-cells by mycoplasma 
was intermittently checked for using specific DNA probes and PCR .   
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Figure II-1: CD154 expressing L cells and their controls 
A. Staining of CD154- cntl cells and B. CD154+ L cells with the isotype control (left) and 
CD154 PE (right).  
 
 
 
 
 
A.
B.
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II.4 B cell culture and activation protocol: 
II.4.1 ELISA experiments:  
The experiments were performed using CD19+ B cells selected from fresh or frozen 
PBMC. CD19+ selected total B cells were plated at a concentration of 2x105 cells per well 
in 200 μl of 10% FCS in complete RPMI 1640 (Sigma-Aldrich), supplemented with 12.5 
μg/ml Gentamicin, 5 μM HEPES both from (GIBCO/ Invitrogen, Paisley, UK), in U-bottom 
96-well plates (BD FalconTM, Oxford, UK). B cells were stimulated for 72 hours with CpG 
OND200- 5G (InvivoGen, USA) at a dose of 0.1, 0.2 or 0.8 μg/ml in a humidified incubator 
at 37 °C with 5% CO2. L cells were irradiated (60 Gy), plated and rested for a minimum 
of 1 hour and added to  CD19+ selected B cells at a ratio of one L cell to 10 B cells (1:10), 
(from here on referred to as BL condition). In other experiments, CD19+ selected B cells 
were first incubated with F (ab’) 2 Goat anti Human IgG+ IgM (H+L) (Jackson 
ImmunoResearch Laboratories, USA) for one hour to engage the B cell receptor (BCR) 
followed by L cells (1 L cell: 10 B cell) for 48 to 72h, (from here on referred to as BXL 
condition). At 72 hours of culture, the plates were centrifuged at 1200 rpm for 5 
minutes. A hundred and fifty μl of the supernatant was collected from replicate wells 
into eppendorf tubes and frozen at - 20°C for batch ELISA analysis.  
II.4.2 IL10 quantitative ELISA: 
IL10 was assayed using OptEIA ELISA kits (BD PharningenTM, San Diego, CA), following 
the manufacturer’s protocol. Briefly, after washing and blocking of the plate with 50 μl 
ELISA diluent, 100 μl of sample per well were incubated for 2 h at room temperature. 
Following five washings, the samples were incubated with 100 μl of the appropriate 
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detection antibodies for one hour at room temperature. Finally, after seven washings, 
colour was developed using 100 μl provided (TMB) tetramethylbenzidine reagent per 
well and incubated for 30 minutes at room temperature in the dark. Fifty microlitres of 
the stop solution was added and the absorbance was read at 450 nm within 30 minutes 
of stopping of the reaction. The sensitivities and linear ranges were obtained using the 
provided standard cytokine and test sample dilutions were determined accordingly, 
figure (II-2). 
 
 
Figure II-2: Example of standard curves for IL 10 detection (n = 6). 
 
II.5 Cell selection 
II.5.1 B cell selection: 
B cells were selected from fresh and frozen PBMC using human B cell isolation kit II 
(Miltenyi Biotec Ltd), an indirect magnetic labelling system for the isolation of 
untouched B cells, following the manufacturer’s protocol.  Briefly, PBMC were washed 
using MACS Buffer (autoMACSTM rinsing solution and MACS BSA both from Miltenyi 
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Biotec Ltd). A total of 107 cells were then re-suspended in 40 μl of MACS buffer. 
Subsequently, 10 μl of Biotin-antibody cocktail against CD2, CD14, CD16, CD36, CD43, 
and CD235a (Glycophorin A) was added per 107 of total cells and the mixture incubated 
in the refrigerator for 10 minutes. Thirty μl of MACS buffer and 20 μl of anti-Biotin micro-
beads were then added to the tube and incubated in the refrigerator for another 15 
minutes. A final wash using the buffer was undertaken and the pellet resuspended in 
500 μl of MACS buffer. The suspension was applied to primed MS MACS columns 
(Miltenyi Biotec Ltd) and an additional 3 volumes of the buffer were used to wash the 
columns. The pass through which contained the purified unlabelled B cells was then 
centrifuged at 1200 rpm for 10 minutes. The pellet was re-suspended in RPMI/FCS 10% 
to achieve the required cell concentration. B cell purity was confirmed by staining the 
cells with anti-CD19 PE (BD PharmingenTM Cat# 555413) and was consistently between 
88.5%-99%, figure (II-3) 
 
Figure II-3: Purity checks of B cell selection 
Purity of selected B cells from a healthy donor stained with CD19 PE and analysed by 
FACSCalibur.  
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II.5.2 T cell selection: 
II.5.2.1 Total CD4+ T cell selection: 
CD4+ T cells were selected from fresh PBMC using human CD4 T cell isolation kit II  
(Miltenyi Biotec Ltd), an indirect magnetic labelling system for the isolation of 
untouched CD4+ve T cells, following the manufacturer’s protocol.  
Briefly, PBMC were washed using MACS Buffer (autoMACSTM rinsing solution and MACS 
BSA both from Miltenyi Biotec Ltd). A total of 107 cells were then re-suspended in 40 μl 
of MACS buffer. Subsequently, 10 μl of Biotin-antibody cocktail against CD8, CD14, 
CD16, CD19, CD36, CD56, CD123, TCR γ/δ, and CD235a (glycophorin A) was added per 
107 of total cells and the mixture incubated in the refrigerator for 10 minutes. Thirty μl 
of MACS buffer and 20 μl of anti-Biotin micro-beads were then added to the tube and 
incubated in the refrigerator for another 15 minutes. A final wash using the buffer was 
undertaken and the pellet resuspended in 500 μl of MACS buffer. The suspension was 
applied to primed MS MACS columns (Miltenyi Biotec Ltd) and an additional 3 volumes 
of the buffer were used to wash the columns. The pass through which contained the 
purified unlabelled T cells was then centrifuged at 1200 rpm for 10 minutes. The pellet 
was re-suspended in RPMI/FCS 10% to achieve the required cell concentration. The 
purity of the CD4+ T cell purity was confirmed by staining the cells with anti-CD4 PerCP 
(BD Cat# 555413) and was consistently between 90%-99%; figure (II-4).  
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Figure II-4: Purity checks of T cell selection 
Purity of selected CD4+ T cells from a healthy donor was determined by staining with 
CD4 PerCP and analysed by FACSCalibur.  
 
II.5.2.2 CD4+CD127loCD25- and Treg magnetic selection “Treg 
depletion”: 
CD4+CD127loCD25- cells were selected from fresh PBMC using  CD4+ CD25+ CD127dim/- 
regulatory T cell isolation kit II human (Miltenyi Biotec Ltd), an indirect two-step 
magnetic labelling system for the isolation of Treg cells, following the manufacturer’s 
protocol.  Briefly, PBMC were washed using MACS Buffer (autoMACSTM rinsing solution 
and MACS BSA both from Miltenyi Biotec Ltd). A total of 107 cells were re-suspended in 
40 μl of MACS buffer. Subsequently, 10 μl of Biotin-antibody cocktail were added per 
107 cells to magnetically remove non CD4+ and CD127 hi and the mixture incubated at 
+4o C for 10 minutes. Thirty μl of MACS buffer and 20 μl of anti-Biotin micro-beads were 
then added to the tube and at +4o C for 15 minutes.  
A subsequent wash using the buffer was undertaken and the pellet suspended in 500 μl 
of MACS buffer. The final suspension was applied to LD MACS columns (Miltenyi Biotec 
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Ltd) and 3 volumes of the buffer used to wash the columns. The flow-through which is 
enriched for CD4+ cells was then centrifuged at 1200 rpm for 10 minutes. In step two, 
the pellet was re-suspended in 90 μl of MACS buffer followed by 20 μl of CD25 
MicroBeads. The mixture was incubated for 15 min on ice and finally washed and re-
suspended in 500 μl of MACS. This cell suspension was passed through an LS MACS 
magnetic column. The pass through contains untouched CD4+ cells depleted of Treg 
(CD4+CD127loCD25hi) and the column contains labelled Treg that were flushed out by 
firmly pushing the plunger into the column. The cells are then checked for viability by 
staining in Trypan blue, counted and seeded in plates as required. 
The purity of both subsets was confirmed by staining the cells with anti-CD25, anti-CD4 
and anti-CD127 and was found to be consistently between 80-90%; figure (II-5). 
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Figure II-5: Purity check of Treg selection  
A. Purity of selected Treg cells from a healthy donor was determined by staining with 
CD127 FITC, CD25 PE and CD4 PerCP. B. Phenotype of the flow through (depleted of 
Treg) shows CD4 purity of 90% and lower CD127 expression (CD127loCD4+) (grey) 
compared to total CD4+ T cells (black) 
 
II.6 Cell sorting: 
II.6.1 Sample preparation and sorting: 
B cells subsets: 
Cell sorting was performed using BD FACS Aria IIu at the FACS core facility, Respiratory 
Sciences, St Mary’s hospital. 
Briefly, freshly prepared PBMC were stained with 2 µL of FITC anti-CD27 
DakoCytomation (# F7178), 10 µL of PC7 anti-CD19 BC/Immunotech (# 3628) and 2 µL 
A.
B.
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of PerCP cy5.5 anti-IgM (# 561285) for 30 min. Positive controls for each individual 
parameter were included in addition to the negative unstained control.   One microlitre 
of Propidium Iodide (PI) was added to samples prior to sorting to assess their viability. All 
samples were filtered prior to sorting to prevent aggregates clogging the 70 μm nozzle. 
A concentration of 107 cells/ml of sorting medium was determined to achieve a sorting 
efficiency of > 80%.   In view of the rarity of some target populations and to reduce 
sorting time and improve cell viability, enrichment for CD19+ cells using a B cell Miltenyi 
isolation kit (section II-5.1) was undertaken in some experiments.  
The gating strategy for B cell subset sorting is presented in figure (II-6). Four CD19+ B cell 
subsets, namely IgM memory (CD27+ IgM+/hi), transitional B cells (CD27- IgM+/hi), 
switched memory (CD27+ IgM-) and naive B cells (CD27- IgM+) were sorted in purity 
sorter mode; figure (II-7). Purity checks were undertaken at the end of each sort to 
ensure high purity population; typically 99%. 
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Figure II-6:  Gating strategies of B cell sorting 
Multicolour flow cytometric gating strategy for B cell subset sorting on BD FACS ARIA IIu. 
Following a lymphocyte gate, cell doublet and dead cell discrimination, live cells (PI-) are 
further gated for CD19+ B cells. CD19+ B cells are then sorted based on CD27 and IgM 
expression into 4 subsets, namely IgM memory, transitional, naïve and switched 
memory B cells.  
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Figure II-7: Purity checks of B cell sorting 
FACS plots demonstrating the high purity of sorted B cell subsets are shown within the 
CD19+ gate  
 
The sorted population were collected in 12 X 75 mm sterile polypropylene tubes 
containing MACS buffer solution and transferred to culture media (10% FSC in RPMI-
1640 complete media) to minimise apoptosis. 
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II.7 Proliferation Assay: 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a cell permeable division 
tracking dye that is retained within cells and covalently couples to intracellular 
molecules. The dye allows the monitoring of lymphocyte proliferation, both in vitro and 
in vivo, in view of the progressive halving of CFSE fluorescence within daughter cells 
following each cell division (Hawkins et al., 2007).  
Freshly isolated PBMC were re-suspended in PBS at cell concentrations of 2.5 to 5 × 
106/ml. For each independent experiment, CFSE (65-0850; eBioscience, USA) was 
diluted from a stock solution (500µg/ml; stored at -20oC in DMSO) to reach final 
concentration of 2 µM. This was achieved by adding 2 µL of aliquoted CFSE per each ml 
of prepared sample and mixing well; in experiments where the sample volume was 
greater than 5 ml, cells were vortexed following the addition of CFSE to achieve uniform 
cell labelling. After incubation for 10 minutes at room temperature in the dark, 2 to 3 
volumes of neat FCS were added to the tube for 5 minutes to stop the labelling process. 
Labelled cells were seeded into a flat-bottom 96-well tissue culture plates at a 
concentration of 2x105 per well in 10% FCS/RPMI and incubated for 96h at 37ºC with 5% 
CO2.  
FACS analysis was undertaken after 96 hours on the FACSCalibur to assess cell 
proliferation. CFSE labelled unstimulated cells, incubated for the length of the 
experiment, served as negative control, and stimulated cells as positive controls. The 
proliferation of the test lymphocytes was interpreted relative to the negative and 
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positive controls. The percentage of dividing cells, proliferation index and rounds of 
divisions were calculated using FlowJo’s, Treestar flow cytometry analysis software, 
proliferation platform; figure (II-8).  
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Figure II-8 : CD4 and CD19 proliferation assay 
Proliferation of gated CD4+ (top) and CD19+ cells (bottom) following stimulation of PBMC with anti-CD3 and anti-CD28 beads. Dot 
plots and histograms show the serial dilution of CFSE as with each cell division, the CFSE is divided between the two daughter cells. 
FlowJo is used to generate data related to the proliferation index.  
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II.8 Phenotypic and functional characterisation of B cells using 
flow cytometry:  
II.8.1 Intracellular cytokine assay for detection of IL10+ B cells and 
phenotyping:  
The experiments were performed using either CD19+ selected B cells derived from fresh 
or frozen PBMC or total PBMC. To determine the kinetics of IL10 production using 
intracellular cytokine assay, CD19+ selected B cells or total PBMC were stimulated with 
irradiated L cells at a ratio of 1:10 for 6, 18, 24, 48 and 72 hrs. PMA (50ng/ml), Ionomycin 
(250 ng/ml) and Brefeldin A (5 µg/ml) were added for the last six to eight hours of the 
incubation. The aim was to determine the incubation time points at which maximal IL10 
production could be achieved without major activation induced alterations of B cell 
phenotype. 
To investigate whether T cells are capable of inducing B cells to produce IL10, PBMC 
were stimulated with CD3/CD28 Dynabeads® Human T –activator (Invitrogen, Oslo, 
Norway) for 72h in a humidified incubator at 37 °C with 5% CO2. At the end of the culture 
duration, T cell activation defined as upregulation of CD154 was examined by flow 
cytometry with anti CD154 PE and CD4 PerCP. Using intracellular cytokine assay, IL10 
production was assessed on gated CD19+ B cells. 
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II.8.2 Phenotypic analysis of IL10 producing B cells:  
For IL10+ B cell characterisation PBMC were stimulated with irradiated L cells for 12 to 
15 hours. PMA (50 ng/ml), Ionomycin (250 ng/ml) (Sigma Aldrich) and Brefeldin A (5 
µg/ml) (Golgi-plug Sigma Aldrich) were added for the last 6-8h of the culture. Cells were 
harvested, washed in staining buffer (1x PBS, 2% heat-inactivated FCS, 0.1% Sodium 
Azide) and incubated for 20 min at room temperature with a cocktail of CD19-PE, CD3 
PerCP, (BD Biosciences), CD22 FITC, CD24 FITC, CD5 FITC, BAFFR FITC, CD1d PE, CD27 PE, 
IgD PE, CD40 PE and IgM PerCP Cy5.5, all from BD PharmingenTM, CD21 FITC and FCRL4 
PE (BioLegend) and CD38 PE Cy7 (eBioscience).  Cells were then washed with staining 
buffer and fixed/permeabilised for 30-45 min at 4C with intracellular staining kit 
(eBioscience).  At this stage, 20 µl of FcR Blocking Reagent, Miltenyi Biotec (120-000-
442), was added. Without washing, cells were incubated for 30 min at 4C with the 
following antibodies: 10 µl of FITC conjugated anti-TNFα, 10 µl of FITC conjugated IFN-γ 
or 5 µl of FITC conjugated IL-2 and 0.5 µl of either APC conjugated IL10 or IgG2aК isotype 
antibodies. All incubations were performed in Perm-wash solution. Cells were washed 
twice with perm-wash and re-suspended in staining buffer at approximately 0.5-1 x105 
cells per tube prior to acquisition using BD FACSCalibur (Becton Dickinson). Data analysis 
was performed using FlowJo® software; figure (II-9). The volume of IL10 monoclonal 
antibody was determined in dose titration experiments. The volume which resulted in 
maximal mean fluorescence intensity (MFI) and maximal percentage of positively 
stained cells with minimum background (negative control) was selected.  
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Figure II-9: Intracellular staining of IL10  
A representative FACS plot illustrating intracellular IL10 production when PBMC from a 
healthy control were stimulated with L cells from a healthy donor for 48 h. A. IgG2aκ 
isotype control B. IL10  
 
II.8.3 Phenotypic characterisation of B cells: 
B cell Phenotyping using an extended panel of surface antibodies:  
The relatively unique multidimensional nature of flow cytometry allows for particular 
cell populations to be identified through the use of specific staining and various gating 
strategies. The selection of fluorochromes was optimised in light of the commercially 
available options and the instrument configuration; lasers and detectors and the 
intended cell markers.   
A panel of 9 antibodies (as defined in Table II-1) was used to determine the following B-
cell subsets: 
 
A. B.
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Transitional B cells: CD10+, CD19+, CD21-/lo, CD24hi, CD27-, CD38hi, IgMhi and IgD+  
Naïve B cells: CD10-, CD19+, CD21+, CD24-/lo, CD27-, CD38+, IgM- and IgD+ 
Pre Germinal Centre: CD10+, CD19+, CD21hi, Cd24-, CD27+, CD38hi, IgM + and IgD +  
Memory B cells; isotype switched: CD10-, CD19+, CD21+, CD24-/lo, CD27+, CD38+/-, IgM- 
and IgD-  
IgM memory or marginal zone B cells (MZB cell): CD10-, CD19+, CD21+/hi, CD24-/lo, CD27+ 
CD38 lo/-, IgM+/lo and IgD+/lo  
Tissue like memory cell, exhausted B cells: CD10-, CD19+, CD21-, CD24-, CD27-, CD38 -, 
IgM - and IgD- 
Plasmablasts: CD10-, CD 21-, CD24 –, CD 38hi, CD27+/hi IgM- and IgD- 
II.8.3.1 Antibody titration: 
Each individual antibody was titrated to determine the concentration at which high 
resolution of the desired populations was achieved with minimal loss of population 
positivity. The optimum titre or dilution is the concentration which gives the best 
staining with minimum background / nonspecific binding (Hulspas et al., 2009).  
Briefly, serial dilutions of each antibody were made in 3 fold increments starting from 3 
times the recommended volume, if the concentration was unknown. Whenever the 
concentration of the tested Ab was provided by the manufacturer, the titration started 
from three times the recommended quantity and down to the desired final dilution. 
Samples and experimental conditions, including staining methods and cell numbers, 
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were identical to that of the intended experiment. Unstained controls were used to set 
up the flow cytometer and define the negative populations. Histograms were generated 
for each antibody dilution and gates were drawn based on the unstained control and 
the clarity of the positive peaks. However, when the positive population was small 
and/or the separation from the negative events was not clear enough to ascertain the 
gates, bivariate plotting against forward or side scatter was used. The gates were 
manually adjusted at higher concentrations to make for the right-shift of the background 
accompanying the high concentrations especially when there was clear delineation of 
the different populations.   
Using FlowJo, the MFI and percentages of positive and negative populations as well as 
the standard deviation of the negative population were determined. 
The stain index (S.I) takes into account the width of the background and the distance 
from the positive population (Hulspas et al., 2009) and is defined as MFI of the positive 
population – MFI of the negative population (background)/2x standard deviation of the 
background (Hulspas et al., 2009) figure (II-10). 
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Figure II-10 : stain index 
Stain index: The effective brightness of an antibody depends on the distance (D) between the 
positive (red) and the negative (blue, green) populations and the width of the negative 
population (W); adopted from reference.(Maecker, 2009) 
 
 
The calculated stain index and median fluorescence intensity acquired from single 
stained samples of the studied antibodies’ serial dilutions were then plotted against the 
antibody concentrations; figure (II-11). The concentration with the highest stain index, 
an MFI close to the saturation segment on the MFI curve and the smallest drop in the 
percentage of the positive portion was chosen for each individual antibody.  
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Figure II-11: Antibody titration: CD21 APC 
An example of antibody titration: CD21 APC. MFI of the positive population (MFI+) and 
S.I. are plotted against increasing CD21 APC volumes. The asterisk indicates that 1 to 3 
μl/100μl of the antibody is the optimum concentration as it represents a high S.I. and 
MFI before the saturation plateau.   
 
II.8.3.2 Cell staining and FACS acquisition: 
Briefly, approximately 1 × 106 of fresh or thawed PBMC were stained with 1µl of the 
viability marker invitrogenTM LIVE/DEAD Fixable Aqua Dead cell stain Kit cat# L34957 
(L_D) for thirty minutes in the dark at room temperature. Cells were then washed and 
incubated with the cocktail of mAb (table II-1) at the titrated concentrations in x1 PBS 
in the dark for a further 30 min at room temperature. Subsequently, stained cells were 
washed once more before acquisition on a three-laser BDTM LSRII (BD Biosciences). 
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Instrument setup was standardised to reduce experiment-to-experiment variation. 
Cytometer Settings & Tracking (CST) beads (Becton Dickinson) were run daily, by the 
core facility laboratory, St Mary’s Hospital, at the pre-optimised detector PMT voltages. 
Colour compensation was accomplished by using a mixture of negative and positive 
antibody-capture beads (BDTM Comp Beads) singly stained with the panel antibodies. 
Before sample acquisition, PMT values were adjusted using unstained cells to exclude 
auto-fluorescence and to control the intensity of the background; normally by 
restraining the negative population below log 102. The single-stained beads were then 
run and checked individually to ensure that each stain was the brightest in its own 
channel before acquisition of 5000 events per tube. 
The compensation matrix of acquired control tubes was computed using FACSDiva 
(automated and acquisition defined) and exported with FACS files or using FlowJo 
compensation editor at later analysis.  Manual compensation was rarely used and only 
on occasions when optimal adjustment of the spectral overlap between the different 
fluorochromes did not allow compensation by the software.  
Data analysis was performed using FlowJo (v.7.6.5) software (Tree Star) on live cell gate 
as shown in figure (II-12). 
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Figure II-12 : Gating strategies of B cell surface phenotyping  
A. The gating strategy is presented here: Following a lymphocyte gate, cell doublet and 
dead cell discrimination, live cells (L_D-) are further gated for CD19+ B cells. B. Dot plots 
of live/dead positive (L/D) control. PBMC are exposed to high temperature in boiling 
water bath (positive control). The right dot plot illustrates the dead population in red, 
that uptakes the dye with the corresponding location on the forward and side scatter 
dot plot on the left. 
A.
B.
B.
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Table II-1: antibodies used for B cell characterization: 
 
 
 
 
 
 
 
 
Antibody Volume μl Manufacturer Description Clone
CD19 APC H7 5 BD PharmingenTM Pan B cell marker (BCR activation) SJ25C1
CD21 APC 3 eBioscience complement component receptor 2 HB5
CD24 FITC 5 BD PharmingenTM B cell proliferation and maturation HB5
CD27 PE 5 BD PharmingenTM TNF-receptor superfamily M-T271
IgD v450 5 BD HorizonTM Surface antibody IA6-2
IgM PerCP cy5.5 3 BD PharmingenTM Surface antibody G20-127
CD38   PE Cy7 3 eBioscience Ectoenzyme (calcium signalling) HIT2
CD10 Qdot® 605 1 InvitrogenTM membrane metallo-endopeptidase MEM-78
Aqua florescent 
reactive dye 
1 InvitrogenTM Live/Dead marker binds to intracellular 
amines of dead cells
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II.9 In vitro suppression Assay: 
II.9.1 Proliferation Suppression: 
To assess the suppressive properties of sorted B cell subsets on the proliferation of 
CD4+ve T cells, B cells were co-cultured with CFSE stained CD4 T cells in vitro.  
Total CD4+ or CD127-/dim CD4+ T cells were magnetically selected as described in section 
II.5.2.2, and labelled with CFSE (section II.8). Labelled cells were seeded in 96-well flat-
bottom tissue culture plates and FACS sorted B cell subsets including IgM memory, 
switched memory and naïve were added to separate wells at a B cell-to-T cell ratio of 
1:1 in a total volume of 200 µL of 10% FCS in supplemented RPMI medium; maximum 
cell count in each well was 2x105 per well. T cells were activated by adding Dynabeads® 
human T- activator CD3/CD28 (InvitroGen, Oslo, Norway) at a concentration 2µl/8x105 
cells following the manufacturer’s protocol. CFSE stained T cells cultured with no 
stimulation (negative control) and CFSE stained T cells cultured with CD3/CD28 coated 
beads (positive proliferation control), were included in each experiment for reference. 
Furthermore, selected Treg were co-cultured with tested autologous CD4 T cells as 
quality control of suppression, as shown table (II-2). The plate was then incubated at 
37ºC in the presence of 5% CO2 for 96 hours, at which point the cells were harvested 
from the wells and transferred into FACS tubes. Following one wash, cells were stained 
with APC anti-CD4 and PE anti-CD19 (both from BD Biosciences) for 20 min and acquired 
on BD FACSCalibur. 
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Table II-2: experimental conditions for CFSE suppression assay 
 
 
II.9.2 Suppression of cytokine production:  
To assess the suppressive effects of sorted B cell subsets on cytokine production by CD4+ 
T cells, magnetically selected total CD4+ or CD127-/dim CD4+ T cells (II.5.2) were seeded 
into a 96-well flat-bottom tissue culture plate, to which the FACS sorted B cell subsets, 
namely IgM memory, switched memory and naïve B cells were added at a B cell-to-
effector T cell ratio of 1:1 as described in II.9.1. Negative and positive controls were 
included with each experiment for reference as shown in table (II-3). The plate was then 
incubated at 37ºC in the presence of 5% CO2 for 48 hours.  Brefeldin-A (BFA) (Sigma 
5mg/ml DMSO cat# B-7651) was added for the last 5 hours of the culture at a final 
concentration of 10μg/ml. At the end of the culture period, the cells were harvested 
from the wells and transferred into FACS tubes. Following one wash, cells were stained 
in a 2-step process; the first step involved surface staining with anti-CD19 PE, CD4 PerCP 
Condition CD4+ / CD4+ CD25- CFSE CD3/CD28 Subset
Negative Control + + - -
Positive proliferation control + + + -
Positive quality control + + + Treg
Condition 1 + + + IgM memory
Condition 2 + + + Switched 
memory 
Condition 3 + + + Naive 
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(both from BD Biosciences) for 20 min. Cells were fixed and permeabilised using the 
eBioscience FoxP3 Staining Buffer Set (cat.72-5776) and eBioscience Permeabilisation 
Buffer (1x) (cat. 00-8333) as per manufacturer’s protocol. For the second step, 
intracellular antibodies IFNγ FITC and TNFα APC were added for 25 minutes. After the 
last wash, samples were acquired on BD FACSCalibur and analysed using FlowJo. 
Table II-3: Experimental conditions for cytokine production suppression assay 
 
II.9.3 IL10 blocking:  
To assess whether suppression could be mediated through IL10 from B cells, IL10 
receptors were blocked using Purified NA/LE rat anti-human CDw210 (BD PharmingenTM 
cat# 556011). The antibody was added to the wells at a concentration of 2 μg /ml on day 
0 of the culture. Production of IFNγ and TNFα by stimulated CD4 T cells was assessed in 
the presence or absence of IL10 blocking antibody as described in section II.9.2. 
Condition CD4+ / CD4+ CD25- CD3/CD28 Subset
Negative control + - -
Positive proliferation 
control
+ + -
Positive quality control + + Treg
Condition 1 + + IgM memory
Condition 2 + + Switched 
memory 
Condition 3 + + Naive 
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Chapter III. B cell subset and characterization of CD21- B cells in 
healthy controls 
III.1 Introduction 
B cells are divided into a number of subsets ranging from immature to mature terminally 
differentiated cells. Immature B cells with non-self-specificity survive the scrutiny of 
immune surveillance and differentiate into more mature stages in the periphery. 
Knowledge of B cell subsets and their phenotypic characteristics is essential for studying 
B cell involvement in both health and disease. A number of B cell classifying schemes 
have been used to identify B cells subsets; Bm1-Bm5, CD27/IgD and CD24/CD38, figure 
(III-1 A to D). Correlation between different classifications has been addressed by Sanz 
et al (Sanz et al., 2008).  
Bm1-Bm5 classifies B cells in the human tonsil based on relative expression of IgD and 
CD38 (Bohnhorst et al., 2001). Five categories are separated: virgin naïve cells (Bm1: 
IgD+CD38−); activated naïve cells (Bm2: IgD+CD38+); pre-GC cells (Bm2`: IgD+CD38++); GC 
cells (Bm3-centroblasts and Bm4-centrocytes, both are IgD−CD38++); and memory cells 
(Bm5: IgD−CD38+/−) which are further divided into early Bm5 (CD38+) and late Bm5 
(CD38−). All memory B cells (BM5) are IgD- which makes this scheme inherently unable 
to recognise IgM+CD27+ memory B cells. Moreover, IgM memory B cells which are IgD+ 
will fall into the Bm1 or Bm2 region. Bm1-Bm5 can be therefore applied to identify PB B 
cells with the exception of GC B cells which do not normally circulate. 
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The second classiﬁcation is based on the expression of CD27 and IgD (Maurer et al., 
1992). This strategy implements CD27 as a universal marker of human memory B cells 
to distinguish between CD27+ memory and CD27- antigen-naïve B cells. In the peripheral 
blood, naïve as well as transitional B cells are CD27-IgD+, therefore, this classification 
does not distinguish naïve and transitional B cells. Furthermore, the CD27- fraction also 
includes isotype switched CD27- IgD- memory B cells. CD27+ memory cells are subdivided 
into IgD+ (usually co-expressed with IgM+ or alone in a minor fraction of memory cells) 
and IgD− isotype switched (predominantly IgG+ or IgA+). A major limitation of these two 
classifications is that they do not identify transitional B cells as an independent category. 
Another scheme uses CD24 and CD38 (Carsetti et al., 2004) to classify B cells into four 
subsets: CD24hiCD38hi transitional B cells, CD24+CD38+ naïve B cells, CD24hi CD38lo 
memory B cells and CD24-CD38hi plasmablasts. Memory B cells are defined in one 
population regardless of their isotype status. Immature/ transitional B cells can be 
further characterised based on other markers expression such as IgM, CD10 and CD21 
(Suryani et al., 2010, Carsetti et al., 2004, Palanichamy et al., 2009). 
The above-mentioned classifications do not include CD21 expression to define B cell 
subsets despite the fact that CD21-/lo B cells have be shown to be expanded in a number 
of diseases. In health, there is scanty literature about this cell population. Four B cell 
groups have been reported to lack CD21 expression; namely, activated memory cells, 
early transitional B cells, plasmablasts and exhausted B cells (Moir et al., 2008). 
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In this chapter I aim to validate an extended panel of monoclonal antibodies against a 
number of B cell antigens, in addition to CD21, CD10, IgM and IgD to define B cells more 
comprehensively. Titration of the monoclonal antibodies is crucial to optimise the 
separation of cell populations and to assure reproducibility and comparison of the 
phenotype plots. I implemented the panel to phenotype B cell subsets in the PB of 
healthy individuals. I also defined CD21- B cells more comprehensively. 
 
Figure III-1: CD19+ B cell classifications 
Gated CD19+ B cells are plotted according to the three classifications A. CD24/CD38: 
Transitional (Trans), memory, naïve and plasmablasts (PB). B. IgD/CD27: naïve (Q1), IgM 
memory B cells (Q2) and switched memory B cells (Q3) with IgD-CD27hi PB encircled. C. 
Bm1-Bm5 classification with D. schematic representation and subsets.    
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III.2 Results 
III.2.1 Titration of monoclonal antibodies and flow cytometry settings 
Each antibody was titrated as outlined in section II.8.3.2 The same number of PBMC was 
stained with serial dilutions of anti-CD21 APC. Standard lymphocyte gating and 
subsequent gating of CD21+ and CD21- populations was performed. Gates were adjusted 
according to positive and negative populations. Standard deviation of the negative 
population and the Median Fluorescence Intensity (MFI) of both negative and positive 
populations were calculated using the FlowJo software. The stain index was calculated 
as [(MFIpos - MFIneg)/ 2xSDneg] and a scatter plot of Antibody Concentration versus Stain 
Index was generated.  The concentration of mAb that yielded the maximum Stain Index 
with the best separation of negative and positive populations, while achieving a high 
positive frequency, was considered the optimal volume to be used in subsequent 
experiments. As shown in figure (III-2), 1 µl of anti-CD21 APC, associated with the 
highest stain index (SI=24.5), was considered the optimal volume to use per 100 µl of 
sample.  
Similar analyses were performed for each of the remaining antibodies and optimal 
concentrations were determined. Finally, the chosen mAbs concentrations based on 
single staining titrations were combined in one panel, table (III-1). 
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Table III-1:  titrated antibodies’ volumes in the final master mix 
 
 
 
 
 
 
 
 
 
Reagent (µL) CompBeads Master mix
CD24 FITC 3 1
CD27 PE 3 1
CD19 APCH7 1 .5
CD38 PC7 1 1
CD21 APC 1 1
CD10 QDOT .4 1
IgM PerCP-Cy5.5 1 1
IgD v450 1 1
Total antibodies volume (µL) 11.4 7.5
Sample volume (µL) 0 92.5
Final volume (µL) 50 100
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Figure III-2: Stain index and MFI: CD21 APC 
Stain index and median fluorescence intensity (MFI) titration curves for anti CD21-APC: 
5×105 cells were stained with serial amounts of anti CD21-APC. Unstained cells were 
used as negative control. Calculated stain index and MFI of the positive population were 
plotted against the corresponding antibody volume. Three microlitres was determined 
to be the optimal volume as it corresponds to the highest S.I. and MFI. 
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III.2.2 Characterisation of human B cell subsets and panel validation 
III.2.2.1 Transitional B cells 
Using the titrated panel of mAbs, and in keeping with published data, CD24hiCD38hi 
transitional B cells were mostly CD27- (~ 97%), IgD+ and IgMhi. Around 32% (21.5%- 
42.6%) of gated CD24hiCD38hi B cells expressed CD10, indicating that these cells are the 
most immature subset in the PB, figure (III-3). In studies of B cell repopulation, the most 
immature transitional cells were shown to be CD10+ with the highest expression of CD24 
and CD38. In keeping with these data, CD10+ transitional B cells in my samples also 
expressed high levels of CD24 and CD38. Dividing transitional B cells phenotypically into 
T1 and T2 revealed that T1 were more immature, expressing CD10 and completely 
lacking CD21; figure (III-4).  
Around 20% (11.5%- 23.1%) of CD24hiCD38hi transitional B cells did not express CD21. 
Interestingly, the majority of CD10+ transitional B cells were negative for CD21. Gaining 
CD21 expression marks the transition to more mature transitional and naïve B cells and 
follows the known T1 to T2 pattern.  
I also correlated the phenotype of CD24hiCD38hi transitional B cells with the other two 
classification systems; figure (III-5 A). CD24hiCD38hi B cells overlaid the Bm2` pre-GC 
region defined by IgD and CD38 of Bm1-Bm5 classification. With respect to the IgD/CD27 
scheme, CD24hiCD38hi transitional B cells were mainly contained within the CD27-IgD+ 
naïve B cells; although they did not fall within a distinctive population, as transitional B 
cells express lower IgD than naïve cells. In contrast, transitional B cells fell within the 
CD27-IgMhi B cells when analysed in relation to IgM and CD27. This distinct location 
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makes it possible to sort an enriched transitional population using IgM and CD27, figure 
(III-7). 
 
Figure III-3: Surface expression of B cell markers   
Surface expression of CD10, CD21, CD27, IgM and IgD of CD24-CD38hi plasmablasts 
(yellow), CD24+CD38+ naïve B cells (green), CD24hiCD38lo memory B cells (blue) 
andCD24hiCD38hi transitional B cells (red). Fluorescence minus one controls were used 
to determine positive populations (grey). 
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Figure III-4: Transitional B cell subsets: T1, T2 and T3 
A. Transitional B cells are gated into T1, T2, T3 based on CD24 and CD38 expression in a 
reconstituting patient post SCT. T1 B cells, most immature transitional cells, have the 
highest expression of both CD24 and CD38. B. Histograms compare the differential 
expression of CD10, CD21 and IgD. T1 (red) are mostly CD10+CD21- and express highest 
level of these markers. T2 (blue) gain gradual expression of CD21 and lose CD10 
expression as they mature. T3 (yellow) and naïve (green) share similar expression of 
these markers  
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III.2.2.2 Naïve B cells 
Using the optimised antibody panel, and in keeping with previously published reports, 
the majority (~ 95%) of gated CD24+CD38+ naive B cells were CD27-, IgD+, IgM+, CD10- 
and CD21+, figure (III-3).   
CD24+CD38+ naïve B cells mainly overlaid Bm2 activated naïve B cell and early Bm5 
regions in relation to IgD and CD38. Only a minority of the gated CD24+CD38+ naïve B 
cells correlated with Bm1 early naïve B cells. In fact, gated Bm1 (IgD+CD38−) B cells were 
divided between CD24hiCD38hiCD27+ memory and CD24+CD38+CD27- naïve B cells, which 
challenges the labelling of Bm1 as naïve B cells. With regard to the IgD/CD27 
classification scheme, CD24+CD38+ naïve B cells were expectedly within the CD27-IgD+ 
naïve B cell subset figure (III-5 B). In addition, naïve B cells fell within CD27-IgM+ B cells 
when analysed according to IgM and CD27, figure (III-7). 
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Figure III-5: B cell subsets correlation with different B cell classifications 
Colour coded gating of B cell subsets according to CD24/CD38 with their phenotypic 
correlation with IgD/CD27, IgM/CD27 and IgD/CD38 classifications; A. transitional (red), 
B. naïve (blue), C. memory (green) and D. plasmablasts (yellow).  
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III.2.2.3 Memory B cells 
In keeping with published phenotype, ~ 85% of gated CD24hiCD38- memory B cells were 
CD27+ and mostly CD10- and CD21+, figure (III-3). Around 20% of the CD27- fraction was 
double negative for IgM and IgD suggesting that they are CD27- memory B cells. Adding 
the CD27- memory B cells, around 13% of cells of gated CD24hiCD38- B cells were 
phenotypically naïve B cells. This gating strategy doesn’t allow the distinction between 
switched and non-switched memory B cells. Further analysis revealed that around 40% 
were switched memory B cells and remaining proportion IgM+ or IgM+IgD+ cells.  
CD24hiCD38- memory B cells overlaid early and late Bm5 memory B cell and some of Bm1 
regions. As regard to the IgD/CD27 classification scheme, CD24hiCD38- memory B cells 
were expectedly within the CD27+ quadrants; both switched and non-switched memory 
B cells, figure (III-5 C).  Using IgM and CD27, memory B cells overlaid CD27+IgM+/hi non-
switched memory B cells and CD27+IgM- switched memory B cells, figure (III-7). 
IgM+IgD+ and IgM-IgD- memory B cells were examined for CD24, CD38 and CD27 
expression. Non-switched memory cells expressed higher CD24, measured by MFI, 
(12200 vs. 7626; p=0.02), lower CD27 (966 vs. 2700; p=0.0006) and similar CD38 (1197 
vs. 1143, p= 0.6) respectively, figure (III-6A). Both subsets were superimposed on each 
other in the CD24hiCD38- memory region. When compared with regards to IgD and CD38, 
Bm1-Bm5 classification, IgM-IgD- memory B cells overlaid early and late Bm5 subset and 
IgM+IgD+ memory B cells fell between Bm1 and Bm5, figure (III-6B). 
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Figure III-6: Memory B cells 
A. IgM+CD27+non switched (red) and IgM-CD27+ switched (green) memory B cells are 
overlaid on total CD19+ B cells (grey) with their corresponding representation in 
CD24/CD38 and IgD/CD38  schemes. Switched memory B cells fall under early and late 
Bm5, while non-switched memory B cells are superimposed on Bm1, naïve cells, and 
partly on Bm5. B. Switched memory B cells express higher CD27, lower CD24 and 
equivalent CD21 and CD10 compared with non-switched memory B cells. C. CD27- 
memory B cells were determined from total CD19+ cells and as being double negative 
for IgD and IgM. D. CD27- memory B cells (red) and total CD19 (grey) overlay:  CD27- 
memory B cells are superimposed mainly on memory and plasmablast regions when 
plotted against CD24 and CD38.   
 
Although CD27 is used as a universal B cell memory marker, around 5% of PB B cells are 
CD27- B cells(Sanz et al., 2008). My panel allows the study of this subset based on isotype 
status; IgM and IgD, as well as assessing CD24 and CD38 phenotype. I found that around 
3% (1.2%-4.6%) of peripheral blood B cells were CD27- and double negative for IgM and 
IgD. This population was mainly CD24hiCD38- or CD24-CD38hi which substantiates the 
memory origin of these cells. Of interest, the presence of CD27- cells within the CD24-
CD38hi plasmablast region suggests that these memory cells may also differentiate into 
effector cells, figure (III-6C and III-6D).   
III.2.2.4 Plasmablasts 
CD24-CD38hi plasmablasts expressed higher levels of CD27 compared with memory B 
cells. Most of the gated plasmablast population did not express IgM or IgD in keeping 
with their function. In addition, this population did not express CD10 or CD21; figure (III-
3).    
CD24-CD38hi plasmablasts B cells mainly fell over Bm3+4 in relation to IgD and CD38. 
With regard to the IgD/CD27 classification scheme, plasmablasts were observed in 
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CD27hiIgD- position and CD27hiIgM- B cells when analysed according to IgM and CD27, 
figure (III-5D). 
 
Figure III-7: IgM/CD27 B cell classification scheme 
Colour coded B cell subsets plotted according to IgM and CD27 expression. Five distinct 
populations can be enriched transitional (red), naïve (blue), switched (dark green), non-
switched (light green) and plasmablasts (yellow) 
 
III.2.2.5 CD21- B cells  
Gated CD19+CD21- cells were first analysed for the expression of CD27. CD27+ cells were 
mainly distributed between CD24hiCD38lo activated memory cells and CD24-CD38hi 
plasmablasts. IgM+IgD+ non-switched and IgM-IgD- switched memory phenotypes were 
observed within this population. The CD27- fraction overlaid CD24hiCD38hi transitional B 
cell and extended into CD24+CD38+ naïve B cell. A second population of CD21-CD27- cells 
CD27
Ig
M
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was also observed. These cells were CD24-CD38- and mostly negative for CD10, figure 
(III-8). The latter phenotype is reminiscent of exhausted B cells described in chronic HIV 
viraemia (Moir et al., 2008).  
The observed subpopulations discussed above varied between healthy subjects. More 
detailed analysis was hindered by the low number of events detected in the CD21- B 
cells subpopulations in view of the low frequencies of total CD21- B cells in PB of healthy 
individuals.  
 
Figure III-8: CD21- CD19+ B cells inter-individual variation  
CD21- CD19+ B cells from 2 healthy representatives were subdivided according to CD27 
expression into CD27+ (red) and CD27- (blue). A. SUB1; The majority of CD21-CD27- B 
cells fell under CD24hiCD38hi transitional B cells and some under naïve B cells. CD21-
CD27+ fraction in this case were mainly CD38hiCD24- plasmablasts. B. SUB 2; Fewer CD21-
CD27- (transitional) and more in CD24-CD38- (exhausted cells). CD21-CD27+ fraction were 
mainly CD24hiCD38lo activated memory cells and CD38hiCD24- plasmablasts in addition 
to a proportion in the CD38-CD24- quadrants.  
  
SUB 2SUB 1
CD38
C
D
2
4
CD38
C
D
2
4
A. B. 
124 
 
  
III.2.3 Peripheral blood B cell subset frequencies  
17 healthy volunteers (10 males and 7 females) were phenotyped using the extended 
panel. The median age of the volunteer cohort was 33.5 y (21 to 47).  
III.2.3.1 B cell subsets 
On average CD19+ B cells comprised 5.6% (3.34%-11.4%) of peripheral blood 
lymphocytes. Antigen naïve; transitional (CD24hiCd38hi) and CD24+CD38+ naïve B cells 
constituted 4.5% (2.7%-7.6%) and 60% (42.2%-74.6%) of the total CD19+ B cells 
respectively.  
Antigen experienced B cells; memory B cells (CD24hiCD38lo) and CD24-CD38hi circulating 
plasmablasts comprised 26.8% (17.6%-47.1%) and 0.9% (0.3%-4.43%) of total CD19+ B 
cells, respectively. Likewise, CD27+ memory B cells constituted 29.3% (12.7%-43.8%) of 
PB CD19+ cells. This population was further divided according to IgM and IgD expression 
into four subsets: double negative isotype switched (median 45.7%, range 19.7%-
63.6%), double positive IgM memory B cells (median 45.29%, range 29.2%-75.7%), IgM 
only expressing (median 6.15%, range 1.65%-11.7%) and IgD only expressing (median 
3.02%, range 1.45%-5.5%) of total CD27+ memory B cells, figure (III-9). 
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Figure III-9: B cell subsets in healthy controls 
FACS analysis of B cell subsets in healthy controls (n=16). A. B cell subset frequencies out 
of total CD19+ B cells defined as per CD24/CD38 scheme. B. CD27+ memory B cells 
subdivision according to the expression of IgM and IgD. Percentages of the four 
subpopulations out of CD27+ memory B cells, IgD only, IgM only, double positive  and 
double negative are shown. 
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III.2.3.2 CD21- B cells 
The majority of circulating B cells expresses CD21; an essential molecule for B cell 
activation and function. Expanded populations of CD21- B cells have been observed in 
chronic inflammatory conditions. Therefore, we studied the phenotype of CD21-B cells 
and their representation in the peripheral blood of healthy volunteers.   
Approximately, 3.5% (1.02%-7.54%) of circulating CD19+ B cells lacked CD21 expression; 
CD21-CD19+. CD21- B cells were gated on B cells that lacked CD21 expression using an 
FMO control for CD21. Further analysis of this population revealed that 45.3% (18.8%-
71.10%) were CD27+, suggesting that a proportion of this population have undergone 
somatic hypermutation. The majority [65.04% (34.2-84.6%)] of CD21-CD27+ B cells 
carried switched isotype i.e. negative for both IgM and IgD. This phenotype most likely 
represents the activated memory B cells. In addition, it includes the CD27hiIgM-IgD- 
plasmablasts that naturally lose CD21 expression.  
The remainder of CD21- B cells [54% (28.9-81.2%)] did not express CD27 i.e. these cells 
are Ag naïve B cells. Almost half expressed IgM, IgD or both which makes this population 
likely to be transitional B cells. The other half [46.69% (15.10-72.50%)] did not express 
IgM or IgD. This phenotype did not fall within any of the ‘conventional’ B cell subsets; 
however, it shared similarity with exhausted B cells described in chronic HIV patients.  
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III.2.3.3 Gender has no effect of B cell subsets  
Next, I compared the frequency of B cell subsets based on gender (10 males and 7 
females), median age 33.5 (21-45) vs. 34 (24-55); p=0.58. I found no significant 
difference in the percentage of memory B cells defined as both CD24hiCD38lo and CD27+ 
(35% vs. 43.8%; p=0.59) and naïve B cells defined as CD24+CD38+ and CD27- B cells (62% 
vs. 45.2%; p=0.8) in females compared to males, respectively. In addition, the frequency 
of total CD19+ B cells, CD21- B cells, transitional B cells and plasmablasts were 
comparable between the two groups.   
III.2.3.4 Effect of Cryopreservation of the frequencies of B cell subsets 
Aliquots of same healthy control samples were frozen in order to study the effect of 
cryopreservation on the extended phenotype panel. Samples were frozen in liquid 
nitrogen for a minimum of 2 months before performing the surface staining.   
Frozen samples yielded comparable FACS plots with distinctive populations similar to 
the freshly obtained ones, figure (III-10A). There was significantly more CD19+ B cells, 
out of lymphocyte gate, in the frozen samples compared with their corresponding fresh 
ones; 8.06% (4.9%-21.05%) vs. 4.6% (3.34%-11.4%) ; p=0.005. Out of the CD19+ gate, 
lower frequency of CD27+ events was observed in the frozen than the fresh samples, 
23.9% (11.5%- 41.3%) vs. 29.1% (12.7%- 43.8%); p=0.0004. However, the difference was 
concordant i.e. in one direction; figure (III-10B).  
The frequency of B cell subsets were also compared between frozen and fresh samples 
based on CD24 and CD38 expression. There was no significant difference between the 
observed frequencies of transitional B cells; p=0.47, naïve B cells; p=0.75 and memory B 
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cells; p=0.8. The frequency of CD24-CD38hi plasmablasts was significantly lower in the 
frozen samples compared to their corresponding fresh counterparts; p<0.05.    
Although CD27+ CD19+ B cells were lower in frozen samples, the representation of both 
IgM+IgD+ memory B cells and switched memory B cells was comparable. The frequencies 
of CD10+CD19+ and CD21-CD19+ B cells were not different between frozen and fresh 
samples; figure (III-10). 
Overall, these results validate our panel to study frozen patient samples which are 
prospectively collected and cryopreserved for batched processing. 
 
CD38   
C
D
2
4
CD19
F
S
C
-A
CD27
F
S
C
-A
IgD
Ig
M
A. 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure III-10: Cryopreservation effect on B cell subset phenotypes  
Cryopreservation effect on B cell subset phenotypes. A. Data acquired from a 
representative frozen sample are depicted in various bivariate plots. Frozen samples 
produce interpretable plots and distinctive populations similar to fresh samples. B. 
Cumulative data comparing different B cell subsets between paired fresh and frozen 
samples, n=10. The results were analysed with two-tailed nonparametric paired t test 
analysis, *P<0.05, **P<0.01. 
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III.3 Discussion 
Different schemes have been used to classify B cells based on different B cell markers.  
Correlation between different subsets defined by one scheme with the same subset 
defined by another is not clear. A recent review by Sanz and colleagues has addressed 
the heterogeneity of memory B cell phenotypes in these classifications (Sanz et al., 
2008). 
Flow cytometry provides a powerful tool to study cell populations through the use of 
specific staining and various gating techniques. Titration of antibody is crucial to achieve 
optimal interpretable plots with the possibility to quantitate cell marker expression. 
Using the right amounts of the antibodies is particularly important to control 
background staining and to enhance the separation of negative and positive events 
(Baumgarth and Roederer, 2000).  
I implemented an extended phenotypic panel to correlate defined subsets by one 
scheme with the other two. The majority (~85%) of CD24hiCD38lo cells defined as 
memory B cells in the CD24/CD38 classification expressed CD27, a universal B cell 
memory marker. Moreover, the CD27+ fraction of the CD24hiCD38lo population was 
distributed among IgD+ and IgD- as well as IgM+ and IgM- B cell subsets when examined 
according to the IgD/CD27 and IgM/CD27 classifications.  A fifth of the CD27- fraction 
was double negative for IgD and IgM, which make these cells likely to be CD27- memory 
B cells. The remaining CD27- cells expressed IgM and IgD which classifies them as naïve 
B cells according to other schemes. This finding validates the CD24/CD38 definition for 
memory B cells, with the provision that a minority of naïve B cells may fall within this 
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gate, however this classification fails to distinguish switched and nonswitched memory 
B cells.   
CD24hiCD38lo and CD27+ memory B cells overlaid the early and late Bm5 region with a 
minority of events spilling into the bm2 naïve region. A major limitation of Bm1-Bm5 
classification for memory B cells (Bm5 group) is that it does not recognise IgM+ memory 
B cells as this population also expresses IgD. Interestingly, we found that IgM memory B 
cells had higher CD24 and lower CD27 expression, true to their lower level of somatic 
hypermutation (Weill et al., 2009). Plasmablasts, a minor circulating population (Piatosa 
et al., 2010) defined as CD24-CD38hi overlaid CD27hi IgD-, CD27hiIgM- and Bm5. 
Interestingly, gated CD24-CD38hi included isotype switched CD27- B cells which may 
indicate that CD27- memory cells differentiate towards plasmablasts.  
CD27- memory B cells form about 5% of total B cells (Sanz et al., 2008). Around 3% (1.2%-
4.6%) of peripheral blood B cells were CD27- and double negative for IgM and IgD. This 
population was mainly CD24hiCD38- memory B cells, or CD24-CD38hi plasmablasts, which 
substantiates their memory origin. Of interest, finding CD27- cells within the CD24-
CD38hi plasmablasts region may support that these memory cells also differentiate into 
effector cells. This analysis is based on the negative expression of IgM and IgD rather 
than positive expression of IgA or IgG.  
CD24hiCD38hi transitional B cells were mostly CD27-IgMhi and IgD+ in keeping with 
published data (Palanichamy et al., 2009). In my study 40% of CD24hi CD38hi transitional 
B cells were CD10+, marking the more immature cells (Carsetti et al., 2004). Interestingly, 
the majority of CD10+ transitional B cells were also CD21-, another feature of immature 
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transitional B cells (Suryani et al., 2010). Of note, I found that CD24hi CD38hi transitional 
B cells superimposed on Bm2’ pre-germinal centre cells of the CD38/IgD classification 
and on IgD+CD27- naïve B cells, which makes these classifications unsuited to study 
transitional B cells.  
Using the IgM/CD27 marker combination was equivalent to IgD/CD27 in separating the 
different B cell subsets, with one main difference. Transitional B cells (CD24hi CD38hi) 
were superimposed in the IgMhi region of the IgM+CD27- naïve B cell compartment, 
which allows this combination to identify four subsets and therefore be used as a sorting 
panel.  
CD21- B cells constituted around 4.5% of peripheral B cells in keeping with published 
data (Moir et al., 2008). Further analysis of CD21-CD19+ B cells revealed that this 
population could be allocated to 4 subsets.  CD27+ cells were mainly distributed among 
CD24hiCD38lo activated memory cells, both isotype switched and nonswitched, and 
CD24-CD38hi plasmablasts. The CD27- fraction constituted mainly transitional B cells and 
another population bearing phenotypical resemblance to exhausted B cells described in 
HIV patients (Moir et al., 2008).  More detailed analysis was hindered by the low number 
of events in each CD21- B cell subpopulations in view of the low frequencies of total 
CD21- B cells in the PB of healthy individuals.   
Finally, subset frequencies obtained by my panel were in keeping with published data 
(Palanichamy et al., 2009, Sanz et al., 2008). In our cohort, there was no statistical 
difference observed between age matched genders with regards to each subpopulation. 
A number of reports did not detect any gender-specific differences in total CD19+ B cells 
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(Jentsch-Ullrich et al., 2005). To the best of my knowledge, no studies compared B cell 
subsets between genders. 
Cryopreservation led to increased percentage of CD19+ events and reduced percentage 
of CD27+ memory B cells and plasmablasts. However, the difference was concordant and 
overall the panel produced distinctive populations. It is plausible that plasmablasts, 
defined as CD38hiCD24-, may not withstand the freezing process relative to naïve B cells. 
Importantly, I observed no effect of freezing on CD21 expression on B cells. A few studies 
reported conflicting effect of cryopreservation on total CD19+ B cell frequency. There 
was no effect on CD19+ percentage in thawed samples, however freezing increased 
CD19 MFI in one study (Romeu et al., 1992, Rosillo et al., 1995).  In another study, 
cryopreservation was associated with lower CD19+ frequency (Tollerud et al., 1991). 
Again to the best of my knowledge, no studies compared the effect of cryopreservation 
on B cell subset frequencies.  
Overall, the panel produced FACS plots and cell population frequencies comparable to 
published data. Furthermore, it provides a powerful tool to study B cell subsets and 
correlate the different schemes available for B cell classification.  
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Chapter IV. IL10 producing B cells  
IV.1 Introduction 
IL10 production as a trademark of regulatory B cells was introduced simultaneously in 
two different inflammatory models (Mizoguchi et al., 2002, Fillatreau et al., 2002). To 
date, IL10 producing B cells remains the most studied regulatory B cell population.  
In animal models, the regulatory potential of B cells is demonstrated in vivo by the 
amelioration or recovery of model-associated inflammatory conditions. A number of 
mouse models have been used for this purpose (Mizoguchi and Bhan, 2006). Early 
studies showed that lack of B cells, either by transferring inoculum, e.g. splenocytes, 
lacking B cells (Katz et al., 1974, Neta and Salvin, 1974) or generating B cell deficient 
knockout (KO) mice (Wolf et al., 1996) led to more severe inflammatory disease.  
Interleukin 10 produced by total B cells was shown to be instrumental in immune 
regulation using IL10 KO mice (Mizoguchi et al., 2002), chimera mice (Fillatreau et al., 
2002); where IL10 deficiency is limited to B cells, or by demonstrating the loss of B cell 
suppressive effect when B cells from IL10 KO mouse were transferred to normal 
recipient mice (Mauri et al., 2003). These studies investigated B cells as a whole and no 
phenotype was attached to IL10 producing regulatory B cells.  
Insight into the IL10 producing B cell phenotype was possible by using intracellular IL10 
staining technique and surface phenotyping or by measuring IL10 in supernatants of 
purified B cell subsets. Yanaba and colleagues found that IL 10-producing B cells shared 
features common to marginal zone (MZ), T2-MZ precursors, and CD1dhi CD5+ B-1a B cells 
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(Bouaziz et al., 2008).  Others detected higher amount of IL10 in the supernatant of 
purified MZ B cells in comparison with follicular B cells (Gray et al., 2007). A number of 
phenotypes have been reported by different groups for IL10+ regulatory B cells (Mauri 
and Blair, 2010a).  
In humans, two main phenotypes for IL10+ regulatory B cells have been reported, namely 
transitional and CD27+ memory B cells. In the study by Dr. Mauri’s group, IL10+ Breg were 
found to be enriched within the CD24hi CD38hi transitional B cell compartment. In an in-
vitro culture system, sorted transitional B cells displayed a suppressive effect on 
autologous effector CD4 T cells and reduced the production of IFNγ+ and TNFα+ by 
activated CD4+ T cells (Blair et al., 2010). Conversely, Iwata and colleagues reported that 
IL10+ Breg are enriched within the mature CD24hi CD27+ memory B cell subset. Although 
sort-purified CD27+ B cells failed to suppress CD4+ T cells directly, they exerted their 
suppressive effect through inhibiting cytokine production by CD14+ monocytes (Iwata et 
al., 2011). Other groups reported IL10 production across the transitional and memory 
compartments (Bouaziz et al., 2010). In these studies, IL10+ B cell frequencies were 
examined in a number of autoimmune conditions where immune dysregulation is 
implicated, with variable findings.  
Based on current available techniques and in the absence of specific cell markers, it is 
not possible to accurately define the phenotype of IL10+ B cells.  Searching for unique 
markers that enable purifying regulatory B cells to allow their study is highly warranted.  
The aim of my project was to optimise IC staining protocols for IL10+ B cells and to test 
their functional properties by assessing their suppressive activity in vitro.  
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IV.2 Results 
The purpose of this chapter is firstly to define human IL10 producing B cells in the 
peripheral blood and secondly to examine their suppressive properties against 
autologous CD4+ T cells. All data are presented as mean± SE and the unpaired two tailed 
T test is used unless otherwise specified. 
IV.2.1 In vitro production of IL10 by B cell 
IV.2.1.1 IL10 production by B cells from fresh PBMC:  
Human B cells have been shown to produce distinct patterns of cytokines under 
conditions designed to mimic bystander B cell activation (CD40 alone), or full dual 
stimulation (BCR and CD40).  BCR cross-linking with T cell help via CD154 (CD40L) leads 
to pro-inflammatory cytokine production, reflecting B cell reaction to a specific antigen, 
whereas stimulation via CD40L alone is associated with an anti-inflammatory cytokine 
profile (Duddy et al., 2004).  
Using the method outlined in section II.4.2, I found that un-stimulated selected B cells 
(mean purity 92%± 3.75) from 3 healthy subjects produced either no detectable cytokine 
or only small amounts of IL10 (mean 25±25 pg/ml, n=3).  Of note, irradiated CD154 
expressing fibroblasts (L cells) and their control counterpart, CD154- fibroblasts (cntl 
cells), produced only negligible amounts of IL 10 (mean 6.5± 6.5 and 21± 12 pg/ml 
respectively, n=3).  
When selected B cells, from 7 individuals, were stimulated with L cells alone at a ratio of 
1:10 (BL), high levels of IL10 (mean 4433± 803 pg/ml; n=7) were detected in the culture 
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supernatant compared with B cells cultured with cntl cells (mean 695± 140 pg/ml; n=3, 
p= 0.018), (5 independent experiments). Although dual stimulation, consisting of BCR 
crosslinking and co-culturing with L cells (BXL) induced IL10 production, the levels of 
cytokine measured in the supernatant were significantly less than that achieved 
following stimulation with CD40L alone (mean 636±274 pg/ml; n=7, p=0.0008); figure 
(IV-1). 
 
Figure IV-1: IL 10 ELISA  
Levels of IL10 measured by ELISA in the supernatant of purified B cells cultured for 72h 
with L cells, (BL), control cells, (Bcntl) and with L cells and anti-human IgG + IgM (H+L) 
(BXL). Purified B cells from healthy donors stimulated with L cells alone produced higher 
amount of IL10 compared with dual stimulation. Data were compared by statistical 
analysis with the two-tailed nonparametric t test analysis; ∗p < 0.05, ∗∗∗p < 0.0001. 
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I also observed high inter-individual variations in IL10 production. Notably, however, the 
intra-individual variability was minimal and the levels of IL10  produced following 
stimulation of B cells from the same individual in repeated experiments was highly 
reproducible  IL 10. 
IV.2.1.2 Effect of cryo-preservation on in vitro IL10 detection by ELISA: 
I tested the effect of freezing on IL10 production. A proportion of PBMC from three 
donors were frozen at -80oC for a minimum of four weeks. After thawing, the cells 
were rested overnight in a humidified incubator and B cells were selected as 
outlined in section II.5.1 The IL10 levels measured in the supernatant of selected B 
cells cultured with CD40 alone and following the dual stimulation protocol were 
(mean IL10 646± 264 pg/ml and 40± 21.9 pg/ml; n=3) respectively. Although 
measured levels of IL10 were lower in the frozen runs compared to their freshly 
prepared counterparts, the IL10 production pattern remained consistent among the 
three tested subjects. These results suggest that frozen samples can be used for 
cytokine detection provided that all samples are subjected to the same freezing and 
thawing conditions. 
IV.2.2 Intracellular staining for interleukin 10 in human B cells: 
Based on ELISA experiments, I used stimulation with L cells to optimise IL10 
intracellular staining of both selected and gated CD19+ B cells. Protein transporter 
inhibitors were added to enhance IL10 signals by blocking extracellular transport of 
the cytokine. Intracellular cytokine staining for IL10, IFNγ, and IL2 were carried out 
according to methods described in II. 8. 1.  
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IV.2.2.1 Optimising negative controls for IL10 intracellular staining  
A number of known negative controls were explored, namely, manufacturer 
recommended isotype control, (IgG2aκ), co-culture with CD154- cntl cells (PBcntl), 
unstimulated control incubated with BFA alone (unstimulated, BFA), FMO where 
anti-IL10 antibody was not added, and appropriately stimulated B cells without the 
addition of BFA (stimulated, no BFA).  
All tested negative controls produced comparable plots with clear separation of 
negative and positive populations; figure (IV-2). For most of the subsequent 
experiments I used isotype or unstimulated controls incubated with BFA alone. 
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Figure IV-2: Comparison of intracellular staining negative controls 
FACS plots compare gating strategies of IL10+CD19+ B cells based on available negative 
controls. Isotype control:  PBMC were stimulated for the same duration with L cells and 
PMA, Ionomycin and BFA were added for the last 6 hours of culture and subsequently 
stained with isotype control, IgG2aκ. Stimulated, no BFA control; cells were stimulated 
with L cells, PMA and Ionomycin and were stained with anti-IL10; BFA was not added to 
this control. Bcntl: PBMC were cultured with CD154- fibroblasts for same duration and 
stained with anti-IL10 after the addition of PMA, Ionomycin and BFA for the last 6 hours 
of culture. Unstimulated cells, PBMC cultured without L cells for 48h, were stained with 
anti-IL10 after the addition of BFA alone for the last six hours of the culture.   
IV.2.2.2 Optimisation of IL10 intracellular staining technique 
In order to optimise IL10 intracellular staining I tested a number of incubation lengths 
with L cells.  The addition of Brefeldin A, PMA and Ionomycin for the last 6 to 8h of the 
culture period, and permeabilisation using formaldehyde containing solution, section II, 
8, 1, for a minimum of two hours prior to adding intracellular antibodies were crucial.  
At 24 and 48h, an IL10+ population from CD19+ B cells was reproducibly obtained in 
comparison with the negative control; figure (IV-3A). Furthermore, IL10 producing B 
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cells were negative for IL2, IFNγ and mostly for TNFα production, suggesting that IL10 
producing B cells represent a distinct cell population, figure (IV-3B). 
 
Figure IV-3: IL10 IC staining of CD19+ B cells 
A. Representative FACS plot of IL10 IC staining in gated CD19+B cells.  PBMC from healthy 
donors were cultured for 48 hours with L cells. PMA, Ionomycin and BFA were added for 
the last 6 hours of culture. Cells were then stained with CD19-PE and CD3-PerCP mAb 
and intracellularly stained with IL10-APC mAb or with an appropriate isotype control and 
acquired on FACSCalibur cytometer. Isotype control was used to determined IL10+CD19+ 
gate. B. IL10+B cells represent a distinct cell population. Intracellular staining for IL10, 
IL2 and IFNγ of B cells stimulated with L cells. IL10+ B cells are negative for IL2 and IFNγ.  
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IV.2.3 Kinetics of inducible IL10 production using intracellular staining 
Next, I studied the kinetics of IL10+ B cells following in vitro stimulation with anti-CD3/ 
anti-CD28 activated CD4+ T cells and L cells.  
IV.2.3.1 Anti-CD3/ anti-CD28 stimulated CD4 T cells upregulated surface 
expression of CD154 
First, I confirmed that in vitro stimulation of PBMC with anti-CD3/anti-CD28 beads 
induced CD4+ T cells to upregulate CD154 expression, figure (IV-4 A), which in turn 
stimulated B cells to produce IL10.  At baseline a negligible fraction of unstimulated CD4+ 
T cells expressed CD154 (0.2%± 0.02). Induced expression of the molecule was time 
dependent with the highest level of expression of CD154 achieved at 72h, (58.3%± 4.9). 
Activation of cultured B cells was confirmed on flow cytometry as increases in forward 
and side scatter.  
IV.2.3.2 Stimulation with activated T cells 
PBMC obtained from three healthy controls were stimulated with anti-CD3/anti-CD28 
beads and analysed for intracellular IL10 on gated CD19+ B cells at 24, 48, 72, and 96 h.  
The frequency of IL10+ CD19+ B cells observed in the negative control (BFA) was almost 
the same at each time point; on average 0.29%± 0.12.  Stimulating B cells with activated 
T cells induced a time dependent increase in IL10+ CD19+ B cell frequencies (0.66%± 0.14, 
2.37%± 0.37, 4.08%± 0.19 and 2.3%± 0.22) at 24, 48, 72 and 96 h respectively. 
Interestingly, IL10+ B cells percentage correlated with the percentage of CD154+CD4+ T 
cells in the culture system; figure (IV-4 B). 
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Figure IV-4: Inducible expression of CD154 by activated CD4+T cells  
A. Inducible expression of CD154 by activated CD4 T cells. PBMC were incubated with 
anti-CD3/ anti-CD28 beads and gated CD4+ cells were assessed by surface staining for 
CD154 expression. The highest level of expression was observed at 72 hours which 
declined thereafter. B. Kinetics of IL10+CD19+ B cells stimulated with activated T cells. 
The frequency of IL10+ CD19+ B cells correlated with that of CD154 expression and 
compared with unstimulated PBMC control. C. Kinetics of IL10+CD19+ B cells stimulated 
with L cells alone and L cells with anti-BCR using Intracellular IL10 staining. The highest 
frequency of IL10+CD19+ B cells was observed at 48 h in a time dependent manner. In 
comparison, B cells stimulated with dual stimulation PBXL produced less IL10. 
 
IV.2.3.3 Stimulation with L cells with and without anti-BCR 
In a minimum of three independent experiments, PBMC obtained from healthy controls 
were cultured with irradiated L cells (PBL) as well as with L cells and anti-BCR (PBXL) and 
analysed for intracellular IL10 on gated CD19+ B cells at 6, 12, 24 and 48h.  
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After six hours of incubation with L cells, BFA, Ionomycin and PMA, only 0.4% ± 0.09 of 
total PB CD19+ B cells stained positive for IL10. The observed frequency of IL10+ CD19+ B 
cells was not different from that seen with BFA alone or BXL conditions (0.33%± 0.07 
and 0.32%± 0.09) respectively. Stimulating B cells with CD154 alone (PBL) induced a time 
dependent increase in IL10+ CD19+ B cells (2.1%± 0.3, 3.3%± 0.06 and 5.73± 0.31) at 12-
15, 24 and 48h respectively; figure(IV-4 C).  In contrast, the PBXL condition led to 
frequencies of IL10+ CD19+ B cells above baseline only after 48 hours of incubation 
(1.9%± 0.49). In keeping with ELISA findings, the percentage of IL10+ B cells detected at 
48 hours was significantly higher in B cells stimulated with the BL condition when 
compared with BXL; p= 0.02.  
These results indicate that at normal resting state, an inducible population of IL10+ B 
cells exists in the PB. Moreover, the induction of IL10 production is condition and time 
dependent. 
IV.2.4 Comprehensive phenotyping of human IL10+ B cells 
I sought to determine the phenotype of IL10+ B cells using a number of 4-colour surface 
antibody panels, previously shown to be expressed by murine IL10 producing regulatory 
B cells. I found that stimulating PBMC with L cells for 15h is optimal; it allowed sufficient 
numbers of IL10-producing B cells to be detected for rare events analysis by flow 
cytometry without significant change in overall B cell phenotype. The phenotype of B 
cells started to change after 24 hours of incubation, characterised by down-regulation 
of CD24 and up-regulation of CD27 and appearance of a plasmablast population, figure 
(5).  
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Figure IV-5: Determination of optimal time point for IL10+ B cell study 
Determination of the optimal time point for studying IL10+ B cells.  Gated CD19+ B cells 
are analysed for CD24 and CD38 expression at baseline, 12-15 hours and 24-36 hours. 
CD24-CD38hi plasmablasts are gated and compared between the three time points. A 
distinct population starts to appear at 15-25 hours (~1.5%) when stimulated with L cells 
alone; top, and (~2.5%) with dual stimulation; bottom, associated with overall reduction 
of CD24 expression.   
 
Analysis of three independent experiments and six healthy controls showed that IL10+ 
CD19+ cells (IL10+ cells) were positive for CD1d, CD20, CD21, CD22, CD40, CD268 (BAFFR), 
and HLA-DR with the majority expressing CD27, CD24, IgD and IgM. Although almost all 
IL10+ cells expressed high levels of CD25 reminiscent of regulatory T cells, this was 
associated with CD69 expression suggesting that CD25 upregulation may be activation 
induced; figure (IV-6A and 6B). Interestingly, the majority of IL10+ cells lacked CD23 
expression and had low or no expression of CD38. Compared to IL10- CD19+ B cells, IL10+ 
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cells had higher expression of CD24, IgM and CD1d. I calculated median fluorescence 
intensity (MFI) of CD1d for both IL10+ and IL10- populations since all B cells expressed 
CD1d.  IL10+ B cells expressed higher CD1d compared with the IL10- B cells (CD1d MFI; 
62.5 vs. 44.5; p=0.05). Both IL10- and IL10+ CD19+ B cells expressed similar levels of CD5.  
IL10+ cells were enriched within the CD24hi CD38-/lo memory cell compartment; [72%; 
(65.5-81%)].  In our setting, the majority of IL10+ B cells were CD27+, which further 
supports their memory phenotype. In addition, the co-expression of IgD and high level 
of IgM indicates the non- switched nature of these cells. Furthermore, IL10+ cells lacked 
CD23 expression. Collectively, the majority of IL10+ B cells were CD24hi CD38-/lo CD27+ 
IgD+ IgMhi CD23-, a pattern of expression suggestive of IgM memory B cells or marginal 
zone B cells. I tried to combine these markers in one extended panel to confirm this 
phenotype; however, attempts to combine five colour flow cytometry with intracellular 
staining were unsuccessful due to the poor separation of IL10- IL and IL 10+ populations; 
(data not shown).  
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Figure IV-6: Phenotypic characterisation of IL10+CD19+ B cells 
Phenotypic characterisation of IL10+CD19+ B cells. A. A representative bi-dimensional FACS plot of IL10+ CD19+ B cells (red) relative 
to IL10-CD19+ B cells (grey).  PBMC from healthy donors were cultured for 15 hours with L cells. PMA, Ionomycin and BFA were 
added for the last 6 hours of culture. Cells were then stained with CD19, CD24, and CD38 or CD19, CD27 and CD21 mAbs and 
intracellularly stained with IL10 mAb or with an appropriate isotype control.  B.  Extended phenotyping of IL10+ B cells (red) 
compared with IL10- B cells (blue) and isotype control (grey) 
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IV.2.5 Effect of cryopreservation on IL10 IC staining  
Aliquots of PBMC from 6 healthy controls were frozen for later intracellular staining. 
After thawing, cells were rested for a minimum of 6 hours and stimulated thereafter 
with irradiated L cells at a ratio of 1:10 for 24 h. BFA, Ionomycin and PMA were added; 
section II, 8, 1, for the last 6 to 8 h of the incubation. Tested samples were stained with 
CD19, CD24, CD38 and IL10. Frozen samples yielded FACS plots with distinctive 
populations comparable to the freshly processed ones. Furthermore, similar to the 
freshly stained samples, cells stained positive for IL10 were also enriched within CD24hi 
CD38h figure (IV-7A). Frequencies of IL10+ achieved from the frozen samples were not 
different to their non-frozen counterparts; (2.81% vs. 2.86%; p=0.5) respectively; figure 
(IV-7B). 
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Figure IV-7: IL 10 IC staining in frozen samples 
A. FACS plots from a representative frozen sample show IL10+ CD19+ B cells gated based 
on unstimulated control. PBMC were stimulated for 48 hours with L cells (PBL) and PMA, 
Ionomycin and BFA were added for the last 6 hours of the culture.  B. IL10+ B cells are 
also CD24hiCD38- (red) compared with total CD19+ B cells (grey) similar to that observed 
with freshly processed samples. C. IL10+ B cell frequencies from paired fresh and frozen  
healthy control samples (n=6), there was no significant difference in the frequencies of 
IL10+CD19+ B cells between fresh and frozen samples. The results were compared with 
two-tailed nonparametric paired t test analysis. 
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IV.2.6 Functional assays 
Regulatory B cells modulate immune responses through a variety of mechanisms. The 
regulatory function has been demonstrated in a number of published studies with in 
vitro suppression assays of T cell cytokine production and/or proliferation. To date, IL10 
production by a B cell subset remains by and large the hallmark of regulatory B cells. 
Therefore, I examined whether or not our identified population, enriched in IL10+ B cells, 
possessed regulatory properties. I designed an in vitro culture system whereby sorted B 
cell subsets were incubated with purified autologous CD4+ T cells. The proliferation and 
pro-inflammatory cytokine production, namely IFNγ and TNFα, of CD4 T cells following 
in vitro stimulation was assessed by flow cytometry and compared with that of other T 
cells cultured with different B cell subsets as detailed in section II, 9, 1 and II, 9, 2. 
IV.2.6.1 Sort purification of B cell subsets  
I employed a B cell sorting strategy based on the identified IL10+ B cell phenotype. As 
demonstrated in IV.2.4 above, IL10+ cells expressed a phenotype suggestive of IgM 
memory B cells. CD27+ B cells can be divided according to class switching recombination 
into switched memory B cells, IgM- IgD-, non-switched, IgM+ IgD+, and two minor 
populations IgM only and IgD only memory B cells. The phenotype CD27+IgM+ defines 
almost all non-switched memory B cells. Therefore, we used a 4 colour sorting panel 
including CD19, CD27, IgM and PI. This panel allows the separation of four B cell subsets 
starting from a viable CD19+ cell gate, namely, CD27- IgMhi transitional, CD27- IgM+ naïve, 
CD27+ IgM+/hi IgM memory B cells and CD27+ IgM- switched memory B cells. The 
population CD27- IgMhi cells are enriched for transitional B cells, however, may also 
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include naïve B cells. The set sorting gates for naïve and transitional populations took 
into account this fact and were well separated into high IgM, for transitional and 
intermediate IgM, for naïve B cells within the CD27- B cells.  The purity of each subset 
was excellent: naïve 96.5%; (92%-99.7%), transitional 91%; (82.2%- 93.5%), switched 
95.8% (91%- 99.4%) and IgM memory B cells 93.7%; (92%-96.6%), figure (IV-8). 
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Figure IV-8: Gating strategy of B cell sorting 
Gating strategy for B cell sorting.  A. Gated PI- live lymphocytes, after excluding doublets, 
were assessed for CD19 expression. CD19+ B cells were subdivided according to IgM and 
CD27 expression into IgM+CD27- naïve, IgMhiCD27- transitional, IgM+CD27+ nonswitched 
and IgM-CD27+ switched memory B cells. B.  Post sort purity check. 
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IV.2.6.2 Suppression of CD4+ T cell proliferation 
CFSE stained selected CD4+ T cells were cultured with each sorted B cell subsets at a ratio 
of 1:1 and stimulated with anti-CD3/ anti-CD28 beads. The percentage of divided CD4+ 
cells was assessed by flow cytometry after 96 h of incubation. For each experiment a 
proliferation control (PC); stimulated CD4+ T cells cultured without any B cells, and 
negative control; unstimulated selected CD4+ T cells were included, figure (IV-9A). I 
found from seven independent experiments using different healthy controls that 
unstimulated CD4+ T cells did not proliferate at all by the end of the incubation. The 
percentage of dividing CD4+ T cells from each condition was compared with that of PC 
and with each other. Eighty four per cent of positive control cells divided in the absence 
of B cells; [84%± 2.6%; (75%-92%]. There was no suppression of CD4+ T cell proliferation 
when cultured with CD27- IgM+ naïve B cells ; [88%± 2.8%; (77%-97%] and CD27+ IgM- 
switched memory B cells; [78%± 5.09%; (52%-93%]; p=0.4 and p=0.3 respectively.  
However, IgM memory B cells significantly suppressed CD4+ T cell proliferation when 
compared with PC, naïve and switched memory B cells; [53%± 5.8; (33%-75%)] p=0.002. 
Analysis of transitional B cells effects on CD4+ T cell proliferation was possible in three 
experiments only due to the reduced viability of this subset in culture. I observed a 
suppressive effects of this subset [33%± 10.5% (25%-60%), n=3]; consistent with 
published data,(Blair et al., 2010) figure (IV-9B and IV-9C). The reduced proliferation of 
CD4+ T cells upon culturing with IgM memory or transitional B cells indicates that these 
154 
 
subsets possess inducible regulatory properties or contain a specialised regulatory B cell 
population.    
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Figure IV-9: Proliferation suppression assay (CD4+ T cells) 
B cell subset suppression assay showing CFSE proliferation profiles of CD4+ T cells 
cultured for 96 hours with anti-CD3/anti-CD28 beads and sorted B cell subsets at 1:1 
ratio. Stimulated selected CD4+ T cells labelled with CFSE (positive control) and 
unstimulated CD4+ T cells (negative control) were included with each experimental run. 
At end of culture cells were stained with PI, CD19-PerCP and CD4-APC. A. Representative 
FACS plots of CD4+ T cell suppression assay with gating strategy. Gated CD4 T cells from 
live PI- lymphocyte population were analysed for CFSE dilution by flow cytometry after 
4 days with sorted IgM+ CD27- naïve B cells at 1 to 1 ratio.  B. Proliferation of CD4+ T cells 
cultured alone (blue), with IgM-CD27+ switched memory B cells (green), IgM+CD27- naïve 
B cells (brown), IgM+CD27+ nonswitched memory B cells (red) and IgMhiCD27- 
transitional B cells (yellow) at a ratio of 1:1. Negative unstimulated control (grey) was 
included. IgM+CD27+ nonswitched memory B cell exhibited suppressive effect on CD4 T 
cells. C. in vitro suppression effect of different CD19+ B cell subsets (1:1 ratio) was 
assayed using anti-CD3/anti-CD28-stimulated CD4+T cells and determined by inhibition 
of CFSE-labelled cell proliferation (mean ± SEM of seven independent experiments). D. 
Suppression of CD4+ T-cell proliferation in the presence of IgM+CD27+ nonswitched T-
cell incubated at the indicated B to T cells ratios. Data are representative of 3 
independent experiments. 
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IV.2.6.3 The suppressive property of IgM memory B cells is cell dose 
dependent   
I showed that at a ratio of 1 to 1 (B to T), IgM memory B cells exhibit a suppressive effect 
on autologous CD4+ T cells. I then asked the question of whether this effect is cell dose 
dependent. To address this question, I repeated the same experiment, as in IV.2.6.2, 
with selected IgM memory B cells from three healthy individuals in three independent 
runs. The ratio of (B to T) cell was sequentially halved starting from 1 to 1 down to 1 in 
16. From these three experiments, the proliferation of CD4+ T cells was reduced from 
90± 3.7%; (80%-92%) in PC to 54%±7.17%; (53-75%) at the ratio of (1:1). Notably, the 
inhibition of CD4+ T cell proliferation was reduced in a stepwise manner from 54% at 1:1 
to 74% at 1:2 to 83% at 1:4 and fully abrogated afterwards; figure (IV-9D). In view of the 
poor viability of transitional B cells in my in vitro system I was not able to carry out the 
same experiment with this subset. Overall, this observation suggests that the inhibitory 
effects of IgM memory B cells may require a minimum B: T cell ratio to be achieved.  
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IV.2.6.4 IgM memory B cells suppressed IFNγ but not TNFα production 
by CD4+ T cells 
Selected total CD4+ T cells were cultured with each sorted B cell subsets at a ratio of 1:1 
and stimulated with anti CD3/ anti CD28 beads. The percentage of IFNγ+ and TNFα+ CD4+ 
cells was assessed by intracellular staining after 48 h of incubation. For each experiment 
a positive control (PC); stimulated CD4+ T cells cultured without any B cells, and negative 
control; unstimulated selected CD4+ T cells were included as detailed in II.9.2. 
Furthermore, I used autologous regulatory T cells (Treg) cultured with total CD4+ T cells 
also at a ratio of 1 to 1 as a positive control according to published protocols.(Collison 
and Vignali, 2011) The relative frequency (RF) of each IFNγ and TNFα production 
resulting from culturing with a given B cell subset was calculated relative to each 
corresponding PC as follows:   
𝑅𝐹(𝑐𝑦𝑡𝑜𝑘𝑖𝑛𝑒) =
% 𝑐𝑦𝑡𝑜𝑘𝑖𝑛𝑒˖𝐶𝐷4˖ 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛
% 𝐼𝐹𝑁𝛾˖𝐶𝐷4˖ 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑜𝑓 𝑃𝐶
 
For instance, 5.4% of CD4+ T cells stained positive for IFN+ upon culture with IgM memory 
B cells compared with 9.2% IFN+CD4+ T cells in the positive control tubes which would 
mean 58.6% (5.4%/9.2%) of the control.  
The same equation was employed for TNFα experiments RF (TNFα). Therefore, RF for PC 
condition was calculated as 1. RFs of each condition are presented as mean± SEM with 
(range) and statistically compared with RF of positive control using one way ANOVA and 
two tailed t test for comparing means and the p value was considered significant when 
<0.05.   
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IV.2.6.4.1 IgM memory B cells Suppress IFNγ+ CD4+ T cells 
I found from five independent experiments using healthy controls that unstimulated T 
cells produced negligible amounts of IFNγ. As expected, CD4+ T cells stimulated with anti 
CD3/CD28 produced IFNγ in the absence of B cells [mean IFNγ+ CD4+ T cells; 4.07%± 1.36 
(1.02-9.2%)]. CD4+ T cells cultured with all three sorted B cell subsets namely naïve, 
switched and IgM memory B cells produced less IFNγ compared with the positive 
control. The mean percentages of IFNγ+ CD4+ T cells for each condition were [3.2%± 1.01 
(0.9%-7%); 2.99%±0.67 (1.07%-4.8%) and 2.5%±0.79 (0.6%-5.4%)] respectively. There 
was a trend to statistical difference when comparing the percentage of IFNγ+ CD4+ T cells 
among the groups (p=0.07). Lack of significance could be explained by the considerable 
variation of IFNγ+ CD4+ T cells’ frequencies observed per condition between tested 
individuals. To eliminate the variation effect, I calculated RF for each culture condition 
relative to each individual’s own positive control.  
𝑅𝐹(𝐼𝑁𝐹𝛾) =
% 𝐼𝐹𝑁𝛾˖𝐶𝐷4˖ 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛
% 𝐼𝐹𝑁𝛾˖𝐶𝐷4˖ 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑜𝑓 𝑃𝐶
 
Based on this analysis, the mean RF (IFNγ) of CD4+ T cells cultured with naïve, switched 
and IgM memory B cells were [0.83± 0.02 (0.77-0.9); 0.95±0.16 (0.5-1.5) and 0.62±0.04 
(0.53-0.78)] respectively, figure (IV-10A). One way ANOVA test showed that the relative 
frequency of IFNγ+ CD4+ T cells cultured with IgM memory B cells at 1:1 was the only 
significantly lower frequency than the control p=0.021. Figure (IV-10B) shows the 
cumulative IFNγ percentage inhibition induced by co-culturing CD4+T cells with B cell 
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subsets. Unfortunately, for the same reason explained above, we could not analyse the 
effect of transitional B cells on CD4+ T cell production of IFNγ.  
 
Figure IV-10: IFNγ suppression assay (CD4+ T cells) 
A. in vitro suppression effect of different CD19+ B cell subsets was assayed using anti-
CD3/anti-CD28-stimulated CD4+T cells and determined by inhibition of IFNγ+CD4+ T cells 
cultured for 48 hours with sorted B cell subsets at 1:1 ratio. At the end of the culture 
cells were stained with PI, CD19-PerCP and CD4-APC and IFNγ-FITC. Unstimulated 
controls were used as negative control. Relative inhibition of IFNγ production was 
calculated relative to positive control, (CD4+ T cells). The results were compared with 
ANOVA and two-tailed t test analysis (n=5). B. Cumulative results expressed as median 
± interquartile range. The results were compared with nonparametric two-tailed t test 
analysis (CD4: IgM+CD27+ versus other groups), ∗p < 0.05, ∗∗p < 0.01 
 
IV.2.6.4.2 IgM memory B cells do not suppress TNFα + CD4+ T cells 
We also analysed TNFα+ CD4+ frequencies from the same controls as in section 
IV.2.6.4.1. The positive control cells produced TNFα in the absence of B cells [TNFα + 
CD4+ T cells; 16.4%± 1.3 (13-21%)]. CD4+ T cells cultured with all three sorted B cell 
subsets naïve, switched and IgM memory B cells produced comparable TNFα to the 
positive control. The means of for each condition were [15.2%± 1.3 (10.7-23.1%); 19.4%± 
1.2 (17.4-23.5%) and 14.92%± 1.47 (11.5-20%)] respectively, p=0.2. I also calculated RF 
for each culture condition relative to each individual’s own positive control. 
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𝑅𝐹(𝑇𝑁𝐹𝛼) =
% 𝑇𝑁𝐹𝛼˖𝐶𝐷4˖ 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛
% 𝐼𝐹𝑁𝛾˖𝐶𝐷4˖ 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑜𝑓 𝑃𝐶
 
The means RF of for naïve, switched and IgM memory B cells were [0.91± 0.1 (0.7-1.2); 
1.15± 0.06 (1.06-1.4) and 0.89± 0.05 (0.69- 0.97)] respectively, figure (IV-11). Similarly, 
ANOVA test and two tailed t-test for pairwise comparisons of each condition with the 
control did not reveal any significant difference.   
 
Figure IV-11: TNFα suppression assay (CD4+ T cells) 
in vitro suppression effect of different CD19+ B cell subsets was assayed using anti-
CD3/anti-CD28-stimulated CD4+T cells and determined by inhibition of TNFα+CD4+ T cells 
cultured for 48 hours with sorted B cell subsets at 1:1 ratio. At the end of the culture 
cells were stained with PI, CD19-PerCP and CD4-APC and TNFα-FITC. Unstimulated 
controls were used to determine TNFα+CD4+ T cell gate. Relative inhibition of TNFα 
production was calculated relative to positive control, (CD4+ T cells). The results were 
compared with ANOVA test for multiple comparison analysis (n=5). 
 
IV.2.6.4.3  IgM memory B cell induced suppression is comparable to Treg 
In order to estimate the inhibitory capacity of IgM memory B cells, I compared its 
suppressive effect on cytokine production of CD4+ T cell to that of regulatory T cells 
 
CD4+ T cells IgM+CD27- IgM-CD27+ IgM+CD27+
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 i
n
h
ib
it
io
n
 o
f
T
N
F

(%
)
161 
 
(Treg); defined as CD25hi CD127- CD4 T cells. Selected Treg were co-cultured with 
autologous CD4+ T cells at 1:1 ratio in 4 independent experiments. The inhibition of IFNγ 
and TNFα production induced by Treg was compared with that of IgM memory B cells 
and the positive control from the same run. Unlike IgM memory B cells, Treg suppressed 
both IFNγ and TNFα production by autologous CD4 T cells. The means RF (IFNγ) of Treg 
and IgM memory B cells were significantly lower than that of positive control [0.5± 0.08 
(0.34-0.71); p=0.001 and 0.62± 0.04 (0.53-0.78); p=0.014] respectively, figure (IV-12A 
and IV-12B).  Interestingly, there was no significant difference between the inhibitory 
effect of both Treg and IgM memory B cells on IFNγ production by T cells (mean RF 0.5 
vs. 0.62; p=1.0), figure (11C).  However, the mean RF (TNFα), on the other hand, was 
only significantly lower than that of positive control for Tregs [0.59± 0.08 (0.32-0.8); 
p=0.001]. The inhibitory capacity of IgM memory B cells on IFNγ production is therefore 
predicted, under our experimental conditions, to be comparable to Treg.  
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Figure IV-12: Breg suppression capacity is comparable to Treg 
IgM+CD27+ B cells suppressive effect on IFNγ production and CD4 T cell proliferation is 
comparable to Treg. A. Sorted IgM+CD27-CD19+PI− B cells and CD25hiCD127- Treg from 
healthy individuals were cultured 1:1 with autologous CD4+T cells for 48 hours with anti-
CD3/anti-CD28 beads. PMA, Ionomycin and BFA were added in the last 6 hours of culture 
and subsequently cells were surface stained for the expression of CD4 and intracellularly 
stained for IFNγ. Frequencies of IFNγ+ CD4+ were assessed relative to the corresponding 
unstimulated controls. Representative FACS plots for 1 out of 3 individuals, showing the 
frequencies of IFNγ+ CD4+T cells. B. Proliferation of CD4+ T cells cultured alone (blue), 
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with IgM+CD27+ nonswitched memory B cells (red) or CD25hiCD127- Treg (pink) at a ratio 
of 1:1. Negative unstimulated control is shown in grey. C. Bar graphs show percentage 
inhibition of the frequency of CD4+IFNγ+  T cells after co-culture with IgM+CD27-
CD19+PI− B cells and CD25hiCD127- Treg; n=3.   
 
IV.2.6.5  Direct CD4+ T cells suppression by IgM memory B cells is not 
dependent on the presence of Tregs in the culture system 
I also examined the effect of culturing B cell subsets with Treg depleted-CD4+ T cells at 
a ratio of 1:1. For this purpose I used a commercially available Treg kit as shown in 
section II.5.2.2. The kit produces positively selected CD127- CD25hi CD4+ regulatory T 
cells and negatively selected CD4 T cells. Similar to the effect on total CD4 T cells, IgM 
memory B cells were suppressive on the proliferation of Treg depleted CD4 compared 
with total CD4+ T cells [(79%±10.9 (58-94%) vs. 6.5%±2.07 (2.8-9.7%) n=3, p=0.021)], 
figure (IV-13A and IV- 13B).  
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Figure IV-13: Proliferation suppression assay (Treg) 
A. Proliferation of Treg-depleted CD4+ T cells cultured alone (blue), with IgM-CD27+ 
switched memory B cells (green), IgM+CD27- naïve B cells (brown) or IgM+CD27+ 
nonswitched memory B cells (red) at a ratio of 1:1. Negative unstimulated control (grey) 
was included. IgM+CD27+ nonswitched memory B cell exhibited suppressive effect on 
CD127loCD4+ T cells. B. in vitro suppression effect of different CD19+ B cell subsets (1:1 
ratio) was assayed using anti-CD3/anti-CD28-stimulated Treg-depleted CD4+T cells and 
determined by inhibition of CFSE-labelled cell proliferation (median ± interquartile 
range); n=3; *<0.05.  
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IV.2.7 Suppressive effects is IL10 dependent and cell specific 
I have shown that IL10+ B cells are enriched within the CD27+IgM+ memory B cell subset. 
Sort-purified IgM memory cells displayed regulatory properties by suppressing the 
proliferation and cytokine production of autologous CD4+ T cells. Furthermore, I showed 
that the suppressive ability of IgM memory B cells is comparable to that of Treg. To 
further understand the mechanism underlying the regulatory properties of IgM memory 
B cells, I repeated the experiments outlined in section II. 9. 3 in the presence or absence 
of IL10 blocking antibodies.  
IV.2.7.1 IL10 blocking experiments:   
IV.2.7.1.1 Effect of IL10 blocking on IFNγ production by CD4+ T cells 
To address this question, I performed IL10 blocking experiments by adding anti-CD210 
(IL10 R) blocking antibodies to the culture system in 4 independent experiments. 
Relative frequency RF (IFNγ+) in CD4+ T cells cultured with sort-purified B cell subsets in 
the presence or absence of IL10 blocking antibodies was calculated.  
Blocking IL10 R in the positive control wells had no effect on IFNγ production (2.47%± 
0.7 vs. 2.5%± 0.9, p=0. 8]. Similarly, there was no difference between the relative 
frequencies of IFNγ+ CD4+ T cells seen when CD4+ T cells were cultured with naïve B cells 
with and without IL10 blocking; [83.8%± 0.4 (76-93%) vs. 86.5%± 1.6 (60-128%), p=0.9] 
and with switched memory B cells with and without IL10 blocking; [120%± 0.04 (106- 
160%) vs. 115%± 1.0 (101-139%), p=1] respectively. However, the addition of IL10R 
blocking Ab in wells containing stimulated CD4+T cells + IgM memory B cells led to 
significant recovery of IFNγ production, [62.%± 0.4 (58-81%) vs. 115%± 1.0 (91-139%), 
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p=0.02], figure (IV-14A and IV- 14B). 
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Figure IV-14: IgM+CD27+ CD19+ B cell suppression is dependent on IL10.  
A. Purified CD4+ T cells were cultured with sort-purified B cell subsets: IgM+CD27-CD19+, 
IgM+CD27+CD19+, and IgM-CD27+CD19+PI− cells and stimulated with anti-CD3/anti-CD28 
beads in the presence or absence of blocking antibodies IL10R. PMA, Ionomycin and BFA 
were added for the last 6 hours of culture and subsequently cells were surface stained 
for the expression of CD4 and intracellularly stained for IFNγ. Flow cytometry plots of 
IFNγ expression by CD4+T cells cultured alone (positive control) or in the presence of 
indicated B cell subsets with and without IL10 blocking antibodies. Frequencies of 
IFNγ+ CD4+T cells were assessed relative to the corresponding unstimulated controls. B. 
Bar charts compare the relative percentage RF of IFNγ+ CD4+ and C. TNFα+ CD4+ T with 
and without IL10 blocking. Cumulative data are presented as mean ± SEM of three 
independent experiments. The results were compared with two-tailed nonparametric t 
test analysis, ∗p < 0.05. 
 
Overall, these results indicate that the regulatory properties of IgM memory B cells are 
IL10 dependent; however, any contributory effects of cell to cell contact cannot be 
excluded based on these experiments.  
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IV.2.7.1.2 Effect of IL10 blocking on TNFα+ CD4+ T cell frequencies 
As described in section IV.2.6.4.2, B cell subsets did not have significant suppressive 
effects on TNFα production by CD4 T cells.  
Expectedly, blocking IL10 did not have a major impact on TNFα production by CD4+ T cell 
presented as frequencies or RF (TNFα), figure (IV-14C). Interestingly, blocking IL10 in the 
presence of IgM memory B cells resulted in a significant increase of RF (TNFα) compared 
to the “no IL10 blockade” [90%± 0.5 (69- 97%) vs. 116%± 0.8 (101-137%), p=0.019].  
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IV.3 Discussion  
In a B cell activation model proposed by Duddy et al, B cells receiving bystander T cell 
help via CD154 (CD40L)-CD40 interaction produce large amounts of IL10. Whereas B 
cells engaged to an Ag in presence of T cell help produce more pro-inflammatory 
cytokines promoting GC formation (Duddy et al., 2004). In agreement with this 
paradigm, in my experiments, stimulation of purified B cells with L cells alone induced 
more IL10 secretion, as measured by ELISA. On the other hand, BCR engagement in 
addition to CD40 stimulation reduced IL10 production by purified B cells. I therefore 
propose that B cells receiving bystander stimulation in close vicinity to an inflammatory 
signal may regulate over spilling of the reaction via IL10 production.  
The next step was to optimise the intracellular IL10 assay to allow phenotypic 
characterisation of IL10 producing B cells. Using this assay, I found that IL10+ CD19+ B 
cells are enriched within the CD24hiCD38lo B cells. Almost 75% of IL10+ CD19+ B cells were 
positive for CD27 which further support a memory phenotype. In addition, IL10+ CD19+ 
B cells expressed IgD and high levels of IgM. Overall, this combination of markers is 
consistent with IgM memory B cell phenotype.  
CD23 is a marker of follicular and naïve B cells which distinguishes them from CD23- 
splenic marginal zone B cells. Interestingly, marginal zone precursor B cells express CD23 
and become CD23- as they mature towards MZB cells (Pillai and Cariappa, 2009).  
In the PB, IgM memory B cells are the circulating counterpart of MZ B cells and therefore 
do not express CD23 (Weill et al., 2009). The fact that IL10+ CD19+ B cells did not express 
CD23 further supports their IgM memory B cell origin.  
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CD1d is a glycoprotein expressed by various antigen-presenting cells in humans. CD1d, 
related to the class I MHC molecules, presents lipid antigens to, and activates NKT cells. 
Murine B10 regulatory B cells express high levels of the functionally important CD1d and 
are positive for CD5. Except for CD5, the rest of the identified phenotype is shared with 
MZ B cells (Yanaba et al., 2008). I, therefore, assessed CD5 and CD1d expression on 
IL10+CD19+ B cells and found that IL10+ B cells did not preferentially express CD5. 
However, they expressed higher CD1d levels in agreement with the murine studies. 
CD1d has been shown to be important for MZ B cells function in promoting self-
tolerance via communication with NKT cells (Sonoda and Stein-Streilein, 2002, Allan et 
al., 2011).    
CD25, both basal and induced expression, has been studied as a marker of B cells with 
regulatory properties (Tretter et al., 2008, Brisslert et al., 2006). I found that IL10+ B cells 
were positive for CD25; however, the analysis was undertaken after 15 hours of 
activation. All IL10+ B cells expressed CD69 which is also a general marker of cellular 
activation (Maino et al., 1995). In light of the available data, I cannot propose a 
functional role for CD25 expression in B cell regulatory function.  The remainder of the 
IL10+ B cell phenotype included analysis for expression of CD20, CD21, CD22, CD40, HLA 
DR and CD268 (BAFFR). My data suggest that IL10+B cells are CD24hi CD38lo CD27+CD23- 
IgD+ IgMhi CD1dhi CD19+ which are consistent with IgM memory B cell phenotype. To 
further test that the identified cell population in fact possesses regulatory properties, I 
carried out functional assessment of the sort-purified IgM memory B cell population, 
compared to naïve and switched memory B cells. IgM memory B cells (CD27+ IgM+) 
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suppressed the proliferation of autologous CD4 T cells. Proliferation suppression 
revealed a cell dose dependent effect, analogous to Treg suppression (Venken et al., 
2007). Furthermore, IgM memory B cells suppressed specifically cytoplasmic production 
of CD4 IFNγ but interestingly not TNFα. The suppressive effect of IgM memory B cells on 
IFNγ+ CD4 T+ cells was comparable to that of Treg. These findings indicate that the 
identified IL10+ B cells have immunoregulatory function.  
My results are in keeping with Tedder et al’s published data reporting enrichment of 
IL10+ B cells in the memory B cell subset. The authors reported that IL10+ B cells are 
enriched within CD24hiCD27+ B cells which include both IgM+ and switch memory B cells. 
Furthermore, IL10+ B cells were reported to express CD148, a memory B cell marker.  
While sort-purified CD24hiCD27+ failed to suppress cytokine production by CD4 T cells, 
they suppressed both IFNγ and TNFα cytoplasmic production of CD14+ monocytes. I did 
not assess the impact of IgM memory B cells on CD14+ monocytes. Blair and colleagues, 
on the hand, described an IL10+ B cell subset with suppressive effect that shared 
phenotypic similarities with CD24hi CD38hi transitional B cells(Blair et al., 2010). In their 
study, sort-purified CD24hi CD38- memory B cells did not suppress effector T cell 
function. CD24hi CD38- B cell population is more or less equivalent to CD24hiCD27+ B cells 
used in the previous study. In agreement with these two studies, I also found that naïve 
B cells (CD27- IgM+) did not have any suppressive effects. Although, I attempted to purify 
transitional B cells defined as CD27- IgMhi B cells, these studies were challenging due to 
the pro-apoptotic tendency of these cells. Despite discrepancies in the phenotypic 
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assignment of Bregs in the different published studies, my data suggest that 
CD24hiIgMhiCD19+ B cells will likely be enriched in IL10+ regulatory cells. 
To investigate whether the regulatory function was mediated through IL10, I used IL10 
blockade as prescribed previously (Blair et al., 2010). Blocking IL10 led to full reversal of 
IFNγ inhibition observed in the presence of IgM memory B cells. These findings suggest 
that the regulatory function of Bregs are at least partly IL10 dependent.  
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Chapter V. IL10 producing B cells in cGVHD 
V.1 Introduction  
Chronic GVHD resembles in many aspects systemic autoimmune and collagen diseases 
with prominent fibrotic features such as systemic lupus erythematosus (SLE), Sjögren 
syndrome, and scleroderma (Goerner et al., 2002, Lee et al., 2003). Multiple auto-
antibodies associated with autoimmune diseases are frequently detected with 
cGVHD(Kapur et al., 2008). Direct causal relationship with some manifestations of 
cGVHD, however, has been rarely established (Svegliati et al., 2007). The frequent 
production of auto-antibodies in patients with cGVHD may reflect critical breakdown in 
peripheral B-cell tolerance and/or insufficient immune regulation after allogeneic HSCT. 
A number of studies in human regulatory T cells (Treg) post SCT reported both increased 
and decreased Treg numbers with overall impaired regulatory function (Clark et al., 
2004, Zorn et al., 2005). 
Regulatory B cell dysfunction has been observed in a number of autoimmune conditions, 
suggesting a role in disease pathogenesis (Mauri and Blair, 2010b). Virtually no data exist 
on the potential role of regulatory B cells in GVHD as an auto-allo-immune condition. 
Studying this subset may provide an explanation for the pathophysiology of cGVHD and 
may have implications for the treatment of this disease. Chronic GVHD is unique in that 
some therapeutic options, not possible in autoimmune conditions, can be implemented. 
For example, if a deficient subset was associated with cGVHD development or 
manifestation, replacement of this subset from the same donor, in the context of clinical 
trial, is an option.   
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I showed, in Chapter IV, that IL10+ CD19+ B cells enriched within the IgM memory B cell 
subset. Sort-purified IgM memory B cells; enriched for IL10- producing B cells, exhibit 
suppressive effects on CD4+ T cell proliferation. In addition, IgM memory B cells suppress 
IFNγ production by CD4+ T cells. Finally this attribute is likely to be partially IL10 
dependent and is likely to target a specific effector cell subset. Based on these findings, 
I evaluated the role of IL10+ CD19+ B cells in cGVHD. 
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V.2 Results 
The purpose of this chapter is to examine the role of the IgM-memory-like IL10+ B cell 
population in a cohort of cGVHD patients compared to patients with “no cGVHD” and 
healthy controls. I examined whether reduced or hypo-functional IL10+ B cells are 
implicated in the pathogenesis of cGVHD.  
For IL10 intracellular detection, I stimulated PBMC with L cells alone; PBL, and L cells 
with anti BCR; PBXL and determined their frequencies out of a gated population of live 
CD19+ B cells. For IFNγ detection, I stimulated PBMC with PMA and Ionomycin in vitro 
and assessed the frequencies of CD4+ IFNγ+ T cells. 
V.2.1 Patients characteristics 
Blood samples were available for intracellular (IC) cytokine detection from (25/33) 
patients described in Chapter VI and table (VI-2).  All patients were more than six 
months post SCT with no evidence of primary disease relapse. Patients receiving high-
dose steroids (> 50 mg prednisone) at the time of sampling or had received rituximab 
for any indication were excluded. Chronic GVHD status at the time of sample collection 
was classified according to documented clinical and laboratory data using National 
Institutes of Health (NIH) cGVHD consensus criteria and modified Seattle criteria for 
limited versus extensive disease. Of the 23 assessable patients, eleven patients had 
“active cGVHD”. Twelve patients never developed cGVHD after HSCT. None of the “no 
cGVHD” patients were receiving immunosuppressant therapy at the time of sample 
collection. 
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The median time to  samples collections was 384 days (100-2947) after transplantation 
for patients with cGVHD compared to 565.5 days (250-1112) for those without cGVHD 
(P = .53). I also studied six healthy controls. 
V.2.2 Chronic GVHD is associated with reduced IL10+ B cell population 
I examined the frequencies and absolute counts of IL10 producing CD19+ B cells using 
intracellular staining techniques in 13 cGVHD patients, 12 “no cGVHD” patients and 6 
healthy controls. The absolute count of IL10+ CD19+ B cells were calculated by 
multiplying the percentage of IL10+ CD19+ B cell by the absolute number of CD19+ B cells. 
Two cGVHD patients (2/13) were excluded from the analysis in view of the low CD19+ 
events (˂1000) within the live lymphocyte gate secondary to prior rituximab therapy.  
V.2.2.1 B cells from cGVHD patients have impaired in vitro IL10 responses 
to CD154 stimulation in comparison with “no GVHD” and HC groups 
I demonstrated, in Chapter IV, that stimulation of PBMC with CD154-expressing L cells 
for 48 h yields the highest frequency of IL10 production by CD19+ B cells. In contrast, 
stimulation with L cells and anti BCR led to significantly lower level of IL10 production 
by CD19+ B cells in keeping with their proposed pro-inflammatory action.  
Thawed PBMC were rested for 6 hours, followed by co-incubation with irradiated L cells 
at a ratio of 1 to 10 for 48 h (PBL condition). IC cytokine staining for IL10 production by 
CD19+ B cells was performed as outlined in section II.8.1. Post-transplant patients 
without cGVHD had comparable frequencies of IL10+ CD19+ B cells to healthy controls 
[1.72%± 0.45 (0.8-5.52) vs. 2.16%± 0.36 (1.3-5.5), p=0.44]. However, in the cGVHD 
group, a significantly smaller fraction of gated CD19+ B cells were IL10 positive, 
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compared to patients with “no cGVHD” and HC, [1.02%± 0.17 (0.22-2.26) vs.1.72%± 0.45 
(0.8-5.52) vs. 2.16± 0.36 (1.3-5.5), p=0.001] respectively; figure (V-1A and V-1B).  
When PBMC were stimulated with both L cells and anti-BCR for 48 h (PBXL), there was 
no difference in the frequencies of IL10+ CD19+ B cells among cGVHD, “no GVHD” and 
HC, [0.6± 0.18 (0.09-2.1) vs. 0.97± 0.29 (0.15- 3.01) vs. 0.75± 0.28 (0.5-1.98), p=0.4] 
respectively; figure (1C). However, cGVHD patients had significantly lower absolute 
numbers (IL10+ CD19+ B cell per µL) compared with “no GVHD” and HC, [0.32± 0.35 (0.00-
3.01) vs. 3.04± 1.3 (0.6- 17.9) vs. 1.89± 1.9 (1.02- 11.4), p=0.007] respectively; figure (V-
1C). Absolute number of total CD19+ B cells was calculated by multiplying the respective 
percentage obtained by flow cytometry by the absolute lymphocyte number (cell/µl) 
obtained from same day diagnostic FBC.   
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Figure V-1: cGVHD is associated with lower IL10 production  
B cells from cGVHD patients produce less IL10 compared to patients without cGVHD and 
healthy controls. PBMC from cGVHD, no cGVHD and healthy controls (HC) were 
incubated with L cells alone or with L cells and anti-BCR for 48 hours. PMA, Ionomycin 
and BFA were added for the last 6 hours of culture and cells were analysed for the 
expression of CD19, CD3, and PI and intracellularly stained for IL10. A. Representative 
FACS plots of IL10 IC staining in gated CD19+ B cells from cGVHD and no cGVHD patients. 
Frequencies of IL10+ CD19+ B cells were assessed relative to isotype controls. B. cGVHD 
patients had lower frequencies and absolute numbers of IL10+ B cells when stimulated 
with L cells compared to patients without cGVHD patient and healthy controls. C. 
Stimulation with L cells and anti-BCR was associated with lower numbers of IL10+B cells 
in cGVHD patients compared with patients without cGVHD and HC.  
 
Therefore, this observation suggests that cGVHD is associated with impaired IL10 
production by B cells. However, in the absence of a specific marker for Bregs, it is not 
clear whether this represents a numerical defect in Bregs or a functional deficit in IL10 
production by B cells.   
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V.2.2.2 B cells from cGVHD patients produce Less IL10 in response to 
stimulation with CD40L  
In addition to the overall reduced in vitro IL10 responses presented in V.2.2.1, cGVHD 
patients failed to exhibit the expected higher L10 production observed when B cells are 
stimulated with CD154 alone; PBL, compared to combined stimulation, PBXL. In cGVHD 
patients, the frequency  and absolute cell numbers of  IL10+ CD19+ B cells were not 
significantly lower in PBXL compared to PBL [0.6%± 0.18 (0.09- 2.01%) vs. 1.02%± 0.18 
(0.22- 2.26%), p=0.14] and [IL10+ CD19+ B cell per µL, 0.32± 0.35 (0.0- 3.01) vs. 1.09± 0.75 
(0.07-7.84), p=0.23] respectively . Conversely, B cells from patients without GVHD 
mounted a significant increase when stimulated with L cells alone compared to L cells in 
the presence of anti-BCR, in frequencies, [0.98%± 0.27 (0.15-3.01) vs. 1.87%± 0.43 (0.8- 
5.25), p=0.023] and cell counts [IL10+ CD19+ B cell per µL, 3.04± 1.3 (0.6-017.9) vs. 8.98± 
1.44 (1.97- 18.7), p=0.009] respectively, comparable to that observed in HC; figure (V-
2A and V-2B). 
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Figure V-2: B cells from cGVHD patients produce Less IL10 in response to stimulation 
with CD40L 
A. Frequency B. absolute number of IL10+ B cells significantly higher when stimulated 
with L cells alone compared with L cells and anti-BCR in no cGVHD patients and healthy 
controls. There was no significant difference in the frequencies or numbers of 
IL10+CD19+ B cells when stimulated with L cells alone compared with L cells and anti-
BCR.  All values are expressed as mean± SEM; n=11; the results were compared with 
two-tailed nonparametric t test analysis, **P<0.01. 
 
Failure to increment IL10+ B cells upon stimulation with L cells alone in cGVHD samples 
suggests that either IL10 capable B cells are numerically or functionally reduced or are 
less responsive to CD154 stimulation analogous to SLE under-responsiveness to CD40 
activation. 
V.2.3 Chronic GVHD patients have comparable relative IgM memory B cell 
population 
Since IL10+ B cells are enriched within the IgM memory B cells, we analysed the 
frequencies of IgM memory B cells in post-transplant samples from patients with and 
A. 
B. 
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without cGVHD. As presented in Chapter VI, IgM memory B cell frequencies are lower 
in both post-HSCT patient groups compared with healthy individuals. The absolute 
number of IgM memory B cells was not significantly different in cGVHD vs. no cGVHD 
patients (median count, 11 vs. 12.6 cell/µl; p=0.3), although the former had a relatively 
higher proportion of IgM memory B cells (median percentage 5.1% vs. 3.1%; p=0.03). 
However, active cGVHD patients, on the other hand, had a smaller transitional B cell 
population compared with “no GVHD” patients (median 0.5 vs. 22.3 cell/µl; p=0.0003). 
This observation suggests that B cells with the capacity to produce IL10 may be 
numerically deficient in cGVHD; however, in view of the lack of a specific cell marker, it 
is not possible to rule out a specific deficiency of IL10 capable B cells. The other 
possibility, if we assume number sufficiency, is that these cells are functionally defective. 
V.2.4 IFNγ+ CD4+ T cells are increased in post-transplant patients 
As presented in Chapter IV, IL10+ B cells specifically can suppress IFNγ production by 
CD4+ T cells in vitro. To assess the relevance of this observation directly ex-vivo, PBMC 
from patients with or without cGVHD were stimulated in vitro and the frequencies of 
IFNγ+ CD4+ T cells assessed. As previously reported, the frequency of IFNγ+ CD4+ T cells 
was significantly higher in post-transplant patients compared to HC (Nakamura et al., 
2005). However, patients with or without cGVHD had similar frequencies of IFNγ+ CD4+ 
T cells 22.3%± 4.13 (4.2- 44.13) vs. 24.9%± 4.6 (7.2-60.7) p=0.63, figure (V-3A and V-3B). 
Similarly, there was no statistical difference in the absolute number of IFNγ+ CD4+ T cells 
between the two post-transplant groups; p=0.16, figure (3 C).  
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Figure V-3: IFNγ+ CD4+ T cells post SCT   
CD4+ T cells from patients with and without cGVHD produce comparable amounts of 
IFNγ. PBMC from cGVHD, no cGVHD and healthy controls (HC) were stimulated with 
PMA and Ionomycin for 6 hours. Cells were surface stained for the expression of CD4, PI 
and intracellularly stained for IFNγ.  A. Representative FACS plots of IFNγ IC staining in 
gated CD4+T cells from cGVHD and no cGVHD patients. Frequencies of IFNγ+ CD4+ T cells 
were assessed relative to unstimulated controls. B. CD4+ T cells from cGVHD produced 
comparable frequencies and absolute numbers of IFNγ+ CD4+ T cells compared with no 
cGVHD patients and healthy controls.   All values are expressed as mean± SEM; n=11; 
the results were compared with two-tailed nonparametric t test analysis. 
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V.2.5 Active cGVHD is characterised by increased IFNγ+ CD4+ T cell / IL10+ 
B cell ratio 
The frequencies of IFNγ+ CD4+ T cells were not significantly different in patients with or 
without cGVHD. In view of the reduced IL10+ CD19+ B cell population observed in cGVHD 
patients, I expected a relative increase in IFNγ+ effector CD4+ T cell/IL10+ B cell ratio. 
Therefore, I calculated the ratios of IFNγ+ CD4+ T cell/ IL10+ B cell (IFNγ/IL10) frequencies 
and absolute numbers for each patient groups. 
As anticipated, cGVHD patients had a significantly higher IFNγ/IL10 ratio (both 
frequencies and absolute counts), than “no GVHD” patients; [frequency ratio: 
17.15±12.35 (9.8- 152.7) vs. 13.95± 2.6 (2.7- 35.5); p= 0.06 and cell/µL: 33.8± 137.1 
(1.83- 1496) vs. 11.76± 11.3 (1.37- 143); p=0.046) respectively, figure (V-4).  
 
Figure V-4: IFNγ+CD4+/IL10+ CD19+ ratio in patients with and without cGVHD 
Box and whiskers plots comparing the ratio of IFNγ+CD4+/IL10+ CD19+ absolute cell 
numbers (#) and IFNγ+CD4+/IL10+CD19+ frequencies. All values are expressed as mean± 
SEM; n=11; the results were compared with two-tailed nonparametric t test analysis. 
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These results imply that on average for every 12 IFNγ+ effector T cells one regulatory B 
cell is available in absence of cGVHD, whereas in patients with cGVHD only one 
regulatory B cell is available for every 34 effector CD4+ T cells. An imbalance between 
the regulatory and pro inflammatory networks is therefore present in cGVHD patients. 
This imbalance appears to be the result of a deficient regulatory network, as opposed to 
increased pro-inflammatory effector mechanisms. 
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V.3 Discussion  
Chronic GVHD resembles autoimmunity both clinically and in terms of its pathogenesis. 
It has been shown that Tregs are numerically and functionally impaired in cGVHD, which 
in turn may contribute to impaired self- tolerance and survival of autoreactive effector 
T cells (Matsuoka et al., 2010).  
Regulatory B cells have been recognised as powerful regulators of the immune response 
with a increasingly identified role in human autoimmune diseases (Mauri and Bosma, 
2012). No data exist on the potential role of regulatory B cells in GVHD. Studying this 
subset may provide insight into the pathophysiology of cGVHD and may have 
implications for its treatment. 
In my thesis, I have shown reduced frequencies and absolute numbers of IL10 producing 
B cells in the PB of patients with cGVHD compared with patients without GVHD and HCs. 
Furthermore, cGVHD patients failed to produce the expected increment, in both IL10+ B 
cell frequencies and numbers, when stimulated with L cells alone over dual stimulation. 
These results suggest either a numerical deficiency in IL10 producing B cells or a defect 
in B cell response to CD154 stimulation. A suboptimal response to activation with L cells 
alone may indicate a deficit in CD40 signalling or reduced CD40 expression on B cells. It 
has been reported that regulatory B cells from SLE patients are refractory to CD40 
engagement; i.e. B- T cell interaction, with reduced phosphorylation of STAT3 
downstream of CD40. In SLE, alternative stimulation with CpG restored a normal IL10 
response (Blair et al., 2010). I was not able to quantify CD40 expression on B cells or 
stimulate B cells from cGVHD patients with CpG in view of the limited patient sample 
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availability. There is some evidence that SCT recipients accumulate less Antigen-driven 
T cell-dependent somatic mutations. . Therefore, an intrinsic B cell deficit or impaired T-
B cell cross talk, rather than a defect in T cell help  may explain this observation (Glas 
et al., 2000).   
The reduced IL10+ B cells in cGVHD may represent quantitative or functional 
deficiencies. Low inducible IL10+ B cell number in cGVHD could be the direct result of 
lower frequencies of IL10 producing B cells or their precursors. The fact that IgM 
memory B cells are normally maintained in the spleen (Weill et al., 2009) and that cGVHD 
worsens the splenic hypofunction post SCT may further support this notion (Cuthbert et 
al., 1995). To further investigate a quantitative explanation and since IL10+ B cells share 
a similar phenotype to IgM memory B cells, I compared IgM memory B cell frequencies 
in patients with or without cGVHD and HC. In our cohort and as previously reported by 
Dana Farber group (Sarantopoulos et al., 2009), chronic GVHD patients had relatively 
higher frequencies of IgM memory B cells compared with patients without cGVHD. This 
finding might suggest that there is no numerical deficiency of IL10+ B cell in cGVHD. 
However, this conclusion cannot be fully supported since, in the absence of specific 
markers for IL10+ B cells, analogous to FoxP3 in Treg, one cannot exclude a specific 
deficit of an IL10+ B cell subset with a maintained overall IgM memory B cell population. 
Other studies have reported reduced IgM memory B cells in cGVHD (D'Orsogna et al., 
2009, Hilgendorf et al., 2012); nonetheless, in our setting, a reduction in IgM memory B 
cells cannot be used to propose a quantitative deficit for IL10 producing B cells in cGVHD. 
Transitional B cells have been shown to possess IL10 dependent immunoregulatory 
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function (Blair et al., 2010). We observed a smaller population of transitional B cells in 
cGVHD patients which may contribute to the overall lower B cell production of IL10. 
Alternatively, a functional deficit in IL10 production by B cells is another possibility. 
However, the lack of a specific marker renders exploring this proposition not possible at 
present.  
I assessed IFNγ+ CD4+ T cells in the study groups as I detected a unique inhibitory effect 
of IgM memory B cells on these cells. In agreement with a previous report (Nakamura et 
al., 2005), I found no significant difference in IFNγ+ CD4+ T cells in cGVHD and “no GVHD” 
patients. However, the ratio of IFNγ+ CD4+ T cells to IL10+ B cells was significantly higher 
in cGVHD patients, which implies an imbalance in the regulatory and effector systems. 
The proposed imbalance adds to the recognised association of Treg imbalance with 
development of cGVHD. A smaller Treg population relative to total CD4 cells, which by 
default includes effector cells, predisposes SCT patients to cGVHD (Matsuoka et al., 
2010). My finding supports a wider regulatory network imbalance, affecting both Breg 
and Tregs, and extends the current investigation to assessing factors that are common 
to both lineages such as post-transplant environment and cell reconstitution. 
Reconstitution of Treg after myeloablative conditioning is characterised by reduced 
CD31+ thymic naïve Treg and predominance of peripherally expanded memory Treg 
(Matsuoka et al., 2010). CD4 lymphopaenia post SCT is associated with rapidly expanding 
Treg, with a subsequent decline attributable to their apoptosis. The post SCT 
environment, with damage inflicted on lymphoid generation sites, could explain this 
pattern of reconstitution which in some recipients may favour the preferential recovery 
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of pro-inflammatory effector cells. Likewise, B cell regeneration sites such as the bone 
marrow, spleen and lymph nodes are damaged by the SCT conditioning (Sale et al., 
1992). Moreover, cGVHD further worsens splenic hypofunction seen in SCT patients 
(Cuthbert et al., 1995). There is experimental evidence to support that cGVHD-
associated damage to bone marrow niche further impairs B cell lymphopoiesis (Shono 
et al., 2010). 
I speculate that the reduction of IL10 capable B cells in cGVHD is the cumulative result 
of B cell regeneration in an environment favouring the disease. Early prophylactic 
intervention with adoptive immunotherapy might therefore tip the balance in favour of 
immune regulation and may therefore be beneficial. One way of achieving this could be 
through infusion of donor lymphocytes enriched with regulatory cells, for instance IgM 
memory cells, at an early stage which minimises damage and predisposition to cGVHD 
development. Obviously, this would need to be confirmed in an animal model and 
subsequently in the context of a clinical study. 
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Chapter VI. GVHD and B cells 
VI.1 Introduction: 
Chronic graft versus host disease (cGVHD) remains a major limiting factor of stem cell 
transplantation (SCT) success. Chronic GVHD occurs in 30 to 65% of allogeneic SCT 
recipients with a 5-year mortality rate of 30 to 50% (Blazar et al., 2012b). At present, the 
immunopathophysiology is not fully understood, which hinders the development of 
effective treatments. Traditionally GVHD has been approached as a T cell mediated 
process and the current therapies reflect this understanding (Inamoto and Flowers, 
2011). Recently, increasing evidence has supported the involvement of B cells in cGVHD 
pathophysiology. The occurrence of GVHD in the settings of immune disparity and the 
identification of auto-antibodies implies either a direct breakdown in the B cell tolerance 
process or T to B cell cross-talk (Kapur et al., 2008, Glas et al., 2000). It has been shown 
that cGVHD patients have lower bone marrow B cell precursors compared with 
transplant patients without cGVHD (Storek et al., 2001, Sanchez-Garcia et al., 2006). 
Chronic GVHD appears to disturb the post-transplant B cell reconstitution in which it is 
characterized by blunt recapitulation with a lower circulating B cells count (Storek et al., 
1993). Generally, the recovery of memory B cells following allogeneic SCT and building 
the immunoglobulin repertoire may need many years to reach normality (Storek et al., 
1997, Avanzini et al., 2005). Multiple studies, however, have demonstrated that cGVHD 
further disrupts the memory population size. The total number of CD27+ B cells was 
found to be significantly lower in cGVHD patients compared with their no cGVHD 
counterpart (D'Orsogna et al., 2009, Hilgendorf et al., 2012, Greinix et al., 2008, Corre et 
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al., 2010).  In addition, memory B cells derived from the cGVHD inflammatory 
environment are expectedly activated and at a higher metabolic state (Allen et al., 
2012). The high BAFF levels required during the reconstitution period, in the presence 
of a relatively smaller naïve B cell population, promotes the survival of autoreactive B 
cells (Sarantopoulos et al., 2009, Sarantopoulos et al., 2007). Increased CD21- B cells in 
the peripheral blood of active cGVHD patients were reported. This population was 
referred to as immature/ transitional B cells based the lack of CD21 expression (Greinix 
et al., 2008). Other groups, however, observed decreased transitional B cells in cGVHD 
patients (Hilgendorf et al., 2012, Storek et al., 1993). 
Classical memory B cells are mainly characterised by the expression of CD27, a member 
of the TNF family, and possess somatically mutated V genes. However, CD27- isotype 
switched memory B cells have been described (Sanz et al., 2008). Of special interest is 
epithelial-associated lymphoid tissues residing FCR L4+ expressing B cells with activated 
phenotype. Although this subset lacks CD27 expression, it is still classified as memory B 
cells by virtue of the class switch and somatic hypermutation. FCR L4+ B cells respond to 
cytokines and CD40L ligation rather than BCR crosslinking, suggesting a potential 
regulatory function (Ehrhardt et al., 2005, Ehrhardt et al., 2008).   
Recently, a similar CD21-/lo B cell population was described in the peripheral blood of 
chronic HIV viraemic patients and individuals living in malaria endemic areas. The subset 
had relatively higher expression of inhibitory and homing receptors compared with 
naïve and classical memory B cells (Moir et al., 2008, Weiss et al., 2009). Likewise, this 
population had lower proliferative potential and reduced ability to differentiate into 
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antibody secreting cells. The inhibitory profile was similar to that of exhausted CD8+ T 
cells observed in chronic viral infections and therefore dubbed exhausted B cells (Moir 
et al., 2008). Interestingly, exhausted B cells were enriched within HIV specific B cells.  
In my project, I studied the frequency and phenotype of CD21- B cells in patients with 
cGVHD. I found that patients with cGVHD had significantly higher frequencies of CD21- 
B cells and that the majority of circulating CD21- B cells in these patients is 
phenotypically and functionally similar to exhausted B cells 
VI.2 Results: 
VI.2.1 Patient Characteristics:  
All patient samples were collected after written informed consent according to local 
policy guidelines at the Hammersmith Hospital, Imperial College NHS trust, and in 
accordance with the declaration of Helsinki.  
Blood samples were obtained from 33 patients who had undergone allogeneic HSCT 
between 1998 and 2011 and were six months or more post HSCT. This cohort included 
patients who underwent reduced intensity or myeloablative conditioning SCT and 
receiving bone marrow or mobilised peripheral blood stem cell grafts. All patients were 
more than six months post SCT with no evidence of primary disease relapse. Patients 
receiving high-dose steroids (> 50 mg prednisone) at the time of sampling or had 
received rituximab for any indication were excluded. Chronic GVHD status at the time 
of sample collection was classified according to documented clinical and laboratory data 
using National Institutes of Health (NIH) cGVHD consensus criteria and modified Seattle 
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criteria for limited versus extensive disease. Of the 30 assessable patients, thirteen 
patients had “active cGVHD” and two had “inactive cGVHD”. Inactive cGVHD was 
defined as patients with a history of cGVHD who were off immune-suppressive therapy 
and had quiescent disease at the time of analysis. Fourteen patients never developed 
cGVHD after HSCT. None of the “no cGVHD” patients were receiving immunosuppressive 
therapy at the time of sample collection. A total of 16 patients were assigned to the 
“cGVHD” group 14 active and 2 with inactive cGVHD and 14 to the “no cGVHD.   
Median time to cGVHD was 335 days (180-2947) after transplantation for patients with 
cGVHD compared with 481 days (349-4000) to sampling after transplantation for 
patients with no cGVHD (p= 0.24). Other clinical characteristics are shown in table (VI-
1). I also studied 11 healthy controls. The rest of cGVHD patients’ characteristics are 
shown in table (VI-2). 
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Table VI-1: Patient characteristics 
 
 
 
All (N=33) no cGVHD 
(N=14)
cGVHD 
(N=19)
Median age in years {range} 47 {25-68} 52.8 {25-65} 46.5 {37-68}
Sex
Male 24 (73) 8 (57) 16 (84)
Female 9 (27) 6 (43) 3 (16)
Diagnosis
Acute leukemia 11(33) 6 (42.8) 6 (31.5)
Chronic myeloid leukemia 11 (33) 5 (35.7) 5 (26.3)
Malignant lymphoma 3 (10) 1 (7) 2 (10.5)
Cutaneous T cel lymphoma 4 (12) 1 (7) 3 (15)
Others 4 (12) 1 (7) 3 (7)
Disease status at transplantation 
Standard risk 19 (58) 7 (40) 12 (63)
High risk 14 (42) 7 (50) 7 (37)
Conditioning regimen
Myeloablative conditioning 17 (51.5) 7 (50) 10 (53)
Reduced intensity conditioning 16 (48.5) 7 (50) 9 (47)
Stem cell donors
Related 16 (48.5) 3 (21.5) 13 (68)
Unrelated 17 (51.5) 11 (78.5) 6 (32)
HLA-identical 31 (94) 12 (86) 19 (100)
HLA-mismatched 2 (6) 2 (14) 0 (0)
Stem cell source
Bone Marrow 6 (18) 4 (28.5) 2 (10.5)
Peripheral Blood Stem Cells 27 (82) 10 (71.5) 17 (89.5)
Median number of CD34⁺ cells x10⁶ /kg 
transplanted 
8.6 {0.79-
12.77} 8.7 {0.79-12.2}
8.7 {2.8-
12.77}
Post-transplant immunosuppressive prophylaxis
Cyclosporine-Methotrexate 14 (42) 6 (42) 8 (42)
Cyclosporine-Methotrexate- Campath 13 (39) 4 (28.5) 9 (47)
Cyclosporine-Methotrexate-ATG 4 (12) 4 (28.5) 0 (0)
other 2 (6) 0 (0) 2 (11)
Acute GVHD
Grade 0 14 (42) 8 (58) 6 (31)
Grades I-II 13 (39) 5 (35) 8 (42)
Grades III-IV 6 (18) 1 (7) 5 (27)
Donor lymphocyte infusion (DLI)
Received DLI 16 (48) 4 (28.5) 12 (63)
Received no DLI 17 (52) 10 (71.5) 7 (27)
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Table VI-2: chronic GVHD characteristics 
  
cGVHD (N=19)
number (percent)
Onset type of chronic GVHD
De novo 9 (47.5)
Quiescent 8 (42)
Progressive 2 (10.5)
cGVHD status
Resolved 2 (10.5)
Active 17 (89.5)
cGVHD organ involvement 
Skin 15 (78)
Eyes 6 (31.5)
Oral mucosa 4 (21)
Liver 5 (26)
Lungs 2 (10.5)
Musculoskeletal 1 (5)
1 or 2 organs 10 (52.5)
> 2 organs 9 (47.5)
Overall cGvHD grade
Mild 5 (26.3)
Moderate 7 (36.8)
Severe 7 (36.8)
Immunosuppressive therapy
None 3 (16)
MMF+ECP+/- steroids 11 (58)
Others 5 (26)
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VI.2.2 B cell subsets in cGVHD: 
VI.2.2.1 Chronic GVHD patients have lower number of circulating B cells: 
Consistent with previous reports (Corre et al., 2010), cGVHD patients had significantly 
lower lymphocyte counts compared with patients without cGVHD and healthy controls 
(median 1300 vs. 2050 vs. 1700 cell/µl; p=0.008 and p= 0.01 respectively); figure (1) A. 
Nevertheless, not all cGVHD patients met the clinical diagnosis of lymphopenia i.e. count 
<1000/ µl.(Mitrovic et al., 2012) Similarly, cGVHD patients had lower numbers of CD19+ 
B cells compared with no-GVHD counterparts (median 216 vs. 378 cell/µl; p=0.02); 
figure (VI-1) B. There was no difference between B cell numbers in cGVHD patients and 
healthy controls.  
 
 
Figure VI-1: lymphocyte and CD19+ B cell counts among patients with and without 
cGVHD and HC 
Box plots, showing medians, 25th and 75th percentiles and ranges, comparing total 
lymphocyte count (A) and total CD19+ve B cells (B) between 16 cGVHD patients, 14 “no 
cGVHD” patients and 11 healthy controls.   
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VI.2.2.2 Chronic GVHD patients have lower number of naive B cells: 
I then examined the frequencies of B cell subsets in the post-transplant groups. Naïve B 
cells were defined as (CD19+IgM+CD27−) B cells, total CD27+ memory B cells were defined 
as (CD19+ CD27+) and further subdivided into IgM memory CD19+ CD27+ IgM+ B cells and 
class-switched memory B cells (CD19+ CD27+ IgM-). To quantify transitional B cells and 
confirm other B cell subsets frequencies, I also performed the analysis using the markers 
CD24 and CD38. Transitional B cells were defined as CD19+CD24hiCD38hi, naïve cells 
CD19+CD24+CD38+; total memory B cells CD19+CD24hiCD38- and finally circulating 
plasmablasts as CD19+CD24-CD38hi. In agreement with the described reduction of 
circulating naïve B cells (Sarantopoulos et al., 2009), active cGVHD patients had lower 
absolute number and frequencies of naïve B cells compared with the “no cGVHD” 
patients (median 158 vs. 338 cell/µl; p=0.03 and 77.7% vs.88.5%; p=0.01) respectively. 
There was no significant difference in naïve B cell number between cGVHD patients and 
healthy controls (median 158 vs. 149.2 cell/µl; p=0.8). Likewise, active cGVHD patients 
had a smaller transitional B cell population compared with both “no GVHD” patients and 
healthy controls (median 0.5 vs. 22.3 vs. 4.75 cell/µl; p=0.0003 and p= 0.0001 
respectively). Table (VI-3) and figure (VI-2)  
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Figure VI-2: B cell subsets in “no GVHD”, cGVHD and a HC 
FACS plots demonstrating CD19+ B cell in a representative “no GVHD” patient, cGVHD 
patient and a healthy control. Gated CD19+ B cells were examined for CD24 and CD38 
expression; transitional (CD19+CD24hiCD38hi), naïve (CD19+CD24+CD38+), memory 
(CD19+CD24hiCD38-) and plasmablasts (CD19+CD24-CD38hi). 
 
VI.2.2.3 Chronic GVHD patients have higher percentage of CD27+ B cells 
cGVHD and “no GVHD” patients had a significantly lower absolute number and 
frequencies of total CD27+ memory B cells compared with healthy individuals 22 vs. 33.5 
vs. 63.6 cell/µl; p=0.012 and p=0.047 respectively and 15.6% vs. 6.6% vs. 25%, p=0.0004 
and p=0.06 respectively. Although cGVHD patients had lower CD27+ memory B cells 
compared with “no GVHD” patients , the difference was not significant median count 22 
vs. 33.6 cell/µl; p=0.23. However, due to fewer CD27- B cells, cGVHD patients had a 
relatively higher proportion of circulating CD27+ memory B cells 15.6% vs. 6.6%; p= 
0.014.  Further analysis of class-switched and IgM memory B cell subpopulations 
revealed that both B cell subgroups were also less frequent in each post-HSCT group 
compared with healthy individuals. Chronic GVHD patients tended to have lower 
number IgM+ 11 vs. 12.6 cell/µl; p=0.3 and IgM- 6.9 vs. 19.2 cell/µl; p= 0.23 respectively 
with relatively higher percentage IgM+ 5.1% vs. 3.1%; p=0.03 and IgM- 7.6% vs. 3.05%; 
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p=0.054 respectively of IgM- CD27+ B and IgM+ CD27+ B memory cells compared with 
their “no GVHD” counterparts, figure (VI-3) and table (3). 
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Figure VI-3: Comparison of B cell subset frequencies in “no GVHD” patients (n=14), 
cGVHD patients (n=16) and healthy controls (n=11) 
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Table VI-3: Absolute counts of cell subsets in “no GVHD” patients (n=14), cGVHD 
patients (n=16) and healthy controls (n=11)  
    
B cell subset (cell/μl) No GVHD cGVHD Healthy Controls 
 
Transitional  
 
22.3 
 
0.5 
 
4.62 
P value  0.0003  0.0001 
 
Naïve  
 
338 
 
158 
 
149.2 
P value 0.01  0.03 
 
Total CD27+  
 
33.5 
 
22 
 
62.3 
P value 0.04  0.012 
 
IgM+ CD27+ 
 
12.59 
 
11.08 
 
14.41 
P value 0.31  0.32 
 
IgM- CD27+ 
 
19.22 
 
6.97 
 
26 
P value 0.023  0.03 
 
Plasmablasts  
 
1 
 
0.42 
 
0.18 
P value 0.26  0.06 
    
 
VI.2.2.4 Chronic GVHD patients have higher frequencies of CD21- B cells: 
An expanded population of CD21- B cells have been recently reported in active cGVHD 
patients (Greinix et al., 2008). We identified an expanded population of CD19+CD21- B 
cells 12.2% (1.3%-34.9%) in patients with cGVHD. In contrast significantly fewer 
CD19+CD21- B cells were present in the peripheral blood of patients without cGVHD 
[2.12%, (0.67%-20.1%); p=0.004] and healthy controls [3%, (1.5%- 8.15%); p=0.01]. 
Notably, the only patient without cGVHD with increased frequencies of CD19+CD21- B 
cells had evidence of EBV reactivation at the time of analysis; figure (4A). The majority 
of CD19+CD21- B cells in the peripheral blood of cGVHD patients expressed high levels 
200 
 
of CD20, lacked expression of CD10, CD27, CD24 and CD38 and expressed lower IgD and 
IgM compared with CD21+ B cells and therefore, did not display the phenotype of 
transitional B cells, figure (VI-2B and VI-2C); such a profile is similar to that of exhausted 
B cells recently described in HIV patients (Weiss et al., 2009).    
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A. 
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Figure VI-4: CD21 expression examination in cGVHD, no GVHD and HC 
A. FACS plots of gated CD19+ B-cell examining CD21 expression in a representative “no 
GVHD” patient, GVHD patient and a healthy control. Chronic GVHD patients (n=16) have 
significantly higher percentage of circulating CD21- B cells compared with “no GVHD” 
patients (n=14) and healthy controls (n=11) B. Colour-coded gating on CD19+ B cells in 
representative “no GVHD” and active cGVHD patients; (Yellow) CD19+/CD21- B cells of 
“no cGVHD” patient, (Red) CD19+/CD21- B cells of “cGVHD” patient, (Black) total CD21+ 
B cells. The majority of CD21- B cells (yellow) in “no cGVHD” fall in the CD24hiCD38hi 
transitional B cell and CD24-CD38hi plasmablast regions. Conversely, the majority of 
CD21- B cells in “cGVHD” case (Red) fall in CD24-CD38- exhausted B cell and CD24-CD38hi 
plasmablast regions. C. Phenotypic characterisation of CD21- B cells, transitional (Yellow) 
and exhausted B cells (Red) compared with CD21+ B cells. Transitional B cells express 
high CD24, CD38 and IgM, positive for CD10, CD20 and IgD and negative for CD27. 
Exhausted B cells are negative for CD10 and CD27; express low CD24 and CD38 and 
variable IgM and IgD.  
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The remaining CD21- B cells in cGVHD patients were distributed among plasmablasts 
(CD19+, CD10-, CD21-, CD27hi), activated memory B cells (CD19+, CD10-, CD21-, CD27+) 
and immature/ early transitional B cells (CD19+, CD10+, CD21-, CD27-). Using CD10 
expression as a marker of immature/ early transitional B cells within the CD21- 
population, cGVHD patients had fewer immature B cells compared to no GVHD patients 
(median percentage 3.15% vs. 9.34%; p=0.045), however the absolute counts were not 
statistically different in the two groups (median count 0.77 vs. 1.2 cell/μl; p=0.16).  
VI.2.2.5 Phenotypic characterisation of CD21- B cells in cGVHD patients:  
Exhausted CD21- B cells have been shown to express an array of chemokine and 
inhibitory receptors a signature of exhaustion and tissue relocation (Weiss et al., 2009). 
Accordingly, I compared the expression of inhibitory receptors FCRL4, CD22 and CD85J 
and trafficking receptors CD11c, CXCR3, CCR6, CD62L and CCR7 on CD19+CD10-CD21-
CD27- B cell population with CD19+CD10-CD21+CD27- naïve and CD19+CD10-CD21+CD27+ 
classical memory B cells.   
CD19+CD10-CD21-CD27- B cells of cGVHD patients expressed significantly higher levels 
of CD22 and CD85J compared with both naïve and classical memory B cells; figure (VI-
5). Although this subset also expressed a higher level of FCRL4 compared with naïve B 
cells, there was no significant difference in the expression of FCRL4 between the 
expanded CD21- B cells and classical memory B cells (p=0.02 and p=0.45 respectively). 
CD21- B cells in cGVHD patients expressed significantly higher CD11c and CXCR3 
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compared to naïve and classical memory B cells (p=0.008 and p=0.03 and p=0.007 and 
p=0.42 respectively). In contrast, the homing receptors CCR7 and CD62L were expressed 
at significantly lower levels on CD21- B cells compared with both classical memory and 
naive B cells (p=0.007 and p=0.008), indicating altered homing of this subset of B cells. 
Little difference was observed in the expression of CCR6 amongst the three B cell 
subsets; Figure 3 B. Overall, the inhibitory and homing profile of expanded CD21- B cells 
in cGVHD is similar to that described for the - exhausted B cells in HIV and in virus-specific 
CD8+ T cell exhaustion in chronic viral infections (Moir et al., 2008, Moir et al., 2004, 
Weiss et al., 2009). 
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Figure VI-5: Inhibitory and chemokine receptor profile of naïve, classical memory and 
CD21- B cells 
A. Colour-coded gating on CD27/CD21-stained B cells of a representative cGVHD patient 
used to examine the expression of inhibitory and chemokine receptors on naïve (blue), 
classical memory (red) and CD21- B cell (black). B. Inhibitory and homing receptor 
expression on CD21- B cells relative to naïve and classical CD27+ memory B cells. Plots 
depict individual median fluorescence intensity (MFI) values for each cell subpopulation 
of 5 cGVHD patients.  
B. 
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VI.2.2.6 B cells from cGVHD patients have impaired proliferative potential: 
To further investigate the hypothesis that the expanded CD19+CD21- B cells in cGVHD 
are exhausted, we compared the proliferative potential of CD19+ B cells in patients with 
or without GVHD and healthy controls. The proliferative capacity of B cells was assessed 
in response to B cell receptor (BCR) and CD40 triggering. CFSE-stained PBMC from 5 
cGVHD, 4 no GVHD patients and 5 healthy controls were stimulated with anti-CD3/anti-
CD28 beads (CD40 triggering), anti IgM/anti IgG (BCR triggering) or the combination of 
anti-CD3/anti-CD28 and anti IgM/anti IgG triggering for 96h. Activated T cells 
upregulated CD154 receptor (CD40L) upon stimulation and in turn activate CD19+ B 
cells. The addition of anti-BCR in the presence of activated T cells provides dual 
stimulation of B cells (Blair et al., 2010).  
B cells from patients with or without cGVHD and healthy controls stimulated with anti-
BCR alone failed to proliferate at 96 hours, figure (VI-6A). Analysis of CFSE-labelled B 
cells stimulated with anti-CD3/CD28 beads alone revealed poor proliferative response, 
with no significant difference in CD19+ B cell proliferation in patients with or without 
cGVHD and healthy controls (median percentage of divided cells, 24.9% vs. 27.7% vs. 
33.7% respectively; p=0.77); figure (VI-6A and VI-6B). The addition of BCR triggering to 
CD40 ligation resulted in significant enhancement in the proliferation of B cells from 
patients without GVHD and healthy controls (27.7% vs. 73.2%; p=0.0002 and 33.7% vs. 
69.6% p=0.0006) respectively; Figure 4C. In contrast, the addition of CD40 ligation to 
BCR triggering failed to significantly enhance the proliferative capacity of B cells from 
cGVHD patients [24.9% (2.5-75) vs. 36.6% (19.2-65.3); p=0.47] and they proliferated at 
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significantly lower levels compared to patients without cGVHD and healthy controls 
(median percentage of divided cells, 36.6% vs. 73.2% vs. 69.6%; p= 0.02 respectively; 
p=0.006), figure (VI-6C). These data indicate that B cells from cGVHD patients with a 
significantly expanded population of CD19+CD21- B cells exhibit proliferative deficiencies 
when compared with B cells from patients without cGVHD or healthy controls.  
 
HC
No cGvHD
cGvHD
Anti BCR CD3/CD28 + anti BCRA. CD3/CD28A. 
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Figure VI-6: Proliferation assessment of B cells in no GVHD, GVHD and HC 
Proliferation of CD19+ B cell in a HC, no GVHD and cGVHD patients. CFSE stained PBMC 
were stimulated with anti BCR alone, anti CD3/ anti CD28 alone or both for 96h. A. 
representative CFSE proliferation histograms comparing gated CD19+ B cells. Figures (B 
and C) Compare B cell proliferation of 5 cGVHD patients, 4 no GVHD patients and 5 
healthy controls. B. Chronic GVHD patients had the lowest proliferative potential in 
response to dual stimulation compared with “no GVHD” patients and HC. C. Only B cells 
from cGVHD patients failed to proliferate when anti-BCR was added to CD40L. 
Percentage of proliferating B cells was calculated using proliferation platform of FlowJo 
analysis software. 
 
 
 
 
 
 
 
B. 
C. 
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VI.2.2.7 The frequency of CD21- B cells correlates with cGVHD severity: 
SCT patients were classified according to the frequency of CD19+CD21- B cells using a cut 
off of 5% (normal upper limit)(Moir et al., 2008) and CD19+CD21- B cell frequencies were 
correlated with disease severity, figure (VI-7) and table 4. The Odds Ratios for severe, 
moderate and mild cGVHD were 26.9 (p<0.001), 19.5 (p=0.001) and 4.5 (p=0.04) 
respectively. The frequencies of CD19+CD21- B cell were also predictive for the 
development and severity of cGVHD when considered as a continuous variable with an 
OR for severe, moderate and mild cGVHD of 1.31 (p=0.001), 1.22 (p=0.005) and 1.17 
(p=0.02) respectively. We also examined the influence of other clinical variables 
including patient age; p=0.47, donor-recipient sex mismatch; p=0.36, conditioning 
regimen; p=0.52, cell dose; p=0.12, stem cell donor; p=0.08, GVHD prophylaxis; p=0.11 
and history of acute GVHD; p=0.09 on the development and severity of cGVHD (Table 
1). Variables found to be predictive at a level p<0.1 (history of aGVHD and stem cell 
donor), were included in a multivariate ordinal logistic regression model. Previous 
history of aGVHD (p=0.01) and CD21- B cell frequencies > 5% (p=0.001) were the only 
variables found to be independently associated with cGVHD. 
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Figure VI-7: Box plot showing the frequency of exhausted B cells per cGVHD grades 
(mild to severe). 
 
 
 
Table VI-4: NIH-defined cGVHD grade and exhausted B cells percentage, based on a 
cut off of 5%.   
 
  
  
cGvHD grade 
Total No cGvHD Mild Moderate  Severe 
CD21-
% 
<5% 12 4 1 0 17 
>5% 2 1 4 5 12 
Total 14 5 5 5 29 
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VI.2.3 Discussion:  
I compared B cell subsets in the peripheral blood of patients with and without cGVHD 
and healthy controls. B cell reconstitution following allogeneic stem cell transplantation 
appears to recapitulate B cell ontogeny (Storek et al., 1993, Marie-Cardine et al., 2008). 
Transitional B cells appear first in the peripheral blood and progressively decrease, giving 
rise to naïve B cells (Marie-Cardine et al., 2008, Anolik et al., 2007). The balance of high 
BAFF levels required for the production of new B cells in relation to B cell number allows 
normal B cell recovery. High BAFF levels have been found to promote survival of auto-
antigen reactive B cells (Lesley et al., 2004). Accordingly, the early period following 
allogeneic SCT is characterised by supranormal B cell numbers with high homeostatic 
levels of BAFF (Storek et al., 1993, Sarantopoulos et al., 2009). The majority of circulating 
B cells are antigen-naïve since the memory compartment remains significantly lower 
than normal up to one year post-transplant (Avanzini et al., 2005, Bemark et al., 2012, 
Cuss et al., 2006, Storek et al., 1997). The development of cGVHD has been found to 
further disrupt bone marrow B lymphopoiesis and consequently lower B cell count 
(Storek et al., 2001, Sanchez-Garcia et al., 2006). Consistent with the described 
lymphopenia associated with cGVHD, my cGVHD patients had significantly lower 
lymphocyte counts compared with both no GVHD patients and healthy controls (Corre 
et al., 2010). However, not all cGVHD patients in my study met the criteria for a diagnosis 
of lymphopenia of less than 1x103 cells per µl (Mitrovic et al., 2012). In my study, 
although cGVHD patients had a comparable B cell count to that of healthy individuals, 
they would still be expected to have a higher BAFF to B cell ratio than normal. 
212 
 
Sarantopoulos et al has proposed that a high BAFF to B cell ratio in the setting of relative 
naïve B lymphopenia of cGVHD is a potential explanation for maintaining auto-reactive 
B cells. Although the absolute number of CD27+ B cells was lower in cGVHD compared 
with no GVHD patients, they had relatively higher representation in the PB 
(Sarantopoulos et al., 2007, Sarantopoulos et al., 2009). Furthermore, cGVHD derived 
memory B cells were found to be chronically activated (Allen et al., 2012). Several 
studies have reported similar observations but with variable effects on the class-
switched and non-switched CD27+ memory B cells. In one study, memory B cell 
deficiency in cGVHD was limited to the IgM+ memory B cell subset (D'Orsogna et al., 
2009). In other studies both subpopulations were numerically and proportionally 
reduced in cGVHD compared with no GVHD counterpart (Hilgendorf et al., 2012, Greinix 
et al., 2008). My data are consistent with published literature. While my cGVHD patients 
had lower CD27+ B cell population compared to no GVHD and HC, cGVHD patients had 
relatively higher CD27+ B memory B cells as well as IgM and class-switch memory B cells 
in the peripheral blood. This observation resulted from the relatively lower CD27- 
(transitional and naïve) B cell numbers.  
Interestingly, I found an extended circulating CD21- B cell population in the PB of cGVHD 
patients consistent with the previously published reports. Greinix el al referred to this 
subset as immature B cells, based on the sole lack of CD21 expression (Greinix et al., 
2008). Using different transitional B cell markers such as the high expression of CD24, 
CD38 on CD19+ B cells, or absence of CD27 and CD21 expression on CD10+ CD19+ B (Sims 
et al., 2005, Palanichamy et al., 2009, Suryani et al., 2010), I demonstrated that cGVHD 
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patients have fewer transitional B cells compared with patients without cGVHD.  I herein 
investigated the expanded CD21- B cell population in cGVHD using an extended 
multicolour flow cytometry panel. The analysis revealed that the majority of CD21- B 
cells were CD10- CD27- CD21- CD20hi, which is similar to the previously identified 
exhausted B cells described in patients with chronic HIV viraemia (Moir et al., 2008). I 
also found that the expanded CD21- B cell population in my cGVHD patients shared 
considerable phenotypic similarity with exhausted B cells. First, the expression of the 
inhibitory receptors CD22, CD85J and FCRL4 was higher compared with the naïve 
compartment. Second, another important feature was the higher expression of the 
chemokine receptors CD11c and CXCR3 and lower expression of the homing receptors 
CCR7 and CD62L. The profile of inhibitory and chemokine receptors favours relocation 
of this population to inflamed tissue.  
Similar CD21- B cell populations have been observed in numerous conditions associated 
with chronic inflammation especially autoimmune and chronic viral infections e.g. 
rheumatoid arthritis (Isnardi et al., 2010), SLE (Wehr et al., 2004), HCV infection (Terrier 
et al., 2011, Charles, 2011), chronic HIV viraemia (Moir et al., 2008), chronic malarial 
infestation (Weiss et al., 2009), CVID (Rakhmanov et al., 2009), and cGVHD (Greinix et 
al., 2008). The expanded CD21- B cell population in these studies was shown to have 
impaired proliferative potential and Ca2+ responses. I therefore sought to examine the 
proliferation capacity of the expanded CD21- B cell population in patients with cGVHD. 
Given that CD21- B cells constituted a considerable proportion of PB B cells in cGVHD, 
and available samples were not enough to sort purify this population, I compared the 
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total B cell response to T cell induced stimulation in vitro. B cells from cGVHD patients 
mounted a lower proliferation response to BCR stimulation. Sorting this subset and 
studying the proliferation and other exhaustion assays in comparison to conventional B 
cells is therefore warranted.  
Chronic GVHD provides a chronic inflammatory environment and in many aspects 
mimics autoimmune and fibrogenic conditions. B cells are constantly exposed to 
pathogenic antigens and are in a persistent activated state. It is conceivable that 
activated B cells compensate by dampening BCR mediated activation to prevent 
activation-induced self-destruction.  Indeed higher expression of CD22, CD85J and FCRL4 
and lower CD21 inhibit BCR mediated signalling and increase the activation threshold of 
B cells (Walker and Smith, 2008, Lamar et al., 2010, Barrington et al., 2005, Sohn et al., 
2011) A number of investigators have shown the expansion of Ag driven clonal CD21-/lo 
B cells expressing autoreactive BCRs in the peripheral blood of HCV infected individuals 
with autoimmune and lymphoproliferative manifestations.  These CD21lo B cells were 
unresponsive to BCR stimulation, with decreased proliferation and attenuated Ca 
response (Terrier et al., 2011, Charles et al., 2008). Similar findings were reported by 
Moir et al in chronic HIV viraemic patients where exhausted B cells were enriched within 
HIV specific B cells (Moir et al., 2008).   
The question of whether exhaustion is a global process or an antigen specific 
phenomenon remains unanswered. Reversing B cell exhaustion in chronic infection may 
improve immunity against pathogenic organisms (Kardava et al., 2011). Using similar 
logic one could suggest that applying the same approach to autoimmune conditions or 
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cGVHD might augment the deleterious effects of Ag specific B cells. Further work is 
needed to study this subset in cGVHD patients and to ascertain its clonality and its origin 
with more in-depth molecular studies.  
If exhausted B cells are clonal and Ag specific reversing their exhausted state may be 
detrimental, in which case eliminating host B cells (as with rituximab) and re-infusing 
normal donor B cells in the form of B cell DLI may be useful. However, if the exhaustion 
is a global phenomenon affecting the B cell repertoire, attempts at reversing it could be 
beneficial, especially if regulatory B cells are also affected. Nevertheless, in light of 
current available knowledge, CD21- B cells may serve as a useful biological marker of 
cGVHD. 
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Chapter VII. General Discussion and future plans  
VII.1 General Discussion  
HSCT is an important treatment modality for a number of haematological conditions. 
The outcome is severely affected by the associated complications especially graft-
versus-host disease (GVHD). Chronic GVHD disease affects a considerable proportion of 
HSCT recipients with a high mortality rate (Blazar et al., 2012a). Alloreactive donor T cells 
play a pivotal role in the initiation and development of GVHD. Therefore, much research 
has been centred on the role of T cells in the pathogenesis of GVHD and clinical practice 
reflects this paradigm. T cell-directed immunosuppression forms the cornerstone of the 
prevention and treatment of GVHD (Ferrara et al., 2009); although, in some cases 
without significant success (Khaled et al., 2009). 
Recently, B cells have been implicated in the pathogenesis of cGVHD in a number of pre-
clinical and clinical studies. In keeping with a pathological role for B cells, around half of 
refractory cGVHD patients respond to rituximab, an anti-CD20 monoclonal antibody 
(Mohty et al., 2008). The fact that only half of cGVHD cases improve with B cell depletion 
indicates that B cells may not be pathogenic in certain circumstances. Moreover, B cell 
derangements are often observed during immune reconstitution following HSCT 
conditioning which further confound the understanding of the role of B cells in cGVHD. 
A number of descriptive studies have analysed the peripheral blood B cell subsets in 
cGVHD patients (Kuzmina et al., 2011, Corre et al., 2010).  Interestingly, an expanded 
population of CD19+CD21- B cells, identified as immature/transitional B cells, was 
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recently observed in cGVHD patients and was correlated with disease severity (Kuzmina 
et al., 2009, Kuzmina et al., 2013).  
Further insight into the role of this subset in cGVHD is warranted especially since a 
number of studies have reported the presence of CD21- B cells with an exhausted 
phenotype in autoimmune disorders and chronic infections (Malaspina et al., 2006, Moir 
et al., 2008, Weiss et al., 2009, Charles et al., 2008, Terrier et al., 2011, Visentini et al., 
2012). Chronic GVHD certainly shares considerable similarities with autoimmune 
diseases and is associated with a propensity to chronic infections.    
Human IL10 producing regulatory B cells have been identified with more than one 
phenotype (Mauri and Blair, 2010b). Controversy with regards to their phenotype 
extends to their roles in human autoimmune diseases and thus far has not been 
resolved. Blair et al have defined these cells as CD24hiCD38hi transitional B cells and 
demonstrated impaired function in SLE patients (Blair et al., 2010). Conversely, Tedder 
and colleagues identified IL10+ B cells as CD24hiCD27+ memory B cells and importantly 
without quantitative impairment in a number of autoimmune diseases (Iwata et al., 
2010). There is considerable evidence from mouse experiments to support both findings 
which suggest that more than one phenotype may actually exist. Further research into 
human IL10+ B cells is therefore required to attempt reconciliation of the available data 
and harness their potential in clinical practice.  
To date, no information is available on role of this subset of B cells in cGVHD. Chronic 
GVHD is a logical candidate for this study in view of its development in a disparate HSCT 
immune environment. It has been shown that regulatory T cells are reduced in cGVHD 
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(Zorn et al., 2005); it is likely that a wider regulatory dysfunction is implicated. 
Furthermore, HSCT allows the transfer of donor immune cells post HSCT which is not 
currently an option in other autoimmune disease settings. 
In my PhD project, I aimed, first, to study B cell subsets in the peripheral blood of cGVHD 
patients with special focus on CD21- B cells. Secondly, I optimised the IL10 intracellular 
staining assay to phenotype IL10+ B cells and ultimately, assess this population in cGVHD 
patients.  
Flow cytometry provides a powerful tool to study cell populations through the use of 
specific staining and various gating techniques. I designed an extended panel that 
incorporates a constellation of markers used in a number of B cell classification schemes, 
in addition to CD21 and CD10 (Sanz et al., 2008). The panel was titrated and validated 
on healthy control samples before applying it to frozen samples from cGVHD patients.  I 
correlated different B cell subsets according to different B cell phenotyping 
classifications. Interestingly, there was a considerable overlap among different 
classification systems, however, each had its own inherent limitation stemming mainly 
from the limited number of markers used. Furthermore, the panel allowed the 
assessment of rare B cell populations including CD27- memory B cells, transitional B cells, 
plasmablasts and CD21- B cells. I acknowledge that the analysis of CD27- memory subset 
in particular is based on the negative expression of IgM and IgD rather than positive 
expression of IgA or IgG. I also demonstrated that the CD27/IgM combination could be 
used as a sorting panel and is potentially superior to CD27/IgD. I also studied and 
compared B cell subsets in both genders as well as the effect of cryopreservation on the 
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expression of B cell specific surface markers. The latter is particularly important to 
validate studies on frozen products. Additional work is required to validate these 
findings on a larger sample cohort.  
Next, I compared peripheral blood B cell subsets in a group of patients with and without 
cGVHD and healthy controls. Consistent with published data, cGVHD patients had a 
significantly lower lymphocyte count compared to patients without cGVHD and healthy 
controls (Corre et al., 2010). Although cGVHD patients had a comparable B cell count to 
that of healthy individuals, they would still be expected to have a higher BAFF to B cell 
ratio than normal. Sarantopoulos et al has proposed that a high BAFF to B cell ratio in 
the setting of relative naïve B lymphopenia of cGVHD is a potential explanation for 
maintaining auto-reactive B cells (Sarantopoulos et al., 2007, Sarantopoulos et al., 
2009). Whilst my cGVHD patients had fewer CD27+ B cells compared to the no GVHD 
group and HC, they had relatively higher frequencies of CD27+ memory B cells (IgM and 
class-switch memory B cell proportions) in the peripheral blood, because of the relative 
naïve B cell lymphopenia (Hilgendorf et al., 2012, Greinix et al., 2008).  Interestingly, I 
also identified an expanded CD21- B cell population in cGVHD patients, consistent with 
previous reports (Greinix et al., 2008). Further analysis revealed that the majority of 
CD21- B cells were CD10-CD27-CD21-CD20hi and expressed a distinct profile of inhibitory 
and chemokine receptors, analogous to that of exhausted B cells described in patients 
with chronic HIV viraemia (Moir et al., 2008). Indeed, B cells from cGVHD patients 
mounted a lower proliferation response to BCR stimulation which further supports their 
exhausted phenotype.  
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I next demonstrated that IL10+ CD19+ B cells are enriched within the CD24hiCD38lo and 
expressed IgD and a high level of IgM. Those with an IL10+ B cell phenotype also 
expressed CD20, CD21, CD22, CD40, HLA DR and CD268 (BAFFR). These data therefore 
suggest that IL10+B cells are CD24hi CD38lo CD27+CD23- IgD+ IgMhi CD1dhi CD19+ consistent 
with an IgM memory B cell phenotype. The functional assessment of sorted IgM memory 
B cells revealed that this population suppressed IFNγ production by CD4 T cells. In 
addition, IgM memory B cells suppressed CD4 T cell proliferation, to a similar extent to 
Treg. IL10 blocking experiments suggested that the regulatory function of IgM memory 
B cells is, at least partly, IL10 dependent. These results are in keeping with Tedder et al’s 
report that IL10+ B cells belong to a memory subset, CD24hiCD27+ B cells, and express 
CD148, another memory B cell marker. Interestingly, in their study, CD27+ B cells 
suppressed both IFNγ and TNFα production by CD14+ monocytes but not CD4+ T cells 
(Iwata et al., 2010). In my study, IL10+ B cells were further defined as CD27+CD24hi IgM 
memory B cells. Transitional B cells are defined as CD24hi IgMhiIgD+CD1dhi, in addition to 
being CD27-, and can be both CD23- and CD23+. Taking all these findings into 
consideration, for clinical purposes, sort-purification based on a phenotype of 
CD24hiIgMhiCD19+ B cells is likely to yield an enriched population of IL10+ regulatory B 
cells. 
It has been shown that Treg are numerically and functionally impaired in cGVHD, which 
in turn may contribute to impaired self- tolerance and survival of autoreactive effector 
T cells (Matsuoka et al., 2010). Regulatory B cells have been recognised as a powerful 
regulator of immune responses, with increasingly identified roles in human autoimmune 
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diseases (Mauri and Bosma, 2012). To date, no data exist on the potential role of 
regulatory B cells in GVHD. I found reduced frequencies and absolute IL10+ CD19+ B cell 
count in the peripheral blood samples from cGVHD patients compared to those with no 
GVHD and HC. Furthermore, cGVHD patients failed to produce the expected higher IL10+ 
B cell frequencies and numbers, when stimulated with L cells alone compared to dual 
stimulation. These results suggest that either there is a numerical or functional 
deficiency of Breg in cGVHD or that these cells have a defective response to CD154 
stimulation. Fewer IL10+ B cells in cGVHD could simply mean fewer B cells capable of 
producing IL10or their precursors. In addition, hypofunction of IL10 capable B cells in 
the presence of normal numbers of IgM memory B cells is another possibility. However, 
the lack of a specific marker renders exploring this proposition challenging at present. It 
has been reported that regulatory B cells from SLE patients are refractory to CD40 
engagement; i.e. B- T cell cross talk, with reduced phosphorylation of STAT3 
downstream of CD40. In this study, alternative stimulation with CpG restored a normal 
IL10 response (Blair et al., 2010). There is some evidence that SCT recipients accumulate 
less Antigen-driven T cells consequent on an intrinsic B cell deficit or impaired T-B cross 
talk rather than on T cell help defect (Glas et al., 2000).   
I also assessed IFNγ+ CD4+ T cell frequencies and function in patients with or without 
cGVHD and healthy controls. In agreement with a previous report (Nakamura et al., 
2005), I found no significant difference in IFNγ+ CD4+ T cells between cGvHD and “no 
GvHD” patients. However, the ratio of IFNγ+ CD4+ T cells to IL10+ B cells was significantly 
higher in cGVHD patients, which implies an imbalance between the regulatory and 
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effector systems. The proposed imbalance adds to the recognised association of 
Treg/Teff imbalance in cGVHD. A smaller Treg population relative to total CD4 cells, 
which by default include effector cells, predisposes SCT patients to cGVHD (Matsuoka et 
al., 2010). My findings support a wider deficit in regulatory networking, which appears 
to affect both Breg and Treg, and extends the current investigation to other factors that 
are common to both lineages such as post-transplant environment and cell 
reconstitution. B cell regeneration sites such as the bone marrow, spleen and lymph 
nodes are damaged by SCT conditioning (Sale et al., 1992). Chronic GVHD further 
worsens the splenic hypofunction seen in SCT patients (Cuthbert et al., 1995). Moreover, 
experimental evidence supports the notion that the cGVHD-associated damage to the 
bone marrow niche may further impair B cell lymphopoiesis (Shono et al., 2010). 
Chronic GVHD provides an inflammatory environment in which B cells are exposed to 
self-antigens as well as pathogen-associated molecules. B cells are thereby constantly 
activated in a T cell dependent and independent manner. Furthermore, regulatory T cell 
deficits reported in cGVHD help maintain the pro-inflammatory environment of the 
disease. I additionally report that regulatory B cells are also defective in cGVHD in 
keeping with the pro-inflammatory nature of cGVHD.  
A number of investigators have reported the presence of expanded populations of Ag-
specific, clonal CD19+CD21-/lo B cells in the peripheral blood of patients with chronic 
viraemia. These CD19+CD21lo B cells were anergic, with decreased proliferation and 
attenuated Ca2+ response to BCR stimulation (Terrier et al., 2011, Charles et al., 2008, 
Moir et al., 2008). In addition, chronic non-specific T- independent activation of B cells 
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induced by HIV- associated molecules such as gp-120 in the presence of high BAFF levels 
was shown to cause functional exhaustion(He et al., 2006). I propose that the cGVHD 
environment may lead to B cell exhaustion, possibly via one or both of the activation 
pathways. Chronic GVHD is a unique condition, in that it mimics autoimmune disorders 
as well as being associated with chronic infections and colonisation. 
It remains unclear whether the exhausted CD19+CD21- B cells in cGVHD patients are 
directly involved in the pathogenesis of the disease, a consequence of constant 
activation, or the result of impaired B cell reconstitution. The question of whether 
exhaustion is a global process affecting all B cells or only antigen-specific B cells remains 
open. Without better tools to analyse Ag-specific B cells at the single-cell level, and a 
better understanding of antigens involved in the B cell-driven immune process in 
cGVHD, many of the concepts regarding the mechanisms of B cell exhaustion in cGVHD 
will remain speculative.  
It is conceivable that B cell exhaustion confers protection from self-destruction and 
autoimmunity, in case the exhaustion was driven by specific self-antigens. On the other 
hand, global B cell exhaustion, in addition to self-protection, may contribute to 
immunodeficiency and susceptibility to severe infections. Interestingly, a recent study 
reported that downregulating the expression of inhibitory receptors on exhausted CD21- 
B cells using RNAi technology can effectively reverse B cell exhaustion in HIV and 
improve immunity against pathogenic organisms (Kardava et al., 2011).  It is tempting 
to suggest that downregulating inhibitory receptors on CD19+CD21- exhausted B cells in 
cGVHD may also improve their effector function and at least partially reverse the 
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immune impairment seen in these patients. Alternatively, if CD21- B cells are in fact 
antigen-specific and directly involved in the pathogenesis of GVHD, reversing their state 
of anergy may have deleterious consequences on disease severity.  
Nevertheless, the findings that patients with more severe active cGVHD have higher 
CD19+CD21− B cells in the peripheral blood by our group and others (Greinix et al., 2008, 
Kuzmina et al., 2013)  supports a causal relationship between cGVHD and CD19+CD21− 
B cells. At present, CD19+CD21- B cells may serve as a potential biomarker to assess the 
severity of cGVHD and may provide a potential target for therapy. In addition, my data 
provide a possible explanation for the inadequacy of the antibody response against 
pathogens and the state of immunodeficiency observed in cGVHD (Hilgendorf et al., 
2011).  
Early studies in cGVHD with limited number of patients reported lower IL10 levels (Barak 
et al., 1995, Liem et al., 1999). In a small study, IL10 secretion by mononuclear cells 
derived from patients with chronic GVHD following in vitro stimulation was reduced 
(Korholz et al., 1997). Studies of donor and recipient IL10 polymorphisms yielded 
contradictory results (Lin et al., 2003, Rocha et al., 2002, Takahashi et al., 2000). Recently 
Hirayama and colleagues reported that IL10-producing CD29+ monocytes were 
increased in cGVHD and that IL10 spot forming cells correlated with disease activity. 
They hypothesised that IL10-producing monocytes play a role in remodelling tissue 
damage in chronic GVHD (Hirayama et al., 2013). IL10 has not been used as an 
immunomodulatory agent for cGVHD treatment. However, recombinant IL10 has been 
tried in some autoimmune diseases such as Crohn’s disease, rheumatoid arthritis and 
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psoriasis. In the majority of clinical trials, systemic administration of recombinant IL10 
was not associated with clinical improvement with the exception of psoriasis (Asadullah 
et al., 2003). Higher doses of systemically administered IL10 may have 
immunostimulatory properties with detrimental effect (Tilg et al., 2002). It is possible 
that IL10 the effect is dose dependent as well as cell specific. My results indicate that 
cellular contact may be required for IL10 to deliver immune regulation.  Moreover, in 
agreement with a B cell activation model by Duddy et al (Duddy et al., 2004),  I also 
propose that regulatory B cells receiving bystander stimulation via CD40 alone in close 
vicinity to a site of inflammation may control the inflammatory reaction. The fact that 
some cGVHD patients respond to rituximab suggests that B cells may have variable roles 
in the disease. B cell depletion is expected to improve cGVHD in cases where B cells play 
an effector role in the complex picture of the disease. Since IgM memory B cells, and in 
fact all described regulatory B cells, express CD20, rituximab will also deplete this subset. 
Targeting effector B cells, while maintaining regulatory B cells or delivering regulatory B 
cells is therefore required. The setting of allogeneic HSCT has the advantage that it 
allows the use of cellular therapy, such as donor lymphocyte infusions (DLI).  
An early prophylactic intervention, such as infusion of regulatory subsets to tip the 
balance in favour of immune regulation, may prevent the development of cGVHD. One 
way of achieving this goal could be through adoptive transfer of donor lymphocytes 
enriched with regulatory cells, for instance IgM memory cells, at an early stage, which 
minimises damage and predisposition to cGvHD. This approach may also facilitate the 
transfer of passive immunity from the donor to recipient, such as B cell memory against 
226 
 
encapsulated bacteria. Applying the same approach i.e. IgM memory B cell DLI can be 
proposed for the treatment of established cGVHD. The validity of these approaches 
must first be confirmed in pre-clinical studies, using xenogenic models of GVHD and 
subsequently in the context of well-designed clinical studies.  
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VII.2 Conclusion 
Based on these data, I propose that the cGVHD environment leads to B cell exhaustion, 
through chronic exposure to an inflammatory environment. Inflammation causes cell 
activation and expression of a phenotype favouring migration to GVHD sites. Deficiency 
of IL10+ B cells, with increased ratio of IFNγ+ CD4+ T cells/IL10+ B cells, in addition to a 
deficit in regulatory T cells in this context, supports the perpetuation of the 
inflammatory process. I propose that IgM+CD27+ B cell DLI could be a potential 
treatment modality for cGVHD. Another possibility is the reversal of B cell exhaustion, 
hence it is important to first establish that exhaustion is not driven by antigens involved 
in the pathogenesis of cGVHD. 
 
 
Figure VII-1: Schematic flow chart summarises the proposed mechanisms involved in 
B cell exhaustion in chronic GVHD. 
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VII.3  Future Plans 
In my thesis, I have demonstrated that regulatory B cells are enriched within a subset of 
memory cells, in agreement with Tedder’s study. Since they were able to show a 
suppressive effect on CD14+ cells, I propose to explore the suppressive effects of 
IgM+CD27+ B cells on CD14+ monocytes.  In addition, CD8+ T cells have a pathogenic role 
in aGVHD, therefore assessing the suppressive effect of regulatory B cells may help to 
understand their potential in acute GVHD. My data suggest that the immunoregulatory 
effect of IgM memory B cells is cell type specific and potentially conducted at a cellular 
level through IL10. To further assess whether cell-cell contact is required for regulatory 
B cells to deliver their suppressive property and to inhibit T cell effector cytokine and 
proliferation, I propose to perform trans-well experiments. Moreover, it has been 
reported that regulatory B cells enhance regulatory T cells and suppress Th 17 cells. I will 
therefore study the effect of IgM+ CD27+ memory B cells on FoxP3+ T cells and IL17+ T 
cells.  
We have shown that IL10+ B cells are reduced in cGVHD patients; therefore, to 
investigate the potential therapeutic role of IgM+CD27+ B cells in cGVHD, I am planning 
to study their suppressive ability on allogeneic CD4 T cells in an allogeneic mixed-
lymphocyte reaction setting. 
Since I found that different regulatory B cells share considerable phenotypic similarities, 
I would like to study the relationship between IgM memory B cells and the transitional 
cells. The question of whether CD23+ or CD23- transitional B cells include the precursor 
for IgM memory B cells is an intriguing one. To investigate this possibility, I plan to 
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perform an in vitro study to evaluate the differentiation of transitional B cell into IgM 
memory cells. Assessment of the change in phenotype as transitional B cells 
differentiate in response to different stimuli and growth factors may provide the 
answer. I will plan to sort purify IL10+ B cells, using IL10 cytokine capture (Miltenyi 
Biotec), to extract RNA and study the gene expression profile and ultimately identify a 
specific marker for this population (Yamada et al., 2010). Finally, to confirm that IgM 
memory B cells could prevent and suppress cGVHD, I plan to study the effect of donor 
IgM memory B cell infusion on the development of cGVHD as well as the treatment of 
established cGVHD in minor and major mismatched mouse models. Cell dose and time 
of infusion post transplantation can be determined for optimal clinical use. 
With regards to the role of B cell exhaustion in cGVHD, I plan to sort purify CD21- CD10-
CD27-   and assess their proliferative capacity as well as their in vitro Ig production and 
compare it with the CD21+ B cells in cGVHD, as well as non GVHD patients. It is hoped 
that this approach would answer the question of whether exhaustion is limited to CD21- 
B cells or is a global process. Furthermore, using T cell independent polyclonal 
stimulation protocols, such as CpG, I will assess whether exhaustion could be non-Ag 
specific, especially in the absence of known GVHD specific antigens.    Transcriptional 
profiling is needed to better understand the origin of these cells and their role in the 
pathogenesis of cGVHD.  
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